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GENERAL INTRODUCTION 
It is increasingly being recognized that human cancers in vivo do not behave as homogeneous 
collections of neoplastic cells but as complex multicellular systems in which malignant cells 
establish bidirectional interactions with neighbouring non-malignant cells. This interplay between 
tumor cells and the stroma—which comprises non-malignant cells and extracellular components—
has been recognized as constituting a ‘tumor microenvironment’, and is now considered to be a 
hallmark of cancer biology. Among the many different cell types in stroma, mature adipocyte 
received relatively little attention according to the view that it is merely an energy-storing cell, 
relatively inert to its surrounding. However, adipocyte has been identified as a highly endocrine cell 
that can secrete various adipokines which are potentially able to modulate tumor behavior through 
heterotypic signaling process (Review 1). Since current epidemiological evidence convincingly 
shows that obesity is associated with greater cancer specific mortality and poor prognosis outcome, 
the involvement of fat cells in the progression of cancer appears of major interest. 
 
The purpose of my PhD study is to shed in light the crosstalk between adipocytes and breast cancer 
cells and underscore the need to fully understand the role of this heterotypic signaling in modulating 
tumor behavior. 
First of all, I participated to the efforts of my team to demonstrate that invasive cancer cells have a 
dramatic impact on surrounding adipocytes. Both in vitro and in vivo, these adipocytes exhibit a 
decrease of lipid content, a decreased expression of adipocyte markers and an activated state by the 
overexpression of proinflammatory cytokines. We named them “Cancer-Associated Adipocytes” 
(CAAs) (Experimental article 1). 
Then, using combined in vitro and in vivo approaches, we identified for the first time that part of the 
cancer-associated fibroblasts (CAFs) which actively participate in tumor progression originate from 
the “dedifferentiation” of mature adipocytes. We named this new stromal cell population “Adipose-
Derived Fibroblasts” (ADFs). They could participate in the desmoplastic reaction composed of 
several fibroblasts embedded in a rich extracellular matrix, commonly found in breast cancer and 
promote tumor dissemination (Experimental article 2). 
Finally, we noticed that one of the key features of CAAs is the loss of lipid content observed both in 
vitro and in human breast tumors. Given that tumor cells possess variety of metabolic 
transformation according to their energy demand and the tumor microenvironment, CAAs may play 
a role in determining the metabolic phenotype of tumor cells. My work is to characterize a new 
metabolic crosstalk between breast cancer cells and tumor-surrounding adipocytes. During our 
investigation, we observed that part of this delipidation is due to the ability of tumor, but not normal 
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breast epithelial cells to induce lipolysis in adipocytes. We showed that the FFAs released during 
the lipolysis process by adipocytes are transferred, processed and stored in tumor cells as 
triglycerides (TG), contained in lipid droplets. When needed, these TG can be released as FFAs by 
an ATGL-dependent lipolytic pathway specifically present in tumor cells as shown both in vitro and 
in human tumors. These released FFAs are used for fatty acid β-oxidation (FAO), an activity 
present in cancer, but not normal, breast epithelial cells and regulated by coculture with adipocytes. 
Inhibition of these lipolytic/FAO coupled pathways either by pharmacological or gene repression 
strategies strongly decreases the invasive abilities of tumor cells that have been cocultivated with 
adipocytes (Experimental article 3).  
Therefore, our results strongly reinforced the concept of a metabolic crosstalk is established 
between adipocyte and tumor cells. For the first time, we showed ATGL, an enzyme that plays a 
key role in regulating lipid network and invasiveness of breast cancer cells in an adipocyte-rich 
microenvironment. 
 
In conclusion, such results provide an important concept in the understanding of the poor prognosis 
of breast cancer in the increasing obese population and warning about the oncological risk after 
autologous lipoaspirate grafting in breast cancer patients (Review 2) as well. Understanding the 
mechanisms of symbiosis between cancer cells and adipocytes should reveal new therapeutic 
possibilities. 
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INTRODUCTION GENERALE 
Il est maintenant établi que les tumeurs humaines ne se comportent pas comme un ensemble 
homogène de cellules néoplasiques, mais comme des systèmes complexes pluricellulaires où les 
cellules malignes établissent des interactions bidirectionnelles avec les cellules qui les entourent. 
Ces interactions entre les cellules tumorales et les cellules du stroma (microenvironnement) sont 
désormais considérées comme des facteurs majeurs impliqués dans la biologie du cancer. Parmi les 
nombreux types cellulaires du stroma, les adipocytes matures ont à ce jour reçu relativement peu 
d'attention, en effet ces derniers ont longtemps étaient considérés comme de simples cellules de 
stockage d'énergie, relativement inertes à leur environnement. Cependant, l’adipocyte a été identifié 
comme une cellule à fortes capacités endocrines sécrétant diverses adipokines pouvant 
potentiellement moduler le comportement de la tumeur via un processus de signalisation 
hétérotopique (voir la revue Wang et al, 2012). Les données épidémiologiques actuelles montrent 
de façon convaincante que l'obésité est associée à une plus grande mortalité par cancer ainsi qu’à 
une faible survie sans progression. L'implication des cellules graisseuses dans la progression du 
cancer apparaît donc d'un intérêt majeur.  
Le but de mon travail de thèse a été de mettre en lumière le dialogue bidirectionnel entre les 
adipocytes et les cellules cancéreuses mammaires et de souligner la nécessité de bien comprendre le 
rôle de cette signalisation hétérotopique dans la modulation du comportement de la tumeur.             
Tout d'abord, nous avons démontré que les cellules cancéreuses invasives ont un impact important 
sur les adipocytes environnants la tumeur. Aussi bien in vitro qu’in vivo, ces adipocytes présentent 
une diminution de leur contenu lipidique, une diminution de l'expression des marqueurs 
adipocytaires et un état activé par la surexpression de cytokines pro-inflammatoires. Nous les avons 
appelé les "adipocytes associés au cancer» (CAA) (voir le document Dirat et al, 2011). Par la suite, 
en combinant des approches in vitro et in vivo, nous avons identifié pour la première fois qu'une 
partie des fibroblastes associés au cancer (CAF) qui participent activement à la progression 
tumorale proviennent de la «dédifférenciation» d’adipocytes matures. Nous avons nommé cette 
nouvelle population de cellules stromales "fibroblastes du tissu adipeux» (ADF). Ces derniers 
pourraient participer à la réaction desmoplastique composée de fibroblastes intégrés dans une 
matrice extracellulaire riche, communément trouvées dans le cancer du sein et pourraient ainsi 
promouvoir la dissémination tumorale (voir le document Bochet et al, 2013). Enfin, nous avons 
remarqué que l'une des caractéristiques clés des CAA est la perte de leur contenu en lipides 
observée à la fois in vitro et dans des tumeurs mammaires humaines. Étant donné que les cellules 
tumorales possèdent une grande plasticité métabolique en fonction de leur besoin énergétique et du 
microenvironnement tumoral, les CAA pourraient jouer un rôle dans la détermination du phénotype 
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métabolique des cellules tumorales. Mon travail se porte sur la caractérisation d’un nouveau 
dialogue métabolique entre les cellules du cancer du sein et les adipocytes environnants. Au cours 
de nos recherches, nous avons constaté qu’une partie de cette délipidation est due à la capacité de la 
tumeur (mais pas des cellules épithéliales mammaires normales) à induire la lipolyse dans les 
adipocytes. Les acides gras libres (FFA) libérés au cours du processus de lipolyse sont ensuite 
transférés, modifiés et stockées dans les cellules tumorales sous la forme de triglycérides (TG), 
contenu dans les gouttelettes lipidiques. En cas de besoin, ces TG peuvent être libérés sous forme de 
FFA par une voie lipolytique spécifiquement présente dans les cellules tumorales. Ces FFA libérés 
peuvent être utilisés pour la β-oxydation mitochondriale, une activité présente dans les cancers, 
mais pas dans les cellules épithéliales mammaires saines. De manière intéressante, cette β-
oxydation des lipides est positivement régulée dans les cellules tumorales co-cultivées avec des 
adipocytes et son inhibition, par des approches pharmacologiques ou de répression d’expression, 
diminue fortement, à la fois in vitro et in vivo, les capacités invasives des cellules tumorales qui ont 
été co-cultivées avec des adipocytes. Pour la première fois, dans des tumeurs primaires du sein, nos 
résultats ont identifié l'une des principales lipases, ATGL, comme étant fortement exprimée dans les 
cellules tumorales en contact des adipocytes comparé aux cellules situées à distance de la tumeur. 
Cette surexpression est intimement corrélée à un mauvais pronostic pour les patientes atteintes d’un 
cancer du sein. Ainsi, cette forte expression d’ATGL dans les cellules cancéreuses agressives leur 
confère une activité lipolytique élevée leur permettant d’utiliser les FFA dérivés des adipocytes 
pour augmenter leurs propriétés malignes via la β-oxydation des lipides (voir manuscrit Wang et al, 
2013). 
En conclusion, notre travail a permis de fournir un concept important dans la compréhension du 
mauvais pronostic du cancer du sein dans la population grandissante de sujets obèses, mais 
également d'alerter sur le risque oncologique lié à une autogreffe de tissu adipeux (lipoaspiration) 
(voir la revue Wang, 2013). La compréhension des mécanismes symbiotiques entre les cellules 
cancéreuses et les adipocytes devrait révéler de nouvelles possibilités thérapeutiques. 
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PART I: THE TUMOR MICROENVIRONMENT. 
1. Abnormalities in the microenvironment during tumor progression 
In the past four decades, many researchers have focused their work primarily on tumor cells. 
Mutations either on oncogenes or tumor suppressor genes are important for tumor initiation. 
However, the concept of “seed and soil” that an appropriate host microenvironment (the soil) is 
needed for the optimal growth of tumor cells (the seed) has been also proposed long time ago [1]. 
Evidences now indicate that solid tumors comprise not only neoplastic cells but also normal stromal 
cells that have been recognized as constituting a ‘tumor microenvironment’. The crosstalk between 
cancer cells and stromal cells plays an important role in tumor survival, growth, metastasis, and 
response to antitumor therapy by secreting growth factors, chemokines, extracellular matrix (ECM) 
components [2];[3];[4]. The surrounding and interwoven stroma provides a connective-tissue 
framework to the tumor tissue. This framework includes a specific type of Extracellular matrix 
(ECM)—the tumor matrix—as well as cellular components such as fibroblasts, immune and 
inflammatory cells, and blood-vessel cells. As its constitution resembles that of the granulation 
tissue formed during wound healing, Hal Dvorak even defined a tumor as “a wound that never 
heals” [5]. 
Cancer cells themselves can alter their adjacent stroma to form a permissive and supportive 
environment for tumor progression by secreting growth factors and proteases, which can act in 
autocrine and paracrine manners. Concomitantly, cancer cells initiate the secretion of specific pro-
migratory and –invasive ECM components, along with their respective receptors, and reduce the 
expression of protease inhibitors. The imbalance between proteases and their inhibitors then lead to 
the degradation of ECM components, resulting in the mobilization of matrix-bound growth factors 
and the generation of reactive ECM fragments. Together with the tumor-derived growth factors, 
these factors then induce angiogenesis as well as recruit and activate stromal inflammatory cells, 
fibroblasts and adipocytes, leading to the secretion of additional growth factors and proteases to 
amplify these signals. This cascade results in the establishment of an activated stroma that promotes 
malignant tumor progression (Figure 1). 
The relative amount of stroma and its composition vary considerably from tumor to tumor and do 
not correlate with the degree of tumor malignancy [6]. But the interactive signaling between tumor 
and stroma contributes to the formation of a complex multicellular organ. In a manner similar to the 
development and function of normal organs, which occurs through reciprocal communication 
between different cell types, the interaction between cancer cells and their microenvironment can 
largely determine the phenotype of the tumor. For example, recent studies have shown that the 
establishment of human breast tumor xenografts in mice depends on the presence of human tumor-
14 
 
derived stromal fibroblasts [7]. We will then first describe the main cellular component of the 
cancer stromal (vascular cells, inflammatory cells and fibroblasts) and their relative contribution in 
tumor progression. 
 
 
 
 
 
 
 
              
Figure 1. Crosstalk between tumor cells and their activated stromal surroundings. Tumor cells initiate 
the secretion of growth factors, ECM components, along with the imbalance between proteases and their 
inhibitors induce angiogenesis as well as recruit and activate stromal inflammatory cells, fibroblasts and 
adipocytes, leading to the secretion of additional growth factors and proteases to amplify these signals. 
(Mueller MM and Fusenig NE, 2004, Nat Rev Cancer). 
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2. Complex cellular components in solid tumors 
2.1 Vascular cells 
Like normal vessels, tumor blood vessels are composed of endothelial cells, mural cells (pericytes 
or smooth muscle cells) and basement membrane. However, all of these components are 
morphologically and/ or functional different from their normal counterparts [8]. 
Tumor-associated endothelial cells (TECs) are the major player in the formation of tumor 
vasculature through sprouting from existing blood vessels (a process called ‘angiogenesis’). During 
blood vessel formation, endothelial cells proliferate, migrate and form the inner layer of a lumen, 
followed by basement membrane formation and pericyte attachment. Angiogenesis is stimulated by 
excessive pro-angiogenic factors secreted by tumor or stromal cells in an oxygen-depleted 
microenvironment. Hypoxia stabilizes the hypoxia-inducible transcription factors (HIF), one of the 
key roles of HIF in hypoxia is the induction of pro-angiogenic factors, including VEGF, 
angiopoietin-2, PDGF and FGF, and downregulation of anti-angiogenic factors, such as 
thrombospondin [9];[10];[11]. New blood vessel formation is critical for tumor development and 
progression, as it delivers nutrients and oxygen to growing tumor and removes metabolic wastes. In 
addition, vascular endothelial cells form a barrier between circulating blood cells, tumor cells and 
the extracellular matrix (ECM), thus playing a central role in regulating the trafficking of 
leukocytes and tumor cells [12]. In this regard, endothelial cells are critical for boosting a host 
immune defense against cancer cells and for controlling tumor metastasis. However, the ‘gate-
keeping’ function of endothelial cells in tumors is heavily compromised. TECs are not tightly 
associated with each other, resulting in wider interendothelial junctions that cause plasma leakage 
and hemorrhage [13]. Consequently, tumor vasculature is often leaky and less efficient in blood 
perfusion, leading to increase interstitial fluid pressure, hypoxia and acidic extracellular pH that 
may significantly affect the delivery and efficiency of chemotherapeutic drugs. The leaky blood 
vessels also facilitate the intravasation of tumor cells and promote tumor metastasis. 
Several experiments have shown the difference between “normal” endothelial cells and endothelial 
cells within a tumor-context. For example, it has been reported that human hepatocellular 
carcinoma-derived endothelial cells, when compared to the ones from adjacent normal liver tissue, 
show increased apoptosis resistance, enhanced angiogenic activity and acquire more resistance to 
the combination of angiogenesis inhibitor with chemotherapeutic drugs [14]. Studies have also 
revealed distinct gene expression profiles of TECs and identified cell-surface markers 
distinguishing tumor versus normal endothelial cells [15]. 
In blood vessels, pericytes are smooth muscle cell-like cells that cover the vascular tube. They are 
intimately associated with endothelial cells and embedded within the vascular basement membrane, 
and play an important role in the maintenance of blood vessel integrity. Pericytes in tumors are 
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different from normal ones: in tumors, pericytes are often less abundant and more loosely attached 
to the endothelial layer [16];[17]. The abnormality in pericytes weakens the vessel wall and 
increases vessel leakiness. Thus, angiogenesis is the first compartment that as a good target for 
cancer therapies [18]. 
2.2 Inflammatory/Immune cells 
Tumors are often infiltrated by inflammatory cells, such as macrophages, neutrophils, lymphocytes, 
mast cells, and myeloid progenitors. This phenomenon was initially observed by Rudolf Virchow 
more than a century ago and thought to be an immunological response attempting to eliminate 
cancer cells. Whereas immune cells play a role in recognizing and eradicating early cancer cells 
[19], mounting evidence has also shown that inflammatory cells within tumors can enhance tumor 
initiation and progression by helping cancer cells to acquire hallmark capabilities [4]. 
Epidemiologic and clinical studies show that approximately 25% of all human cancers in adults 
result from chronic inflammation [20]. For example, chronic viral or bacterial infection in stomach, 
liver and cervical, repeated solar irradiation of the skin, and prolonged exposure to tobacco smoke 
or other environmental chemicals in lung, contribute significantly to the chronic tissue injury and 
subsequently oncogenesis of these organs [21]. During this oncogenic event, persistent tissue injury 
result in changes in the cellular architecture of the epithelium and the surrounding stromal elements 
and promote genetic mutations and epigenetic alterations of epithelia cells. This change in tissue 
homeostasis can in turn lead to a chronic inflammatory response that never fades away, which then 
further promotes tumor growth, angiogenesis, invasion and metastasis through the activation of 
surrounding stromal cells and recruitment of different inflammatory cells.  
Among the abundant inflammatory cells, macrophages form a major inflammatory population in 
most tumors and are important determinants of the inflammatory milieu. Broadly speaking, 
macrophages can be defined as classically (M1) or alternatively (M2) activated. M1 macrophages 
are involved in Type 1 reactions and are classically activated by microbial products, killing 
microorganisms and producing reactive oxygen and nitrogen intermediates. In contrast, M2 cells 
(Tumor associated macrophages; TAMs) are important component of infiltrated leukocytes in most 
malignant tumors, M2 macrophages can be identified using a number of markers, since they express 
arginase, mannose receptor, high-level IL-10, low level MHC II and IL-12. They produce many 
tumor-promoting factors, like EGF and VEGF, release cytokines and enzymes that promote 
angiogenesis and local and distant invasion, like VEGF and MMP9 and down-regulate expression 
of anti-angiogenic factors, like IL-12 to facilitate tumor progression [22];[23];[24]. Macrophages 
are derived from CD34
+
 bone marrow progenitors that continually proliferate and shed for their 
progeny into the bloodstream as pro-monocytes. In breast cancer, infiltrating TAMs correlate with 
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poor prognostic features, higher tumor grade, high vascular grade, increased necrosis and decreased 
disease-free survival [25]. Recently, one study found that CCL18 was highly expressed in TAMs 
and promoted the invasion and metastasis of cancer cells by triggering integrin clustering and 
enhancing their adherence to the ECM [26]. 
Other components of the inflammatory infiltrate also modulate tumor behavior. T-regulatory (T-
reg) cells were first identified in 1971 by Gershon and Kondo [27], followed by reports of T cells 
suppressing the anti-tumor immune response, and then by identification of CD4
+
 T cells that 
suppressed autologous cytotoxic anti-tumor immune response [28]. These T cells are now classified 
as CD4
+
, CD25
+
, FoxP3
+
 and are thought to protect the host from autoimmune disease by 
suppressing self-reactive cells and therefore also blocking anti-tumor responses. Neutrophils also 
generate ECM degrading enzymes, reactive oxygen and nitrogen species. These bioactive factors 
promote cancer cell proliferation, invasion and resistance to apoptosis through, for instance, the 
interleukin-JAK/STAT pathway [29], and induce new blood vessel formation in the tumor. 
Extracellular matrix-degrading enzymes promote cancer cell invasion and metastasis, whereas 
accumulation of reactive oxygen and nitrogen species can cause DNA mutations, suppress DNA 
repair enzymes, increase genomic instability, and aggravate cancer progression. 
While the tumor-promoting effects of infiltrating inflammatory cells have been well documented, 
certain types of immune cells, particularly cytotoxic T cells and natural killer cells, exhibit anti-
tumor activities. The high numbers of these cells within a tumor predict a favorable prognosis 
[30];[31]. Immune surveillance is considered as an important mechanism to inhibit carcinogenesis 
and maintain tumor dormancy [19]. Evading immune destruction by downregulating tumor 
antigens, suppressing immune cell function and other means is an emerging hallmark of cancer cells 
and plays important roles in cancer progression and metastasis [4]. 
2.3 Fibroblasts  
 
2.3.1 Origin and markers of cancer-associated fibroblasts (CAFs) 
Fibroblasts are elongated cells that show a fusiform or spindle-like shape in profile. Fibroblasts 
were first described in the late 19
th
 century. They are the non-vascular, non-epithelial and non-
inflammatory cells of the connective tissue and are its principal cellular component [32]. They are 
embedded within the fibrillar matrix of the connective tissue and are, to a large extent, responsible 
for its synthesis. Fibroblasts in mammals are highly heterogeneous, a recent study comparing the 
genome-wide expression patterns of 50 human fibroblast cultures isolated from 16 different sites 
showed that gene-expression patterns among fibroblast populations from distinct anatomical sites 
are as divergent as the gene-expression patterns observed among distinct lineages of white blood 
cells [33]. The major functions of fibroblasts include the deposition of ECM, the regulation of 
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epithelial differentiation, and the inflammatory responses [34]. Such increased activity is referred to 
as ‘activation’ (figure 2). Once the wound is repaired, the number of activated fibroblasts decreases 
significantly and the resting phenotype is thought to be restored. Unlike wound healing, but similar 
to organ fibrosis, the fibroblasts at the site of a tumor remain perpetually activated.  This leads to 
tumor desmoplasia through excessive ECM deposition.  
It has been demonstrated that cancer-associated fibroblasts (CAFs) are extremely abundant in the 
stroma of many tumors, including breast, prostate and pancreatic carcinomas [35];[36]. Of note is 
that CAFs are heterogeneous populations and their relative composition is greatly different among 
different tumors. The main activation markers are α-Smooth Muscle Actin (α-SMA), Fibroblast-
Specific Protein (FSP), Platelet-Derived Growth Factor (PDGF) receptor-β and Fibroblast 
Activation Protein (FAP) [37];[35]. This large heterogeneity in marker expression for CAF 
subpopulations or in CAFs originating from different tumors may be explained by their possible 
miscellaneous origin. Indeed, CAFs are variously reported to stem from resident fibroblasts, bone 
marrow-derived progenitor cells, or from endothelial or cancer cells through endothelial-
mesenchymal transition or epithelial-mensenchymal transition (EMT) [38] or a brand new 
origination from adipocytes (see article 2). At present, neither the origin of these cells, nor the 
extent to which their origin determines their contribution to tumor progression can be unanimously 
agreed upon. 
The normal stroma in most organs contains a minimal number of fibroblasts in association with a 
physiological ECM whereas the reactive stroma is associated with an increased number of 
fibroblasts, enhanced capillary density and type-I-collagen and fibrin deposition. To date, 
transforming growth factor-β (TGFβ) and CXCL12/SDF-1 are regarded as the major tumor cell-
derived factors affecting CAF activation through a TGFβ and CXCL12/SDF-1 autocrine signaling 
loop. Other profibrotic factors releases by cancer cells like epidermal growth factor (EGF), platelet-
derived growth factor (PDGF) and fibroblast growth factor 2 (FGF2) can also act on resident 
fibroblasts and induce their activation [39]. Another important mechanism in the activation of CAFs 
is the downregulation of tumor suppressor genes such as p53, p21, PTEN, and caveolin-1 (CAV-1) 
[25]. 
 
2.3.2 The role of CAFs in cancer progression: 
Secretion of soluble factors 
CAFs produce growth factors, cytokines, chemokines and ECM proteases to stimulate angiogenesis 
and cancer cell proliferation and invasion (figure 3) [40]. The existence of a large number of CAFs 
in tumors is often associated with poor prognosis [41]. Hepatocyte growth factor (HGF), EGF, 
bFGF, as well as cytokines such as SDF-1 and IL-6, are all substantially expressed by CAFs upon 
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contact with different tumor histotypes. For example, CAFs secret elevated levels of stromal cell-
derived factor 1 (SDF-1; also called CXCL12) that facilitates angiogenesis by recruiting endothelial 
progenitor cells into the tumor [42]. SDF-1 can also interact with the CXCR4 receptor expressed on 
the surface of cancer cells, thus stimulating tumor cell growth and promoting tumor progression in 
vivo [43]. Furthermore, in breast adenocarcinoma, SDF-1 secreted by CAFs has been found driven 
by hypoxia-inducible factor-1 (HIF-1), which is in turn activated by hypoxia-mediated oxidative 
stress [44]. CAFs might contribute to epithelial-to-mesenchymal transition (EMT) in nearby cancer 
cells and promote their invasiveness [40]. TGFβ, another factor produced by CAFs, is a critical 
mediator of the EMT; IL-6 has been found to be 100-fold increased expression in CAFs compared 
with non-cancer-associated fibroblasts and also induces EMT in ER-positive breast cancer cell lines 
(MCF7, T47D) [45]. 
CAFs are also able to secrete several members of the MMP family as well as plasminogen 
activators. These enzymes may act mainly through 3 pathways below: 1) direct degradation of 
ECM; 2) cleavage of membrane-bound growth factors or cytokines as well as their receptors; 3) 
cleavage of cell adhesion molecules like cadherins, leading to an increased motility and EMT [46]. 
The expression of tumor (MMP1, MMP2 and MMP14) and stromal (MMP9, MMP13 and MMP14) 
matrix metalloproteinases is mandatory for squamous cell carcinoma progression [47]. MMP9 
directly cleaves the extra-cellular domain of E-cadherin, promoting normal mammary epithelial 
cells to disaggregate and undergo EMT, promoting cancer-cell invasiveness [48]. MMP13 secreted 
by CAFs promotes tumor angiogenesis by releasing VEGF from the ECM, thereby leading to the 
increased invasion of squamous cell carcinoma or melanoma [49]. MMP1 also shows such a tumor-
promoting effect. The protease-activated receptor PAR1, which is a tethered-ligand receptor, is 
activated by proteolytic cleavage of the extracellular domain by MMP1, promoting cancer cell 
migration and invasion through PAR1-dependent Ca
2+
 signals [50]. 
Alongside MMPs, CAFs from colon and breast carcinoma also express uPA and its receptor uPAR 
[51]. Cancer cells engage with their stromal fibroblasts a specific feed-forward loop mediated by 
paracrine bFGF and EGF, which induce uPA transcription in the fibroblasts. In turn, the serine 
protease system helps in activating these paracrine factors from the tumor cell surface/ECM [52]. 
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Figure 2. Activated fibroblasts. a. Normal fibroblasts are embedded within the fibrillar ECM of connective 
tissue, which  consists largely of type I collagen and fibronectin. b. Fibroblasts can acquire an activated 
phenotype, which is associated with an increased proliferatvie activity and enhanced secretion of ECM 
protein such as type I collagen and tenascin C, and also fibronectin that contains the extra domain a (EDA-
fibronectin) and SPARC (secreted protein acidic and rich in cysteine) (Kalluri and Zeisberg, 2006, Nat Rev 
Cancer). 
 
 
                              
Figure 3. Origins and functions of CAFs. A number of origins have been proposed for CAFs, including 
bone marrow-derived cells (BDMC), response of normal fibroblasts to tumor-derived signals, genetic and 
epigenetic alterations in normal fibroblasts, or epithelial-mesenchymal transition (EMT) of normal or tumor 
epithelial cells. They have many effects on tumor cells (Allen M and Louise Jones J, 2011, J Pathol). 
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ECM remodelling 
CAFs also generate an altered ECM environment. Most solid tumors exhibit a very different profile 
of ECM proteins in the stroma compared to their normal counterparts, and many of these proteins 
interact directly with tumor cells, via integrins and other cell surface receptors, to influence 
functions such as proliferation, apoptosis, migration and differentiation [53]. CAFs retain a major 
role in ECM remodeling since they are mainly responsible for the production of ECM proteins (i.e. 
collagens, fibronectin) as well as proteases and other enzymes involved in the posttranslational 
modification of ECM proteins themselves. Invasive carcinoma is often associated with expansion of 
the tumor stroma and increased deposition of ECM. Such increased deposition of ECM in tumors is 
known as desmoplasia. Indeed, many cancers are associated with desmoplasia, a fibrotic state 
characterized by an accumulation of type I and III collagens and by a degradation of type IV 
collagen [54];[55]. Tumor desmoplasia has been associated with the poor prognosis of cancers and 
it has also been observed in metastatic sites [56]. 
One way in which tensile strength can be modulated is via lysyl oxidase (LOX), an enzyme secreted 
primarily by fibroblasts that serves to cross-link collagens and elastin, increasing the insoluble 
matrix and contributing to tensile strength [57]. Recently, in a mouse model of breast carcinoma, 
treatment with LOX inhibitors led to a decrease of ECM cross links, preventing ECM stiffening and 
delaying tumor progression [58]. LOX pre-conditioning and stiffening of the mouse mammary fat 
pad also resulted in growth and invasion of premalignant mammary cells, suggesting that increased 
ECM stiffness can promote tumorigenesis as well as alter established tumor behavior [58]. In 
addition, ECM rigidity in tumor contributes together with impaired vascular and lymphatic mesh, to 
increase interstitial fluid pressure, leading to a reduced chemotherapeutics delivery inside tumors 
[59]. Together with ECM stiffness, interstitial flow is an important mechanical stress in the tumor 
stroma. It drives TGF-β1 and MMP-dependent fibroblast tissue invasion which, in turn, enhances 
tumor cell invasion by ECM remodeling [60]. These findings confirm that CAFs may serve as 
guidance structures that direct the migration of epithelial cancer cells by inducing protease-
mediated ECM remodeling. 
Fibronectin (FN) and hyaluronan—two other ECM components, mostly produced by CAFs, have 
been shown to play a role in tumor microenvironment. In tumors, there is frequent up-regulation of 
the ‘oncofetal’ forms of FN that contain extra-domain (ED)A, (ED)B, and IIICS sequences [61]. 
FN-EDA is required for the transduction of TGFβ signals, and the conversion of fibroblasts to 
myofibroblasts [62], whereas FN-EDB is particularly associated with neovascular structures in 
many different tumor types [63]. Stromal FN is positively associated with human tumor metastatic 
potential and MMP secretion [56], in addition, FN regulates ovarian cancer metastatic potential by 
promoting a ligand-independent activation of the c-Met proto-oncogene through binding to α5β1 
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receptor [64].  Vascular endothelial growth factor (VEGF) can be released by cancer cells 
themselves, but fibroblasts and inflammatory cells are also the principal source of host-derived 
VEGF. It induces microvascular permeability, which leads to the extravasation of plasma proteins 
such as fibrin, which in turn attract an influx of fibroblasts, inflammatory cells and endothelial cells. 
These cells produce ECM that is rich in fibronectin and type I collagen, both of which are 
conducive to initiating tumor angiogenesis [65]. CAFs mediated the overexpression of hyaluronan 
within the tumor microenvironment, and it has been shown to have a role in the recruitment of 
tumor-associated macrophages, which are key regulatory cells involved in tumor neovascularization 
through endothelial cell recruitment [66]. 
 
Tumor metabolism remodeling 
Cancer cells mainly use glucose by glycolysis, producing lactate even in the presence of oxygen, a 
metabolic phenomenon called: Warburg Effect or Aerobic Glycolysis, whilst normal cells fully 
exploit glucose by oxidative phosphorylation. Recently, accumulating evidence showed that CAFs 
participate in the complex metabolism of tumors, engaging a bidirectional liaison with tumor cells, 
prompting them to overcome energy depletion due to the Warburg effect (This specific role of 
CAFs will be described in the third part of my thesis).  
2.4 Adipocytes  
Among the different cell types frequently found at close proximity of evolving tumors, little 
attention has been given to cells that compose the adipose tissue although a growing interest can be 
noted in recent years. Adipose tissue (AT) is consisting of mainly mature adipocytes and 
progenitors (preadipocytes and adipose-derived stem cells, ADSCs) that are contained in stroma 
vascular fraction (SVF). The role of adipose tissue, and more specifically adipocytes, in tumor 
initiation, growth, and metastasis, is a relatively new area of investigation. Emerging studies 
including our results clearly indicate that a bidirectional crosstalk is established between cellular 
components of AT and cancer cells and that the tumor-surrounding AT contributes to inflammation 
[67];[68], ECM remodeling [69];[70] as well as energy supply within the tumors [71]. Moreover, 
obesity is an epidemic problem nowadays in the world and is associated with several healthy 
problems including cancer. In next part, we will make an overall description of AT composition and 
function with special emphasis on the specificity of adipose depots, key aspects that need to be 
taken in account when paracrine effects of AT on tumor progression is considered. Try to 
deciphering the cellular and molecular mechanisms involved in it and to better understand the link 
between obesity and the poor prognosis of some cancers. 
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PART II: ADIPOSE TISSUE AND CANCER INTERACTION 
1. The adipose tissue (AT) overview 
For decades, adipose tissue was considered an inert mass of stored energy with some advantageous 
properties, such as its function as an insulating substance and as a mechanical support for more 
important structures. However, over the last two decades has seen a surge of interest in the study of 
adipose tissue, from its developmental biology to its physiology. What accounts for this new found 
respect for adipocytes? The discovery of leptin in 1994 presaged a growing awareness that 
adipocytes are essential regulators of whole-body energy homeostasis. These cells have been 
established as a dynamic organ that carries out several important physiological processes as diverse 
as haemostasis, blood pressure, immune function, angiogenesis and energy balance [72]. Another 
reason for the surge in interest in adipocytes is the awareness of abnormal fat accumulation is 
associated with healthy problems. For example, it is well known that overweight and obese 
individuals have a substantially greater risk of developing chronic diseases, such as cardiovascular 
disease (mainly ischemic heart disease and stroke), diabetes, respiratory failure, musculoskeletal 
disorders (especially osteoarthritis), and also cancer (endometrial, breast, kidney and colon) [73]. 
Hence, it is clear that a better understanding of the mechanisms linking adipose tissue development, 
function and expansion is required to improve our chances of identifying the most successful 
therapeutic approaches.  
Adipose tissues are organized to form a large organ with discrete anatomy, specific vascular and 
nerve supplies, complex cytology, and high physiological plasticity [74];[75]. There are two main 
types of adipocyte, brown and white, which differ in several important properties (as discuss 
below). Even among white adipocytes, cells from different locations can have distinct molecular 
and physiological properties. The various adipose depots are the subcutaneous depots (inguinal, 
femoral, abdominal) which present in the deep layer of the skin, the visceral depots (mesenteric, 
omental, retroperitoneal, epididymal, gonadal, perivascular, and pericardial depots) [76], mammary 
depots and the bone marrow depots (Figure 4). All these specific regional depots exhibit differences 
in structure, function, composition, and secretion profiles. This is more evidently demonstrated by 
the links revealed between increased deep abdominal or visceral, but not peripheral, fat extent, and 
the metabolic disturbances associated with obesity [77]. 
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Figure 4. Distribution of adipose tissue in human body. White adipose tissue, mainly composed of 
adipocytes, is located in subcutaneous (inguinal femoral in women) and in abdomen where it surrounds the 
internal organs (visceral adipose tissue). The adipose tissue is also found in bone, women-breast and around 
the men`s prostate (Laurent V et al, 2013, Médecine/sciences) 
 
 
 
 
                                       
 
Figure 5. Components of adipose tissue. Adipocytes are the main cellular component of adipose tissue, the 
other cell types that are present are precursor cells (including pre-adipocytes), fibroblasts, vascular cells and 
immune cells and these cells constitute the stromal vascular fraction of adipose tissue (SVF). (Ouchi N et al., 
2011, Nat Rev Immunol) 
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2. The adipocytes 
Adipose tissue is largely composed of adipocytes, but also contains a stromal vascular fraction 
made up of pericytes, endothelial cells, monocytes, macrophages, and pluripotent stem cells (Figure 
5) [78];[79]. Two main types of adipocytes are easy to distinguish by morphology: white adipocytes 
are spherical cells with ~90% of their volume comprising a single cytoplasmic lipid droplet and a 
‘squeezed’ nucleus, whereas brown adipocytes are polygonal cells with a roundish nucleus and 
several cytoplasmic lipid droplets (Figure 6). Brown adipocytes are also characterized by numerous 
large mitochondria packed with cristae. Mitochondria in brown adipocytes are marked by the 
expression of uncoupling protein 1 (UCP1), a unique protein that uncouples oxidative 
phosphorylation from ATP synthesis and thereby results in the production of heat (thermogenesis) 
[80];[81];[82]. Thus, white and brown adipocytes are quite different in their morphology and 
physiology: white adipocytes store energy for the metabolic needs of the organism, whereas brown 
adipocytes burn energy for thermogenesis. Both cell types are contained in the multiple depots of 
the adipose organ [83];[84]. White adipocytes are considered the dominant adipocyte subtype in 
adult humans with different sizes present in subcutaneous depots (mainly large adipocytes) and 
visceral depots (mainly small adipocytes) [85];[86]. Most brown adipose tissue in rodents is 
localized to the interscapular region. In human fetuses and newborns, BAT is found in axillary, 
cervical, perirenal, and periadrenal regions [80] but decreases shortly after birth and has 
traditionally been considered insignificant in adults, except perhaps in patients with 
pheochromocytoma, where adrenergic activity is extremely high [87], or in outdoor workers in 
northern climes subject to prolonged cold exposure [88]. A third type of adipocyte, the ‘beige’ or 
‘brite’ (brown in white) adipocyte, has recently been identified which are the cells with intermediate 
morphology between that of white and brown adipocytes and has characteristics of both white and 
brown adipocytes. Like white adipocytes, basal UCP1 expression is low in beige adipocytes. 
However, like brown adipocytes, beige adipocytes respond to cyclic AMP (cAMP) stimulation by 
an increase of UCP1 expression [89];[90];[91]. 
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Figure 6. Left, Electron microscopy of murine white adipose tissue. The small and elongated 
mitochondria in the perinuclear area and in the thin rim of cytoplasm surrounding the large unilocular lipid 
droplet. F, fibroblast; CAP, capillary lumen; Ma, macrophage; M, mitochondria; N, nucleus; L, liquid 
droplet. Bar = 2 μm 
Right, Light microscopy of human brown adipose tissue. The characteristic multilocular lipid 
organization of the cytoplasm of adipocytes. Bar = 15 μm (Saverio Cinti, 1999, The Adipose Organ). 
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2.1 The cellular origins of adipocytes and their differentiation 
In the recent past, it was largely accepted that both brown and white adipocytes arose from resident 
mesenchymal progenitor cells that were present in adipose tissue. This idea was supported by 
evidence indicating that both brown and white adipocytes require PPARγ for development. 
However, the notion that brown and white cells arise from a similar origin is outdated. Brown 
adipocytes instead share a common MYF5
+
PAX7
+
 precursor with muscle cells [92]. The 
MYF5
+
PAX7
+
 precursor is driven to brown adipocyte terminal differentiation by bone 
morphogenetic protein 7 (BMP7), peroxisome proliferator activated receptor-γ (PPARγ) and 
CCAAT/enhancer-binding proteins (C/EBPs) cooperating with the transcriptional co-regulator PR 
domain-containing 16 (PRDM16). By contrast, PRDM16 does not affect white adipogenesis. White 
adipocytes can also be stimulated to display characteristics of brown adipocytes by β-adrenergic 
signaling, cold exposure and thiazolidinediones, which seem to function through the indicated 
factors (Figure 7). These results suggest that brown cells in BAT and brown fat-like cells in WAT 
have different cellular origins, and the transcriptional modulator PRDM16 plays an important role 
in both of these cell types to regulate genes required for thermogenesis [93]. There is also evidence 
to indicate that bone marrow progenitor-derived adipocytes and adipocyte progenitors can arise 
from hematopoietic cells via the myeloid lineage [94]. Collectively, these recent studies suggest that 
our understanding of the origin of adipocytes is rapidly changing, and additional studies will be 
necessary to clarify our understanding of this emerging area of biology.  
Despite the functional, developmental and locational differences between white and brown 
adipocytes, these two cell types share many common differentiation features. All adipocytes, along 
with osteoblasts, myocytes and chondrocytes, differentiate from mesenchymal stem cells (MSCs) 
[95] in a process known as adipogenesis. Adipogenesis can be divided into two main phases: 
determination and terminal differentiation. The first phase involves the commitment of a pluripotent 
stem cell to the adipocyte lineage. Determination results in the conversion of the stem cell to a pre-
adipoctye, which cannot be distinguished morphologically from its precursor cell but has lost the 
potential to differentiate into other cell types. In the second phase, the pre-adipocyte takes on the 
characteristics of the mature adipocyte—it acquires the machinery that is necessary for lipid 
transport and synthesis, insulin sensitivity and the secretion of adipocyte-specific proteins. Over the 
past two decades, attention has centred on the role of the nuclear receptor PPARγ and members of 
the C/EBP family in adipogenesis. We briefly discuss the important functions of these factors in 
adipogenesis. 
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Figure 7. Relationship between white and brown adipogenesis. Historically, white and brown adipocytes 
were thought to derive from the same precursor cell. However, brown adipocytes instead share a common 
MYF
+
PAX7
+
 precursor with muscle cells.  MYF
+
PAXA7
+
 precursor  is driven to brown adipocyte terminal 
differentiation by BMP7, PPARγ and C/EBPs with PRDM16. White adipocytes can also be stimulated to 
display characteristics of brown adipocytes by β-adrenergic signaling, cold exposure and thiazolidinediones. 
MSC, mesenchymal stem cell; MYF5, myogenic factor 5; PAX7, paired-box 7; PGC1α, PPARγ co-activator 
1α (Ana G. Cristancho and Mitchell A. Lazar, 2011, Nat Rev Mol Cell Biol). 
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PPARγ: the master regulator of adipogenesis.   
PPARγ is a member of the nuclear-receptor superfamily, and is both necessary and sufficient for 
adipogenesis. Forced expression of PPARγ is sufficient to induce adipocyte differentiation in 
fibroblasts [96], and no factor has been discovered that promotes adipogenesis in the absence of 
PPARγ. These findings are consistent with the observation that most pro-adipogenic factors seem to 
function at least in part by activating PPARγ expression or activity. Studies using in vitro models of 
adipogenesis have consistently shown that PPARγ mRNA is induced by several transcription 
factors, including C/EBPβ, C/EBPδ, EBF1, and KLF5. Repressors of adipogenesis such as GATA2, 
KLF2, and CHOP have been shown to attenuate PPARγ expression [97]. Moreover, crucial 
signaling pathways in adipogenesis converge on the regulation of PPARγ expression or activity. 
PPARγ proteins are expressed in two forms, PPARγ1 and PPARγ2, which are produced by a 
combination of differential promoter usage and alternative splicing [98]. PPARγ1 is expressed at 
low levels in multiple tissues, whereas PPARγ2 is highly expressed in fat cells and differs from 
PPARγ1 by an amino-terminal extension of 30 amino acids [99]. Two studies have addressed the 
relative adipogenic activity of the PPARγ isoforms without coming to a consensus. Ren et al have 
shown that ectopic expression of PPARγ2 rescues adipogenesis, whereas expression of PPARγ1 
does not [100]. By contrast, Mueller et al showed that both PPARγ1 and PPARγ2 can promote 
differentiation in Pparγ-/-fibroblasts; however, PPARγ2 is slightly more efficient at promoting 
adipogenesis [101]. 
In vivo studies have shown that mice with adipose tissue-specific loss of PPARγ display decreased 
fat pad size and insulin resistance in adipose tissue and liver [102]. Although PPARγ is required for 
adipogenesis, there is evidence to suggest that this nuclear receptor may not be needed to maintain 
the differentiated state of the cell after adipogenesis [103]. The importance of PPARγ in human 
adipose tissue has also been established, and subjects with mutations in the PPARγ gene can 
develop severe insulin resistance and lipodystrophy [104];[105]. Taken together, these studies show 
the requirement for PPARγ in adipocyte differentiation and whole-body insulin sensitivity. 
 
C/EBPs 
C/EBPs comprise another family of basic leucine zipper transcription factors. There are six C/EBP 
isoforms, all of which possess a highly conserved bZIP domain that serves as a point of interaction 
for homodimerization or heterodimerization with other family members [106]. The most common 
nomenclature for the members is C/EBPs α, β, δ, γ, ε and ζ. The temporal expression of these 
factors during adipocyte differentiation indicates a cascade whereby early induction of C/EBPβ and 
C/EBPδ leads to induction of C/EBPα. The notion is further supported by sequential binding of 
these transcription factors to several adipocyte promoters during differentiation. Loss of function 
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experiments in 3T3-L1 and NIH-3T3 cell lines confirmed the importance of C/EBPβ and –δ, as 
inhibition of either of these C/EBPs resulted in the attenuation of adipogenesis [107]. C/EBPβ and 
C/EBPδ promote adipogenesis at least in part by inducing C/EBPα and PPARγ. The amounts of 
C/ebpa and Pparg mRNA are normal in the remaining adipocytes of these double-knockout mice in 
contrast to C/EBPβ- and C/EBPδ- deficient MEFs, which do not express C/EBPα and PPARγ [108]. 
Despite the importance of C/EBPs in adipogenesis, these transcription factors can`t function 
efficiently in the absence of PPARγ. For example, C/EBPβ cannot induce expression of C/EBPα in 
the absence of PPARγ, which is required to release histone deacetylase-1 (HDAC1) form the 
C/ebpa promoter [109]. Furthermore, the ectopic expression of C/EBPα cannot rescue adipogenesis 
in Pparg
-/-
 fibroblasts [110]. However, C/EBPα has an important role in differentiated adipocytes. 
Expression of exogenous PPARγ in C/EBPα-deficient cells showed that, although C/EBPα is not 
required for accumulation of lipid and the expression of many adipocyte genes, it is necessary for 
the acquisition of insulin sensitivity [111]. 
 
WNT signaling 
WNT family members are secreted glycoproteins that have key roles during development. 
Canonical WNT signaling is activated following the binding of WNT ligands to the heterodimeric 
cell surface receptors low-density lipoprotein receptor-related 5 (LRP5), LRP6 and Frizzled. This 
induces the family of T cell-specific transcription factors (TCFs) to recruit a β-catenin-dependent 
co-activator complex to activate target gene transcription. Canonical WNT signaling has been 
shown to inhibit adipogenesis [112]. Mice expressing WNT10B, the main WNT ligand expressed 
by preadipocytes, in adipocytes show a decrease in WAT and BAT mass [113]. WNT10B promotes 
osteogenesis in MSCs, indicating that canonical WNT signaling also regulates brown adipogenesis 
and MSC cell fate [114]. WNT signaling maintains preadipocytes in an undifferentiated state 
through inhibition of the adipogenic transcription factors C/EBPα and PPARγ [115]. Repression of 
WNT10B in white primary preadipocytes is required for adipocyte differentiation [116].However, 
there is evidence that the canonical WNT pathway is essential for the survival of pre-adipocyte. 
WNT10B levels increase in confluent cultures of 3T3-L1 cells [115], and WNT1 can protect 
preadipocytes from apoptosis [117]. 
WNT ligands can also signal through β-catenin-independent pathways, a process known as non-
canonical signaling, by signaling through alternative cell surface receptors and activating different 
intracellular pathways. The non-canonical WNT ligand WNT5A activates the histone 
methyltransferase SET domain bifurcated 1 (SETDB1) which involve in inhibiting the ability of 
PPARγ. Thus, WNT5A inhibit the adipogenesis and it can promote osteogenesis in MSCs [118]. By 
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contrast, the non-canonical WNT ligand WNT5B through preventing nuclear translocation of β-
catenin to inhibit the canonical WNT pathway, thereby promoting adipocyte differentiation [119]. 
Despite these main factors gave the field a starting point, other new factors like signal transducers 
and activators of transcription (STATs), Kruppel-like factor (KLF) proteins, TGFβ superfamily 
signaling, the composition and stiffness of the ECM and cell-cell contact and cell shape also play a 
key role to promote preadipocyte differentiation into mature adipocytes [120]; [92]. 
 
2.2 Model systems used to study adipocyte in vitro 
A variety of cellular model systems are used to study the molecular pathways of adipogenesis and 
adipocyte function in vitro. These models can mainly be separated in two categories. The first group 
includes pluripotent fibroblasts that have the ability to differentiate into several cell types, including 
myocytes, chondrocytes, and adipocytes. This group includes the 10T1/2, BALB/c-3T3, RCJ3.1, 
and CHEF/18 fibroblast cell lines. The second group of model systems comprises fibroblast like 
preadipocytes that are committed to differentiating into adipocytes and includes 3T3-L1, 3T3-
F442A, 1246, Ob1771, TA1, and 30A5 preadipocytes. The latter group represents the cells used 
most frequently to study adipogenesis [120]. 
3T3-L1 and 3T3-F442A are the two most extensively characterized and used preadipocyte cell 
lines. Both of these lines were derived from disaggregated 17- to 19-day-old Swiss 3T3 mouse 
embryos [121];[122]. However, unlike 3T3-L1 cells, 3T3-F442A preadipocytes do not require 
glucocorticoid-supplemented differentiation cocktail to induce adipogenesis [123];[124];[125]. It is 
commonly believed that 3T3-F442A precursors are at a more advanced stage of commitment than 
3T3-L1`s. Implantation of 3T3-F442A, but not 3T3-L1, preadipocytes into athymic mice results in 
the generation of ectopic fat that is histologically [126] and biochemically [127] indistinguishable 
from adipose tissue. An original 2D coculture system setup in our laboratory using human breast 
cancer cell lines and in vitro differentiated 3T3-F442A adipocytes mimics the adipocytes changes 
observed at the invasive front of breast tumors [68], underscoring the validity of these mouse 
models in cancer studies. Mature adipocytes can also be obtained from the in vitro differentiation of 
the SVF of adipose tissue (that contains ADSCs) from human and rodents in defined culture 
conditions either in 2D or 3D culture systems [128];[129]. 
A clear limitation of the use of these human and murine pre-adipocyte cell lines and primary 
precursors present in the SVF fraction is that they are not suitable models to study obesity-related 
condition due to their inability to undergo hypertrophy in vitro. Therefore, the use of mature 
adipocytes isolated from AT of lean and obese subjects should be considered. Indeed, the isolation 
of adipocytes from the extracellular matrix and the SVF fraction is a technique available in many 
laboratories whatever the AT considered including MAT [68].Briefly, collagenase treatment of AT 
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release the fat cells from extra-cellular matrix. Fat cells, owing to their own fat content are floating 
and the SVF fraction remains in the pellet [128]. Coculture system using this source of cells to 
obtain insight into the crosstalk with tumor cell population is clearly limited by the fact that these 
isolated mature adipocytes cannot be used for long terms culture. Isolated adipocytes in suspension 
in an appropriate culture medium remain viable for approximately 24 h but after this period both 
survival and function are profoundly altered [128]. Primary culture of AT explants represents a 
useful alternative to both improve adipocyte viability and preserve the entire tissue environment and 
structure. Several laboratories have been using adipose tissue explants culture to study the influence 
of various pharmacological or nutritional factors. Adipocytes can also be isolated from the explants 
after the treatment in order to focus on the fat cell itself [130]. However, such a tri-dimensional 
structure in vitro do not allow an accurate oxygen and nutrients supply during long term periods 
leading to hypoxia-induced alterations of adipocyte function such as for example an increased 
anaerobic glycolysis or TNFα accumulation [131]. Therefore, adipose tissue explants must thus be 
considered as useful over less than 48h period after culture. Again, 3D culture of isolated 
adipocytes from lean and obese subjects on various scaffolds remains the most promising 
alternative for long-term coculture, model which is currently largely untapped with the exception of 
some studies using isolated adipocytes from rat and mice AT [132];[133]. 
 
3. Physiological functions of adipose tissue 
In mammalian cells, lipid droplets (LDs) consist of a core of neutral lipids, predominantly 
triacylglycerols (TAGs) or cholesterol ester, surrounded by a phospholipid monolayer and separated 
from the hydrophilic cytosolic environment by a coat of structural proteins. Several types of 
proteins decorate LDs, including structural proteins which are characterized by the presence of a 
conserved N terminal motif defined as a PAT domain, named after perilipin, adipophilin (also 
called adipocyte differentiation-related protein, ADRP), and tail-interacting protein of 47kDa 
(TIP47) but also including OXPAT/MLDP and S3-12 [134]; Lipid-synthesis enzymes (acetyl 
coenzyme A carboxylase, acyl-CoA synthetase and acyl-CoA: diacylglycerol acyltransferase 2, 
DGAT2) [135]; lipase and membrane-trafficking proteins (Rab5, Rab18 and ARF1) [136]. 
Different LDs in a cell can contain different proteins suggests that cells contain distinct types of 
LDs with specialized functions. 
The neutral lipids that are stored in LDs are used for metabolism, membrane synthesis 
(phospholipids and cholesterol) and steroid synthesis. In addition, LDs have a crucial role in storing 
cholesterol in the form of cholesterol esters, as part of the complex homeostatic mechanisms that 
are involved in regulating the level of intracellular free cholesterol. Indeed, during times of 
increased food intake and/or decreased energy expenditure, surplus energy is deposited efficiently 
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in adipose tissue in the form of neutral triglycerides. This process is mediated by key lipogenic 
enzymes. However, when food is scarce and/or energy expenditure requirements increase, lipid 
reserves are released to provide fuel for energy generation. Therefore, adipocytes also contain 
“lipases” that break down triglycerides into glycerol and fatty acids that can then be transported in 
the blood to the liver, muscle, and BAT, where they are used in fatty acid oxidation. There is also 
evidence that glycerol and FFA can be reesterified in adipocytes, thereby allowing FFA flux to be 
acutely regulated. Therefore, the principal functions of WAT are to store excess energy as 
triglycerides, in large unilocular droplets, to release it in the form of FFA and to secrete large panel 
of adipokines that critical to regulate physiology process. 
 
3.1 Lipid droplet biogenesis  
Despite recent progress in lipid droplet biology (Figure 8), first, we need to solve several 
fundamental questions. 1) How and where are lipid droplets formed? While several theories on lipid 
droplet biogenesis exist, the most widely accepted model states that neutral lipids are synthesized 
between the leaflets of the ER membrane. Fatty acids can be released from TAGs or be synthesized 
de novo from carbohydrates in many cell types, they are carried extracellularly by albumin and 
lipoproteins enter cells to a bioactive pool through conjugation to CoA, forming fatty acyl-CoA, in 
an energy requiring reaction. Fatty acyl-CoA is used by glycerolipid-synthesis enzymes in the ER to 
ultimately generate diacylglycerols (DGs). DGs are either converted to neutral lipids (TGs) by 
DGAT enzymes or enter phospholipid-synthesis pathways. The mature LD is then thought to bud 
from the ER membrane to form an independent organelle that is contained within a limiting 
monolayer of phospholipids and associated LD proteins [137]. Members of both the Rab and ADP-
ribosylation factor (ARF) families of small GTPases, caveolins and phospholipase D (PLD) are 
proteins that intimately linked to vesicular transport, membrane fusion and cytoskeletal motility. 2) 
How lipid droplets growth? One possibility is that LDs, like balloons, expand as single organelles. 
Proteins and newly synthesized lipids could diffuse laterally to the LDs when LDs attached to the 
ER; It is also postulated that smaller LDs from newly formed TAG could fuse together to form 
larger lipid droplets [138]. 3) Does LDs have intimate interaction with other cellular organelles? In 
particular, LDs are often found in close approximation with the ER, mitochondria, endosomes, 
peroxisomes and the plasma membrane [139]. These organelle associations might facilitate the 
exchange of lipids, either for anabolic growth of LDs or for their catabolic breakdown. In addition, 
to help adipocytes deal with large amounts of incoming FAs it has been suggested that both lipid 
droplet biogenesis and growth may occur at the plasma membrane [140]. 
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                              Figure 8. Lipid droplets at a glance. (Yi  Guo, et al, 2009, J Cell Sci) 
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3.2 Fat mobilization from lipid droplets 
The hydrolysis of the triglycerides stored in the fat cell is a complex phenomenon involving lipases, 
plasma membrane transporters, fatty acid binding proteins and proteins associated with the lipid 
droplet. Previously, hormone sensitive lipase (HSL) was considered to be the rate-limiting enzyme 
in TAG hydrolysis [141]. However, HSL knockout mice were not obese and accumulated 
diacylglycerol (DAG) in adipose tissue rather than that TAG, implicating HSL as primarily a DAG 
lipase and suggesting the presence of additional novel lipase in adipocytes. In 2004, a novel TAG 
lipase was reported by three groups and given three different names: desnutrin, adipocyte 
triglyceride lipase (ATGL), and phospholipase A2ζ [459]; [460]; [146], leading to re-evaluation of 
the classic model of lipolysis. ATGL knockout mice have increased fat pad size and accumulate 
excess TAG in most tissues [142]. These mice accumulate so much TAG in the heart that they die 
of congestive heart failure. Like HSL knockout mice, ATGL knockout mice demonstrate 
diminished mobilization of free fatty acids from adipose stores in response to catecholamine. It has 
been proposed that in the mouse, ATGL and HSL act coordinately such that ATGL is the primary 
lipase responsible for hydrolyzing the first fatty acid from TAG and that HSL is the primary DAG 
lipase. Whereas this model applies to lipolysis in humans has been questioned. A competing model 
has been proposed according to which HSL is the primary TAG lipase responsible for 
catecholamine-stimulated lipolysis from adipocytes and ATGL is the primary TAG lipase for basal 
lipolysis [143]. 
In the best-characterized lipolytic pathway, catecholamine binding to β-adrenergic G protein-
coupled receptors on the plasma membrane generates a signaling cascade that activates cAMP-
dependent protein kinase A (PKA) (Figure 9). The anabolic hormone insulin inhibits lipolysis by 
stimulating a phosphodiesterase that breaks down cAMP. PKA activation ultimately leads to the 
hydrolysis of a fatty acids from TAG to yield DAG, from DAG to yield monoacylglycerol, and 
finally from monoacylglycerol to yield the glycerol backbone. The molecular events of this process 
have been under investigation for the past four decades. Lipolytic activation of cultured adipocytes 
is associated with movement of HSL from the cytosol to the surface of lipid droplets, where it acts 
on the neutral lipids within [144]. Perilipin has emerged as a critical organizing component of these 
changes, and serine phosphorylation of perilipin on one or more of six PKA consensus sites is a key 
mediator of this organization. During hormone-stimulated lipolysis in adipocytes, major 
rearrangements take place in the morphology of lipid droplets and in the distribution of lipid 
droplet-associated proteins. Activation of PKA over several hours results in fragmentation of lipid 
droplets, which greatly increases the surface area of droplets available for lipase action. This 
fragmentation is dependent upon phosphorylation of perilipin at serine 492 [145]. 
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In contrast to HSL, ATGL appears to reside on the lipid droplet surface independent of PKA 
activation [146]. Rather than its activation being controlled by phosphorylation and translocation, 
ATGL is activated at least 20-fold by interaction with CGI-58, a member of an esterase/lipase 
family of proteins [147]. Comparative Gene Identification-58 (CGI-58) is also known as α/β-
hydrolase domain-containing protein 5 (ABDH5). CGI-58 lacks lipase activity itself but activates 
the lipase activity of ATGL likely via protein-protein interaction. CGI-58 was shown to bind to 
lipid droplets by interaction with perilipin A in a hormone-dependent way [148]. In nonstimulated 
adipocytes, CGI-58 is tightly associated with the lipid droplet, whereas upon β-adrenergic 
stimulation and concomitant phosphorylation of perilipin, CGI-58 dissociates and becomes 
cytosolic. Once dissociated from perilipin, it colocalizes in close proximity to ATGL [149], 
suggesting the involvement of CGI-58/ATGL interaction in stimulated lipolysis. In summary, in the 
basal state, CGI-58 is closely associated with perilipin A on the lipid droplet where perlipin A has 
barrier function to lipolysis. Hormone sensitive lipase (HSL) is primarily located in the cytosol and 
ATGL is primarily localized to the lipid droplet but not in proximity CGI-58. Here, ATGL mediates 
basal triacylglycerol (TG) hydrolysis, which in the absence of further HSL-mediated diacylglycerol 
(DG) hydrolysis, allows for generation of glycerophospholipids and/or re-esterification into TG. In 
the stimulated state, phosphorylation of perilipin A promotes the release of CGI-58 which then 
translocates to ATGL to promote ATGL-mediated TG hydrolysis. At the same time 
phosphorylation of HSL promotes its translocation to the lipid droplet where it interacts with 
perilipin A to promote DG hydrolysis and hence complete lipolysis.  
Another hormonal lipolytic pathway has been discovered in human fat cells [150]. Atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP) stimulate human fat cell lipolysis as much as 
isoproterenol while C-type natriuretic peptide (CNP) exerted weak effects. Real-time PCR revealed 
that large adipocytes expressed higher mRNA levels of natriuretic peptide receptor (NPR)-A than 
small adipocytes [151]. Cyclic GMP-dependent activation of protein kinase G and phosphorylation 
of HSL occur after ANP stimulation in human adipocytes [152]. In situ microdialysis experiments 
have confirmed the potent lipolytic effect of ANP in abdominal subcutaneous AT of healthy 
subjects and intravenous administration of ANP causes a striking increase in plasma NEFA and 
glycerol levels in normal and obese subjects [153]. 
While the endocrine regulation of lipolysis by catecholamine and insulin has been well 
characterized, much remains to be investigated regarding the local regulation of lipolysis in 
adipocytes by autocrine/paracrine factors, such as: TNF-α, adenosine, prostaglandins and adipocyte-
specific phospholipase A2 (AdPLA) [154];[155]. Other signaling pathways through cytokines, 
growth hormones, AMP-activated protein kinase and nicotinic acid have also been shown to 
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regulate lipolysis [156]. However, future investigation into these pathways will be required to 
establish their relative importance in regulating lipolysis. 
The products of TAG hydrolysis, diacylglycerol (DAG) and free fatty acids, may influence cell 
signaling either directly or via subsequent metabolism, for example to fatty acyl coenzyme A. Free 
fatty acids released from adipose tissue can enter the circulation and be taken up by other organs for 
β-oxidation and subsequent ATP generation. Liberated FAs and glycerol can also serve as 
substrates in the liver for ketogenesis and gluconeogenesis, respectively. Additionally, FFAs may 
influence gene expression by acting as ligands for nuclear receptors, such as the peroxisome-
proliferator activated receptor (PPAR) family. Excess intracellular FFAs can disrupt phospholipid 
bilayer membrane integrity, alter lipid signaling pathways, and induce apoptosis [157]. 
Although, traditionally, mobilization of lipid droplet (LD) by lipolysis has been solely attributed to 
the LD-associated lipases, recent studies have revealed a role for autophagy in LD breakdown 
through a process now described as lipophagy. Lipophagy impacts the cellular energetic balance 
directly, through lipid breakdown and, indirectly, by regulating food intake. Each of the events of 
autophagic process is coordinated by a complex network of more than 32 genes and their protein 
products (autophagy-related genes (ATGs) and proteins (Atgs)). Atgs participate in activation, 
nucleation of the autophagosome membrane that forms de novo through conjugation of proteins and 
lipids from different cellular compartments, elongation of the membrane and sealing to form the 
autophagosome, trafficking toward the lysosomes and fusion of the two membranes [158]. 
Defective lipophagy has been already linked to important metabolic disorders such as fatty liver, 
obesity and atherosclerosis, and the age-dependent decrease in autophagy could underline the basis 
for the metabolic syndrome of aging [159]. 
                    
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
                 
 
 
 
 
 
 
Figure 9. Major pathways involved in the stimulation of human fat cell lipolysis. Signal transduction 
pathways for catecholamines via adrenergic receptors, autacoids- and metabolite-driven inhibitory receptors 
and atrial natriuretic peptides via type A receptor (NPR-A). Protein kinases (PKA and PKG) are involved in 
target protein phosphorylation. HSL phosphorylation promotes its translocation from the cytosol to the 
surface of the lipid droplet. Perilipin  phosphorylation induces an important physical alteration of the droplet 
surface that facilitates the action of HSL and the initiation of lipolysis. Docking of FABP4 to HSL favors the 
outflow from the cell of NEFAs released by the hydrolysis of triacylglycerols. Insulin, via stimulation of fat 
cell insulin receptors and phosphodiesterase-3B stimulation promotes cAMP degradation and antilipolytic 
effects while it is not active on cGMP-dependent pathways. ATGL, adipose triglyceride lipase; FABP4, 
adipocyte fatty acid binding protein; GC, guanylyl cyclase; Gi, inhibitory GTP-binding protein; Gs, 
stimulatory GTP-binding protein; HSL, hormone-sensitive lipase; MGL, monoacylglycerol lipase; NEFA, 
nonesterified fatty acid; NPR-A, type A natriuretic peptide receptor  (M. Lafontan and Langin D, 2009, Prog 
Lipid Res). 
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3.3 Paracrine and endocrine role of adipose tissue 
Adipose tissue is an innervated connective tissue composed of a number of different cell types. 
Besides thought of as a tissue mass that stores excess energy and provides insulation and padding to 
the body, adipose tissue is now accepted to be an endocrine organ that secrets numerous hormones, 
growth factors, matrix proteins, enzymes, and complement factors. These factors are collectively 
referred to as “adipokines”. They play a role by paracrine signals (local effects) or endocrine signals 
(systemic effects) in fat mass regulation and regulation of adipocyte differentiation, vascular and 
blood flow regulation, lipid and cholesterol metabolism, and immune system function. With such 
varied biological functional role, it is likely that these adipokines have a significant role in disease 
processes known to be metabolic consequences of obesity, such as insulin resistance, cardiovascular 
disease, and altered lipid homeostasis. 
The total number of adipokines, both documented and putative, is now well over fifty. The earliest 
to be identified was in practice the enzyme lipoprotein lipase, responsible for the hydrolysis of 
circulating triacylglycerols to NEFA; this was followed in the mid of 1980s by adipsin, a serine 
protease and part of the alternative complement pathway [160]. In 1993, tumor necrosis factor 
(TNF) was identified as a pro-inflammatory product of adipose tissue that is induced in models of 
diabetes and obesity, providing evidence for a functional link between obesity and inflammation 
[161]. Subsequently, leptin was identified as an adipose tissue-specific secreted protein that 
regulates food intake and energy expenditure in an endocrine manner [162]. Similarly, the 
identification of plasminogen activator inhibitor 1 (PAI1), an inhibitor of fibrinolysis, as an 
adipokine that is strongly upregulated in visceral adipose depots in obesity suggested a mechanistic 
link between obesity and thrombotic disorders [163]. At about the same time, the other important 
adipokine adiponectin (also known as ACRP30 and ADIPOQ) was identified which is more 
expressed in SAT [164] ; [165]. Adiponectin expression was found to be decreased in obesity, and 
studies in experimental organisms showed that adiponectin protects against several metabolic and 
cardiovascular disorders that are associated with obesity. The recent discovery of the PGC1α-
dependent myokine FNDC5/irisin is not just a myokine liberated by muscle tissue but also an 
adipokine released by white and to a lesser extent, by brown adipose tissue that is able to stimulate 
brown-fat-like development and thermogenesis in white fat both in vitro and in vivo, it has created a 
new field of research and many expectations in recent months [166]; [167]; [168]. 
From the wide range of protein signals and factors already identified (Table 1, Figure 10) [169], it is 
evident that WAT is a secretory and endocrine organ of considerable complexity which is highly 
integrated into the overall physiological and metabolic control systems of mammals. These results 
were surprising as most adipokines stimulate inflammatory responses, are upregulated in obesity 
and promote obesity-induced metabolic and cardiovascular diseases. Collectively, these findings 
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have led to the notion that metabolic dysfunction that is due to excess adipose tissue mass may 
partly result from an imbalance in the expression of pro-and anti-inflammatory adipokines, thereby 
contributing to the development of obesity-linked complications. Accordingly, the concept that 
adipokines function as regulators of body homeostasis has received widespread attention from the 
research community [77]. 
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Figure 10. The secretory factors of human adipocytes sorted according to a more auto/paracrine or 
more endocrine mode of action (Hauner H, 2004, Physiol Behav).  
 
 
 
          
Table 1. Sources and functions of key adipokines  
 
Apelin 
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4. Different depots of adipose tissue 
4.1 Subcutaneous/Visceral Adipose Tissue (VAT/SAT) 
Fat depots from different region of the body have different incidence in pathology because they 
display distinct functional and structural properties in terms of energy metabolism and bioactive 
molecule release as well. Increased intra-abdominal/visceral fat (central or apple-shaped obesity) 
promotes a high risk of metabolic disease, whereas increased subcutaneous fat in the thighs and hips 
(peripheral or pear-shaped obesity) exerts little or no risk [170]. 
Differences between white adipocytes from visceral and subcutaneous depots have been recognized 
for many years including their unique profiles of adipokines: visceral fat accumulation may induce 
oversecretion of offensive adipokines, such as PAI-1, TNF-α, IL-6, CCL2, and insufficient 
secretion of defensive adipokine, namely adiponectin [77];[171]. In line with these data, obese 
subjects were found to harbour increased AT macrophage content mainly in visceral depots 
(reviewed in [172];[77]) In addition, VAT adipocytes exhibit higher rates of fatty acid turnover and 
lipolysis and augmented plasma FFA and glycerol flux to the portal circulation, which is connected 
directly to the liver. Insulin resistance has been shown to be exacerbated by an increased supply of 
FFA to peripheral tissue and the liver [173]. Some studies indicate that microsomal triglyceride 
transfer protein plays a key role in the lipoprotein assembly of apolipoprotein B and lipids to form 
very-low-density lipoprotein in the liver. This process is considered to be a limiting factor for very-
low-density lipoprotein secretion from the liver to plasma. Matsuzawa et al reported that increased 
FFA influx to the liver from visceral fat may contribute to increase very-low-density lipoprotein 
formation and secretion, and results in hyperlipidemia [174]. Excess glycerol influx to the liver may 
cause hyperglycemia also. VAT adipocytes are also less responsive to the antilipolytic effects of 
insulin and catecholamine than SAT adipocytes [175]. Moreover, it has been observed in obese 
subjects that endothelial cells isolated from visceral fat show a higher expression of genes related to 
angiogenesis and inflammation than endothelial cells from subcutaneous adipose tissue [176]. All 
together these results suggest that visceral fat is more clinically relevant than the subcutaneous fat 
with regard to chronic inflammation and metabolic complication in general. In fact, increase in 
VAT is particularly linked to obesity-related complication such as type 2 diabetes, cardiovascular 
disease and dyslipidemias whereas, storage of fat in subcutaneous adipose tissue (SAT) is linked to 
a lower risk for such conditions [77].  
 
4.2 Mammary adipose tissue (MAT) 
The differential impact of visceral versus subcutaneous fat on health during obesity conditions 
highlight an important concept in adipose tissue biology, namely, that fat in different body locations 
exhibits distinct features and functional characteristics. Regarding this latter point, what is the 
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specificity of MAT? A brief overview of the anatomy of the human adult mammary gland is given 
in order to better understand the particular place of the adipocyte in breast tissues. The mammary 
gland is comprised of myoepithelial and luminal epithelial cells embedded in a complex stroma 
termed mammary fat pad composed predominantly of fibroblasts, adipocytes, and cells of both the 
interspersed vasculature and lymphatic systems [177]. A long-standing line of evidence suggests 
that, at least in rodents, mammary fat pad is essential for the post-natal development of mammary 
epithelium by providing signals mediating ductal morphogenesis [177];[178]. Adipocytes within the 
mammary fat pad specifically participate to the development of the normal mammary gland. For 
example, it has been shown that the total absence of breast fat in transgenic mice prevents normal 
mammary gland development [179]. The mammary adipocytes are very active during the transitions 
from pregnancy to lactation and into involution (corresponding to the post-lactational regression of 
mammary epithelium) underlying their responsiveness to local signals from the epithelium [180]. 
Briefly, during lactation, mammary adipocytes in close proximity to epithelial cells exhibit rapid 
depletion of their lipid storage due to lipolysis. By contrast, the involution period is associated to a 
refilling of mammary adipocytes that is completed approximately within 4 days. Intimate and 
bidirectional interaction with adjacent epithelium is one of the hallmarks of mammary adipocytes, 
suggesting that this dialog might persist in physiopathological conditions such as cancer. It is also 
very important to underline that there is undoubtedly species differences concerning the 
composition and function of mammary fat pad between human and rodents that should be taken in 
account when results obtained in rodents are extrapolated to humans. In contrast to rodents where 
the mammary fat pad consists primarily of adipocytes, human mammary adipose tissue is 
extensively interlaced with a network of fibroblasts and associated connective tissue[178]. 
Therefore, in murine mammary glands, the adipocytes are immediately adjacent to the ductal 
epithelial cells, whereas in human mammary glands, a fibrous layer separates the 2 cell types. In 
addition, it has been clearly shown that human mammary epithelium transplanted into the mammary 
fat pad of mice did not grow out unless human stromal fibroblasts are incorporated into the cleared 
fat pad [181]. 
 
4.3 Bone marrow adipose tissue (BMAT) 
This “nontypical” AT consists of smaller adipocytes loosely bound together when compared to the 
classical collagen-driven shape of those found elsewhere. BM mature adipocytes possess unique 
profiles and have been proposed to exhibit features of both WAT and BAT [182]. BM adipocytes 
might provide nutrients and secrete adipokines to support hematopoiesis when required [183]. 
However, the number of BM mature adipocytes correlates inversely with the hematopoietic activity 
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of the marrow (seen for example during aging) and a very elegant study has recently demonstrated 
that adipocytes act as negative regulators of normal hematopoiesis [184]. 
 
5. Adipose tissue in the obese individual 
Obesity is a problem of epidemic proportions in many developed nations. Both fat mass and 
distribution can be measured by magnetic resonance imaging (MRI) and Dual-Energy X-Ray 
Absorptionmetry (DEXA), but for most purposes, simpler surrogate measurements such as body 
mass index (BMI=weight in kg/height in meters
2
) and waist-hip ratio (WHR) or waist 
circumference are used. The WHO classifications of BMI ranges are shown below [185]. 
 
BMI (kg/m2)      WHO classification               Popular description 
< 18.5                    Underweight                                   Thin 
18.5–24.9          Normal range ‘Healthy’     ‘normal’ or ‘acceptable’ weight 
25.0–29.9          Grade 1 overweight                      Overweight 
30.0–39.9          Grade 2 overweight                         Obesity 
≥ 40.0                Grade 3 overweight                    Morbid obesity 
 
According to the World Health Organization (WHO), there are currently more than 1.6 billion 
overweight (BMI ≥ 25kg/m2) adults and at least 400 million of these are obese (BMI ≥ 30kg/m2). 
Moreover, they predict that by 2015 there will be 2.3 billion overweight and more than 700 million 
obese adults worldwide (http://www.who.int/mediacentre/factsheets/fs311/en/index.html). The 
prevalence of obesity and its associated disorders is increasing at an accelerating and alarming rate 
worldwide.  
The increase in adipose tissue (AT) mass is a result of an increase in adipocyte size (‘hypertrophy’) 
and/or number (‘hyperplasia’). Healthy adipose tissue expansion consists of an enlargement of 
adipose tissue through effective recruitment of adipose progenitors, along with adequate angiogenic 
response, appropriate induction of ECM remodeling as well as minimal inflammation. In contrast, 
during the progressive development of obesity, pathological expansion of adipose tissue consists of 
massive enlargement of existing adipocytes, limited angiogenesis followed by hypoxia, massive 
inflammation, oxidative stress and fibrosis [172]. The sequence of events might be that as the tissue 
expands, the vasculature (which is less extensive in WAT than in brown fat) is insufficient to 
maintain normoxia throughout the organ. Clusters of adipocytes then become relatively hypoxic, 
and an inflammatory response ensues which serves to increase blood flow and to stimulate 
angiogenesis. Immunoreactive HIF-1 has been reported in 3T3-F442A adipocytes and hypoxia 
results in an increase in the amount of this protein in the cultured cells. Furthermore, hypoxia leads 
to an induction of leptin and VEGF expression in these adipocytes, raising the likelihood that a low 
oxygen tension leads to the stimulation of angiogenesis in adipose tissue through the HIF-1 
45 
 
pathway [186]. This results in an increased rate of apoptosis, ultimately triggering the local 
accumulation of inflammatory cells into adipose tissue. 
In another way, in hyperplastic obesity, adipocytes secrete Monocyte Chemoattractant Protein-1 
(MCP-1), which attracts macrophages regulating the inflammatory characteristics of AT [187]; 
[188]. Elevated levels of MCP-1 have been found in the plasma and AT of obese humans and 
animals [189]. Adipose tissue in obese individuals and in animal models of obesity is infiltrated by 
a large number of macrophages, and this recruitment is linked to systemic inflammation and insulin 
resistance. One hallmark of obesity-associated inflammation is the recruitment of macrophages into 
adipose tissue, where they form characteristic “crown-like” structures (CLSs) around apoptotic 
adipocytes (Figure 11) [190]. Because a key function of macrophages is to remove apoptotic cells in 
an immunologically silent manner to prevent the release of noxious substances, it is reasonable to 
speculate that the presence of crown-like structures in adipose tissue reflects a pro-inflammatory 
state that is due, in part, to an impairment of the macrophage-mediated phagocytic process. CLSs 
are 30 times more numerous in obese fat than in lean fat both in mice and human [191]. CLS 
density is positively correlated with adipocyte size in both the subcutaneous and visceral fats of 
obese mice. However, in adipocytes of the same size, CLS density is higher in visceral fat, 
suggesting that visceral adipocytes are more fragile and reach a critical size that triggers death, 
termed the ‘critical death size’ (CDS), earlier than subcutaneous adipocytes [85]. Adipocytes in 
most visceral depots are smaller than subcutaneous adipocytes. Brown adipocytes that have been 
converted into white adipocytes are smaller; thus, one possible explanation of the differences in 
size, expandability and, consequently, CDS, is that visceral adipocytes may be brown adipocytes 
that have been converted to white adipocytes [192]. This theory could offer an explanation of the 
well known higher morbidity potential of visceral fat [193]. 
Different subsets of macrophage are involved in obesity-induced adipose tissue inflammation. 
Macrophages that accumulate in the adipose tissue of obese mice mainly express genes associated 
with an M1 or ‘classically activated’ macrophage phenotype, whereas adipose tissue macrophages 
from lean mice express genes associated with an M2 or ‘alternatively activated’ macrophage 
phenotype [194]. Stimulation with T helper 1 (TH1)-type cytokines, including interferon-γ (IFNγ), 
or with bacterial products leads to the generation of M1 macrophages, which produce pro-
inflammatory cytokines (including TNF and IL-6), express inducible nitric oxide synthase (iNOS) 
and produce reactive oxygen species (ROS) and nitrogen intermediates [195]. By contrast, 
macrophages are polarized to the M2 phenotype by TH2-type cytokines such as IL-4 and IL-13. M2 
macrophages can upregulate production of the anti-inflammatory cytokine IL-10 and downregulate 
synthesis of pro-inflammatory cytokines. Functionally, M2 macrophages are associated with the 
repair of injured tissues and the resolution of inflammation. So, it has been suggested that M1 
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macrophages promote insulin resistance and M2 macrophages protect against obesity-induced 
insulin resistance [196]. 
 
 
 
 
 
 
 
    
Figure 11. Phenotypic modulation of adipose tissue. Adipose tissue can be described by at least three 
structural and functional classification: lean with normal metabolic function, obese with mild metabolic 
dysfunction and obese with full metabolic dysfunction. In states of obesity, adipose tissue generates large 
amounts of pro-inflammatory factors. Metabolically dysfunctional adipose tissue can be associated with 
higher levels of adipocyte necrosis, and M1 macrophages are arranged around these dead cells in crown-like 
structures (Ouchi N et al., 2011, Nat Rev Immunol). 
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6. Relationship between obesity and breast cancer 
Obesity leads to dysfunctional adipose tissue. Dysfunctional adipocytes are less efficient at 
fulfilling their primary functions: lipid storage and secretion of a complement of beneficial 
secretory products, fulfilling their important endocrine role [171]. Dysfunctional adipose tissue has 
been widely appreciated as a major cause of obesity-related metabolic disorders, including insulin 
resistance, type 2 diabetes and cardiovascular disease and it plays a pivotal role in obesity-related 
carcinogenesis due to inappropriate release of mitogenic and proinflammatory factors [171]. Several 
epidemiological studies demonstrate positive associations between the prevalence of obesity as 
judged by increased BMI, cancer incidence, and cancer-related mortality [185]; [197]; [198]; [199]. 
More specifically, one of the most rigorous meta-analysis studies to data revealed strong 
associations of overweight or obesity with an increased risk of a subset of cancers, such as thyroid, 
colon, and renal cancers, and esophageal adenocarcinoma, leukemia, and non-Hodgkin lymphoma 
in both sexes; rectal and malignant melanoma in men; as well as endometrial, pancreas, ovarian, 
and breast cancers in women [198]. Obesity-associated colon, breast, and endometrial cancer 
incidence in women is critically dependent on menopausal status [197] (table 2). Although obesity 
affects tumor incidence, the correlation of elevated body fat mass with cancer-related mortalities 
has also been described for many cancers. Obesity accounted for a 52% higher (in males) and an 
88% higher (in females) mortality rate across all cancers [199]. Although the epidemiological 
evidence connecting obesity with cancer incidence is strong, the underlying mechanistic basis 
linking obesity per se to tumor-initiating events remains largely elusive.   
At anatomical levels, the breast epithelial ducts and lobules are invested with a dense connective 
tissue matrix outside of which islands of AT occupy a large proportion of the stroma. 
Adipocytes/obese may fully exert their endocrine/paracrine role to influence the breast cancer 
progression. So, my work is focusing on the crosstalk between breast cancer and it`s surrounding 
adipocytes. 
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Table 2. Relative risk of cancer incidence and mortality in association to obesity (Park J, 2011, Endocr 
Rev). 
 
6.1 Breast cancer at a glance 
Breast cancer is a complex disease including clinical, morphological and molecular very distinct 
entities. This heterogeneity cannot be explained only by clinical parameters such as tumor size, 
lymph node involvement, histological grade, age; or by biomarkers like estrogen receptor (ER), 
progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) routinely used in the 
diagnosis and treatment of patients. It is the female gender malignant neoplasia with the highest 
incidence in the industrialized world. In the United States, breast cancer is the second leading cause 
of cancer death in women. In 2011, an estimated 230,480 invasive breast cancers and 57,650 in situ 
breast cancers were diagnosed in women, and 39,520 deaths resulted from this disease in the United 
States [200]. 
The hierarchical cluster analysis revealed six molecular subtypes: Basal-like, HER2, Luminal A, 
Luminal B, Claudin-Low and normal breast. The different molecular subtypes were associated with 
different prognosis [201] (table 3). About 60% of breast carcinomas are hormone-dependent. Thus, 
weight increase and obesity, subsequent to menopause, have been identified as the most important 
risk factor for breast cancer in postmenopausal women [202]. Overall, there is a 12% increased 
breast cancer risk for overweight, and a 25% increased risk for obese, postmenopausal women. 
Weight gain after menopause also causes a considerable increase in the risk of developing breast 
cancer. Women who gain at least 22 kg have an 18% increase in risk, and a gain of 55 kg or more is 
associated with a 50% risk increase [203]. While some studies indicate that obesity in 
premenopausal women inversely correlates with breast cancer incidence [202]; [204], obesity is 
associated with poor prognosis for both pre- and postmenopausal breast cancer patients [458]. Three 
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main mechanistic connections have been suggested that may causally invoke obesity with breast 
cancer progression. These include: 1) changes in the levels of adipocyte-derived factors by 
endocrine /paracrine actions; 2) sex hormones; 3) alterations in signaling events along the insulin 
and IGF-I axis [185]. We will extend the discussion to recent advances highlighting evidence for 
direct contributions of the adipocyte toward cancer progression. 
 
 
Table 3. Features of molecular subtypes of breast cancer (Eroles P, 2012, Cancer Treat Rev). 
 
 
6.2 How do adipocytes influence breast cancer biology? 
6.2.1. Endocrine effects of dysregulated adipocytes 
Notably, endocrine signals such as adipokines, other hormones, inflammatory cytokines and lipid 
metabolites are produced by adipose tissue both proximal and distal to the tumor mass. The 
paracrine effect on breast tumor progression will be discussed in the next chapter. 
Adipokines 
Adipose tissue dysfunction results in altered serum levels of adipokines, and these changes may be 
directly involved in obesity-related tumorigenesis. Here, we limit our discussion on two key 
adipokines, adiponectin and leptin, both of which play an important role in tumor development and 
progression. 
 
Leptin:  
Leptin, a 16 kDa adipokine produced by WAT, plays a critical role in the regulation of body weight 
and energy balance by inhibiting food intake and stimulating energy expenditure. Under normal 
conditions, leptin functions as an energy sensor and signals the brain to reduce appetite (circulating 
leptin levels are actively transported through the blood-brain barrier and activates the hypothalamic 
anorexigenic neurons POMC/CART while inhibiting orexigenic NPY/AgRP neuropeptides leading 
to decreased appetite). In the obese state, however, leptin concentrations positively correlate with 
total body fat mass suggesting that resistance to leptin action develops with chronic overfeeding and 
obesity. The release of leptin is stimulated by insulin, glucocorticoids, TNF-α and estrogens [205]. 
Over time, it became apparent that leptin receptors were expressed in many normal cell types 
throughout the body as well as in malignant cells, and the addition of leptin to cells in culture was 
found to promote proliferation and to inhibit apoptosis [206]; [207]. Whereas leptin is localized to 
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the cytoplasm of breast cancer cells, the leptin receptor is both cytoplasmic and membrane bound. 
The leptin receptors (OB-R) have been identified in human breast tumors [208] and increased 
expression of the leptin receptor in mammary tumors may be associated with poor prognosis. It has 
been suggested that leptin induced proliferation of breast cancer cell lines, by activating JAK2-
STAT3, PI3K-AKT-GSK3, ERK1/2, and AP-1 pathways, increasing the expression of proteolytic 
enzymes that are essential in metastatic process and stimulating angiogenesis, which is needed for 
tumor growth [209]; [210]. Specifically, in estrogen receptor-positive human breast cancer cell 
lines, leptin exerts its effects through activation of MAPK pathway. Leptin itself can also enhance 
aromatase activity in MCF-7 cells and increase the production of estradiol or activate the telomerase 
which also promotes cell proliferation [211]. HER2/neu (human epidermal growth factor receptor 
2) is a tyrosine kinase receptor that is homologous to the epidermal growth factor receptor, and its 
overexpression in breast tumors is associated with poor prognosis and invasive breast cancers [212]. 
In a recent study, leptin was shown to transactivate HER2/neu and enhance the growth of breast 
cancer cells with HER2/neu overexpression [213]. Maybe through HIF-1 and NF-κB, leptin 
upregulates VEGF in human and mouse mammary tumor cells, which has been linked to worse 
prognosis of breast cancer [214]. 
 
Adiponectin: 
Adiponectin is one of the most abundant adipokine mainly secreted by adipose tissue, and to a small 
degree also produced by cardiac myocytes, muscle cells and endothelial cells [215]. The molecular 
assembly of adiponectin is complex. There are three major oligomeric forms of adiponectin: a low-
molecular-weight (LMW) trimer, a middle-molecular-weight (MMW) hexamer, and a high-
molecular-weight (HMW) multimer. LMW oligomers are the predominant form in the circulation, 
whereas the majority of intracellular adiponectin consists of HMW oligomers. However, the ratio, 
and not the absolute amounts, of these two oligomeric forms (HMW/LMW), is critical in 
determining insulin sensitivity [216]. Following secretion from the adipocyte, adiponectin 
undergoes posttranslational modifications to generate globular, low and high molecular weight 
isoforms that bind to one of two adiponectin receptors, adipoR1 and adipoR2 [217]. While both 
receptors are ubiquitously expressed, adipoR1 is found mostly in skeletal muscle and adipoR2 is 
found mostly in the liver.  
In contrast to leptin, circulating levels of adiponectin are negatively associated with obesity, BMI, 
visceral fat accumulation and insulin resistance [218].  Plasma concentrations of adiponectin are 
reduced in obesity and clinical studies point out an inverse relation between serum levels of 
adiponectin and the risk of breast, endometrial, prostate, colorectal, and kidney cancer. Several 
case-control studies have observed that serum adiponectin levels were significantly lower in women 
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with postmenopausal breast cancer compared with controls [219]. In addition, women with 
aggressive breast tumors are more likely to be those with low serum adiponectin concentrations 
[220]. In vitro studies have demonstrated that adiponectin treatment suppressed cell proliferation 
and caused cell growth arrest and apoptosis in breast cancer cells [221]. The exact mechanism of 
tumor inhibition with adiponectin treatment is not clear but probably involves adiponectin and the 
adiponectin receptors, since it has been observed that a number of human cancers express both 
adipoR1 and aipoR2 at very high level [222]; [223]; [224]; [225]. AdipoR1 and adipoR2 mediates 
the activation of AMP-activated protein kinase (AMPK). Activated AMPK plays an important role 
in the regulation of growth arrest and apoptosis by stimulating p53 and p21 [226]. Independent of 
AMPK activation, adiponectin decreases the production of reactive oxygen species (ROS), which 
may result in decreased activation of mitogen-activated protein kinases (MAPK) and thereby 
inhibition of cell proliferation [227]; [219]. Moreover, adiponectin has been shown to inhibit 
endothelial NF-κB signaling and to markedly reduce TNF-α production in cultured macrophages. 
Adiponectin deficient mice have increased levels of TNF-α mRNA in adipose tissue and higher 
TNF-α circulating levels [228]. Adiponectin also induces human leukocytes to produce IL-10, IL-
1RA [229]. Taken together, all these results indicate that adiponectin could play potent anti-
inflammatory role in cancer. 
In conclusion, the decreased plasma levels of adiponectin and increased of leptin in obesity may be 
associated with the increased risk of cancer in obesity. Thus, it has been proposed that upregulation 
of adiponectin levels and downregulation of leptin might be of therapeutic use in the prevention or 
treatment of some cancers [219]. 
 
Other hormones 
WAT can secrete different sex steroids. Obesity is associated with an increased serum concentration 
of estradiol and estrone and a decreased serum concentration of testosterone. Estrogens promote cell 
proliferation and growth, and are important in developing and maintaining the normal breast. 
However, studies have shown that estrogen also has important roles in the induction and 
maintenance of breast cancer [230]. Estrogen receptor (ER) status is closely related to prognosis; 
that is, ER-negative tumors tend to have a worse prognosis than do ER-positive tumors [231], in 
part because ER-negative tumors do not respond to important anticancer therapies such as 
tamoxifen. For postmenopausal breast cancer, the increased risk observed in obese women is 
generally explained by the higher rates of conversion of androgenic precursors to estradiol through 
increased aromatase enzyme activity in adipose tissue [232]. In addition, obesity is associated with 
increased insulin and bioactive IGF-1 levels which down-regulate the concentration of the 
circulating sex hormone-binding globulin, resulting in an increased fraction of bioavailable 
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estradiol, but decreased testosterone production [233]. Indeed, overweight or obese postmenopausal 
women exhibit a threefold increased risk for developing breast cancer compared with normal-
weight postmenopausal women [234]. Aromatase in breast adipose tissue versus at other body sites 
might have a substantially higher impact on carcinogenesis because of its proximity to the ductal 
epithelial cells. In fact, the use of aromatase inhibitors that block aromatase activity in the breast 
and the periphery as an effective hormonal treatment of postmenopausal breast cancer has been 
reported that leads to reduce the amount of local estrogen production—which in turn helps to 
suppress recurrence of the breast tumors [234]. 
 
6.2.2 Chronic inflammation 
It is well recognized that inflammation is involved in the promotion and progression of cancer. 
Inflammatory responses play decisive roles at different stages of tumor development, including 
initiation, promotion, malignant conversion, invasion and metastasis. They also affect immune 
surveillance and responses to therapy [235]. Obesity is associated to systemic low-grade 
inflammation, which has been suggested to have an important role in the pathogenesis of some 
disorders such as insulin resistance, atherosclerosis and cancer [236]. In obesity, the expanding 
subcutaneous and visceral AT makes a different substantial contribution to the development of 
obesity-linked inflammation via enhanced secretion of VEGF, HGF, PAI1, Apeline and leptin in 
subcutaneous AT and enhanced secretion of pro-inflammatory cytokines (IL-6, TNF-α), chemikines 
(MCP-1) and adipokines (HGF, PAI-1, leptin, Apeline and VEGF) and both the reduction of anti-
inflammatory adipokines (adiponectin) (Figure 12) [237]; [238].The precise role of these factors as 
described in Figure 13. Very interestingly, several recent publications have shown that a sub-
inflammatory state is observed in the mammary adipose tissue (MAT) of obese versus lean 
individuals (using both human and mouse models) and that in humans, the severity of breast 
inflammation was correlated with both BMI and breast adipocytes size [239]. 
  
 
 
53 
 
                                               
Figure 12. The secretion of adipocytes depend on the origin of adipose tissue and weight status. 
(Laurent V et al, 2013, Médecine/sciences)     
  
                                        
Figure 13. Potential pathways directly linking obesity with cancer. AdipoR1/R2, adiponectin 
receptor1/2; AMPK, 5’-AMPactivated protein kinase; IGF-1, insulin-like growth factor-1; IKK, IκB kinase; 
IR, insulin receptor; JAK, Janus kinase; MAPK, mitogen-activated-protein-kinase; mTOR, mammalian 
target of rapamycin; ObR, leptin receptor; STAT, signal transducer and activator of transcription 3; TRAF2, 
TNF receptor-associated factor 2; TSC2, tuberous sclerosis complex 2; uPA, urokinase-type plasminogen 
activator; PI3K, phosphatidylinositol 3-kinase; NF-κB, nuclear factor- κB  (Pedro L, et al, 2011, Biochim 
Biophys Acta). 
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6.2.3 Adipose tissue angiogenesis and hypoxia 
It is now clear that oxygen levels are substantially lower in the white adipose tissue of obese mice 
compared with lean mice (15.2mm Hg versus 47.9mm Hg) [240] due to the inability of the 
vasculature to keep pace with adipose tissue growth. Adipose tissue hypoxia (ATH) is a key factor 
in the development of systemic insulin resistance, regulation of chronic inflammation, and reduced 
adiponectin and increased leptin gene expression [241].  Therefore ATH might contribute to cancer 
progression. Hypoxia occurs in solid tumors when the consumption of oxygen exceeds its delivery 
by the vascular system. In most large clinical studies, the prognosis is worse for patients with 
hypoxic tumor [242]. Furthermore, hypoxia leads to resistance to radiotherapy and anticancer 
chemotherapy, as well as predisposing for increased tumor metastasis [243]; [244]; [245]; [246]. 
The expansion of adipose tissue is like the propagation of a solid tumor: rapid growth induces 
hypoxia that in turn induces angiogenesis, which fuels more growth [247]. 
Angiogenesis—the process of new blood vessel formation—plays a critical role in tumor 
expansion. Once a tumor exceeds a few millimeters in diameter, hypoxia and nutrient deprivation 
triggers an “angiogenic switch” to allow the tumor to process [248]. The expansion of adipose 
tissue under conditions of nutritional excess is however highly dependent upon angiogenesis. 
Different fat pads vary with respect to their degree of angiogenic potential [172]. Adipocytes, 
adipose stromal cells and inflammatory cells produce multiple angiogenic factors (VEGFA and 
FGF2), adipokines (letpin, resistin and adiponectin) and cytokines (IL-6) all of which stimulate 
angiogenesis and contribute to an overall pro-angiogenic microenvironment [249]. One study 
recently showed that postmenopausal obesity (ovariectomy/high-fat diet) significantly promotes 
breast tumor angiogenesis, which is associated with increased VEGF protein levels in plasma and 
breast tumors in comparison with those in the control mice (ovariectomy/low-fat diet) [250]. 
 
6.2.4 Lipids metabolites 
In the obese, insulin-resistant state, an increased rate of lipolysis is observed in adipocytes. As a 
result, lipid metabolites such as FFA are elevated in circulation, which in turn exacerbates insulin 
resistance further. In addition, several lipid metabolites, such as diacylglycerol and ceramide that 
are released from adipocytes, serve as secondary messengers in signaling pathways that are 
involved in cell proliferation, growth, and apoptosis. Such key signaling pathways include the 
PI3K, the protein kinase C, and the NF-κB inflammatory pathways [251]; [252]; [253]. Moreover, 
FFAs can also serve as ligands for the toll-like receptor 4 (TLR4), thereby induced insulin 
resistance through saturated fatty acid-induced ceramide biosynthesis, further establishing the tight 
link of elevated FFA and insulin resistance [254]. Enhanced lipolysis in host tissues can potentially 
fuel tumor growth by releasing free fatty acids (FFAs) from host adipocytes to be recycled via β-
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oxidation in cancer cell mitochondria. The metabolic interactions between adipocytes and cancer 
cells (see in the third part), are consistent with the “metabolic symbiosis” between cancer cells and 
host stromal cells.  
 
7. Paracrine role of adipocytes in tumor progression 
As stated in the first part of the introduction, the tumor progression is highly dependent on 
heterotypic cell signaling from microenvironment. In fact, an understanding of cancer is impossible 
without a comprehensive description of the tumor microenvironment. Most studies of the tumor 
microenvironment that focused on the tumor-promoting role of cancer-associated fibroblasts (CAF). 
With obesity and its pathophysiological sequelae still on the rise, the adipocyte is increasingly 
moving center stage in the context of tumor stroma-related studies. Moreover, at anatomical levels, 
the breast epithelial ducts and lobules are invested with a dense connective tissue matrix outside of 
which islands of AT occupy a large proportion of the stroma. We have already discussed the 
endocrine effect of dysregulated adipocytes on breast carcinoma, to better understanding the link 
between obesity and breast cancer progression, it is important to decipher the paracrine interaction 
between tumor cells and it`s surrounding adipocytes. 
 
7.1 Evidence for the role of the adipocytes in breast cancer  
There are long standing arguments in the literature showing that fat tissue is able to support and 
amplify breast cancer progression. As early as in 1992, Eliott and colleagues showed that the 
murine breast carcinoma SP1 cell line grew best when injected in the mesenteric and ovarian fat 
pads and in the mammary gland, but very poorly in the subcutis or peritoneal cavity, and it was 
proposed that the adipose tissue exerts an estrogen-dependent positive regulatory effect on SP1 
[255]. The positive influence of the local mammary fat-rich microenvironment on breast cancer 
growth is also sustained by the increase in xenograft success in mice when orthotopic, rather than 
subcutaneous, injections are employed [256]. An in vivo coinjection system using 3T3-L1 murine 
adipocytes and SUM159PT human breast cancer cells to recapitulate heterotypic crosstalk 
occurring in primary breast tumors has demonstrated that adipocytes favor tumorigenesis [257]. 
Except in vivo evidence, in vitro cell models which exclude other local or systemic factors might 
interfere have been designed to uncover the intrinsic properties and functions of adipocytes in breast 
cancer progression. One of the first evidence of their role in breast cancer progression came from 
the study of Manabe et al [258] showing that the rat mature adipocytes, but not the preadipocytes, 
promote the growth of several ER-positive breast cancer cell type. The same year, the pioneering 
study of the group of P. Scherer demonstrated that the full complement of adipokines, represented 
by the conditioned-medium of mature 3T3-L1 murine adipocytes, showed an unparalleled ability to 
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promote the growth, cell motility and invasion of estrogen-receptor –negative and positive breast 
cancer cells in vitro [257]. In our laboratory used 2D coculture system in which adipocytes and 
breast cancer cells were separated by an insert was set up to mimic the adipocyte-cancer cell 
crosstalk at the invasive front [68]. Using this original model, we extensively described tumor-
induced changes in adipocytes that are reproducibly displayed by both mouse and human mammary 
adipocytes. Consistent with the name already used for fibroblasts surrounding tumors (Cancer-
Associated Fibroblast, CAFs) or with macrophages of the tumor microenvironment (Tumor-
Associated Macrophages, TAMs), we named these cells Cancer-Associated Adipocytes (CAAs). 
These adipocytes promote breast tumor cell invasion both in vitro and in vivo (see paper 1). 
Combined, these studies shed in light the crosstalk between adipocytes and breast cancer cells and 
underscore the need to fully understand the role of this heterotypic signaling in modulating tumor 
behavior.  
 
7.2 Paracrine role of adipocytes 
Found at invasive fronts of human breast tumors (Figure 14), the key features of CAAs are decrease 
in size, delipidation, and loss of terminal differentiation markers (PPARγ, ap2, C/EBPα, resistin and 
HSL), over-expression of inflammatory cytokines (such as IL-6 and IL-1β) and proteases (such as 
MMP-11 and PAI-1) and overexpression of ECM and ECM-related molecules [69]; [70]. These 
“activated state” of CAAs strongly enhancing the malignance of tumor through implicated 
mechanism described below. 
 
A.   B.  
 
 
Figure 14. Histology of the invasive front and the center of a human breast carcinoma. 
Hematoxylin-wosin histological examination. A, The invasive front of a primary tumor. Features of 
connective tissues are dramatically modified in response to cancer cell local invasion. Most importantly, 
CAAs located at the interface of invading cancer cells exhibit reduced size in comparison with normal 
adipocytes located at a distance; B, the center of the same tumor shows accumulation of firoblasts/CAFs, and 
adipocytes are no longer present. 
 
                              
Invasive front Tumor center 
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ECM remodeling-related factors 
A very important aspect of this crosstalk is an extensive remodeling of the ECM. It has been shown 
that collagen VI (COLVI) is abundantly expressed in tumor-surrounding adipocytes and adipocyte-
derived COLVI is involved in mammary tumor progression in vivo [257]; [69]. COLVI is 
composed of three chains: α1, α2, and α3, which associate to form higher-order complexes. Human 
breast cancer surrounding adipocytes exhibit increased COLVIα3 expression [257]. In vitro 
recombinant COLVI promotes GSK3β phosphorylation, β-catenin stabilization, and increases β-
catenin activity in breast cancer cell lines, resulting in increased cell proliferation [257]. 
Accordingly, collagen (-/-) mice in the background of the mouse mammary tumor virus/polyoma 
virus middle T oncogene (MMTV-PyMT) mammary cancer model demonstrate dramatically 
reduced rates of early hyperplasia and primary tumor growth [69]. More recently, Scherer et al have 
shown that the cleaved C5 domain of the COLVIα3 chain (COL6A3-C5, a fragment referred to as 
“endotrophin”) augments fibrosis, angiogenesis, and inflammation, and is associated with more 
aggressive mammary tumor growth and metastasis in the MMTV-PyMT mouse model [259]. In the 
same way, adipocytes at the invasive front of human tumors consistently exhibit increased 
expression of metalloprotease 11 (MMP-11)/stromelysin 3 [70].  Part of the MMP-11 effect could 
be relied on COLVI since MMP-11 is able to cleave the native α3 chain of collagen VI [260]. 
Increase local fibrosis and its permanent remodeling (generating ECM components functioning as 
signaling molecules) have been clearly implicated in tumor progression. This association seems to 
justify prominently, the role of both COLVI and MMP-11 over-expression in a tumor context. In 
addition, these events might directly contribute to the occurrence of the CAA phenotype since 
adipocytes actively reorganize the ECM during differentiation processes. For example, it has been 
shown that MMP-11 is a potent negative regulator of adipogenesis [70]. In fact, a relative degree of 
“dedifferentiation” is one of the hallmarks of CAAs [68]. 
 
Inflammatory factors and EMT 
The second major event that takes place in CAAs is the occurrence of an inflammatory phenotype. 
The pleiotropic cytokine IL-6 has many homeostatic functions, including roles in B-cell 
development, myeloid lineage maturation, acute phase immune responses, hepatic function, and 
bone absorption [261]. Multiple studies have established IL-6 as a potent growth factor for several 
cancers, including multiple myeloma [262], prostate cancer [263], cholangiocarcinoma [264], and 
breast cancer [265]. With respect to breast cancer, elevated IL-6 serum levels are known to correlate 
with disease staging and unfavorable clinical outcomes in women with metastatic disease [266]; 
[267]. One of the studies determined that IL-6 promoted growth and invasion of breast cancer cells 
through signal transducer and activator of transcription 3 (STAT3)-dependent upregulation of 
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Notch-3, Jagged-1, and carbonic anhydrase IX [268]. We have shown that CAAs overexpress IL-6 
both in vitro and in vivo and that, in the coculture system, IL-6 blocking antibody inhibits the 
CAAs-dependent proinvasive effect [68]. Interestingly, the human breast tumors of larger size 
and/or with lymph nodes involvement exhibit the higher levels of IL-6 in tumor surrounding 
adipocytes [68]. Such an inflammatory state in the tumor-surrounding adipose tissue has also been 
described for other cancers. High levels of IL-6 were found in the periprostatic adipose tissue of 
tumor-bearing patients and the levels of IL-6 correlated with the aggressiveness of the prostate 
tumor [269], and ovarian cancer cells preferentially migrate towards omental adipocytes-
conditioned medium rather than to adipocytes from other sources in a CXCR-1/IL-8 axis-dependent 
manner [71], highlighting the importance of this cytokine in the adipocyte/cancer cross-talk.     
Breast cancer cells that become invasive and transgress the ductal boundary come into contact first 
with the local adipose tissue. Epithelial-mesenchymal transition (EMT) permits temporally and 
spatially controlled cell migration and differentiation in normal embryogenesis. EMT is a process of 
epithelial cell trans-differentiation to a mesenchymal phenotype that decreases cell-cell adhesion 
properties and increases cell motility. This process is aberrantly reactivated in cancers and plays a 
role in metastasis [270]; [271]. The EMT process can be stimulated by IL-6 [272], IL-8 [273], 
CCL5 [274], and CCL2 [275]. Cancer-associated adipocytes may contribute to the acquisition of an 
EMT phenotype and promote invasion and metastasis of breast and other types of cancer cells 
through secretion of cytokines. In our lab, we have shown that coculturing breast cancer cells and 
adipocytes increases the expression of IL-6 and IL-1β, which contribute to cancer cell invasion both 
in vitro and in vivo [68]. Interestingly, this required bidirectional crosstalk between the CAAs and 
the tumor cells, since adipocytes lacking prior tumor cell contact did not produce factors necessary 
to enhance tumor invasion and metastasis.  
 
Adipokines 
Supported by epidemiological evidence, animal models and in vitro studies, two adipokines leptin 
and adiponectin have been largely involved in breast cancer occurrence and progression [171]; 
[276]. Schematically, leptin appears to promote tumor growth by mainly stimulating the activity of 
signaling pathways involved in proliferation process whereas adiponectin repressed proliferation, 
and induced apoptosis, in breast cancer cells [171]; [276]. The paracrine local implication for these 
adipokines in breast cancer cells appears to be weaker, or at least less characterized, than their 
endocrine effects. We found that CAAs exhibit a decrease in late adipose markers including leptin 
(Dirat et al, unpublished results), suggesting that this adipokine is not primarily involved in the 
negative cross-talk between adipocytes and breast cancer cells at the invasive front. By contrast, 
adiponectin expression is absent in CAAs suggesting that its negative effect on tumor progression 
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might be hampered in these tumor-modified adipocytes [68]. CAAs derived-factors might also 
affect in turns the secreted profile of tumor cells. For example, it has been shown that adipocytes 
stimulate the expression of genes related to immune function and wound healing in tumor cells, 
such as the chemokine CCL-20, the macrophage inhibitory cytokine 1 (MIC-1) or even IL-6 [277]; 
[278], contributing, among others things, to increase tumor invasiveness.  
 
Antitumor therapy 
Finally, one probably underestimated effect of adipocyte/cancer crosstalk is its role in the response 
to antitumor therapy. In our lab, we have recently shown that CAAs contributes to the occurrence of 
a radioresistant phenotype in breast tumor cells [279]. In a different tumor model (i.e. leukaemia) it 
has been demonstrated that adipocytes impairs leukaemia treatment by Vinca alkaloids both in vitro 
and in vivo [280]. Scherer identified endotrophin, a cleavage product of COLVIα3 that is actively 
involved in mammary tumor progression through enhancing EMT, fibrosis and chemokine activity, 
all of these activities are associated with acquired drug resistance [281].  
 
8. Contribution of ADSCs to breast cancer progression 
WAT is mainly comprised of adipocytes, although other cell types contained in so-called stroma 
vascular fraction (SVF) contribute to its growth and function, including Adipose-Derived Stem cells 
(ADSCs), preadipocytes, lymphocytes, macrophages, fibroblasts and vascular endothelial cells [77]. 
Studies have provided compelling in vivo evidences that mesenchymal stem cells (MSCs) distally 
recruited from the bone marrow contribute to breast cancer progression [282]. Recently studies 
demonstrated that ADSCs also contribute to tumor progression. ADSCs promote in vitro and in vivo 
in the growth and survival of breast cancer cells as well as their migratory and invasive capacities 
[283]; [284]; [67]; [285]; [286]; [287]. Several molecules have been involved in the pro-invasive 
effects of ADSCs including IL-6 [67], IL-8 [285], CCL-5 [284] and CXCL-12/SDF-1 [283]. More 
recently, it has been demonstrated that ADSCs promote the expansion of cancer stem cells and 
induce EMT in the cancer cells in a PDGF dependent manner [287]. Different functions of ADSCs 
within the tumor might be considered. First, different studies suggest that ADSCs might be 
activated by tumor cells and in turns express activated fibroblasts markers such as α-smooth muscle 
actin (αSMA) as well as fibronctin and tenascin C [287]. A recent study demonstrated that these 
activated ADSCs led to ECM deposition and contraction in vivo thereby enhancing breast cancer 
tissue stiffness, a parameter clearly contributing to breast cancer progression [288]. Secondly, 
ADSCs might also contribute to tumor vascularization [289]. Recent studies have demonstrated 
that, in mice, ADSCs are recruited by experimental tumors and promote cancer progression [290]; 
[291]. These studies using fluorescent-tagged cells show that these ADSCs contribute to form most 
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vascular and fibrovascular stroma (pericytes, α-SMA positive myofibroblasts, and endothelial cells) 
in murine tumors [291]. Finally, the role of AT to tumor vascularization is also sustained by the 
presence within itself of CD34+ endothelial cell progenitors (EPCs), that have been reported to 
generate in vitro and in vivo endothelial cells and vessels [292]. (For more detail information see 
review 1, 2). 
 
9. Oncological risk after autologous lipofilling grafting in breast cancer patients 
These accumulating experimental evidences have raised a question over the oncological safety of 
autologous fat transfer following breast cancer resection by breast reconstructive surgeons. 
Generally, the procedure used by the majority of surgeons known as the Coleman technique, 
consists of the harvesting of subcutaneous fat usually from the abdominal wall or the thighs, 
followed by a short centrifugation and injection of the cellular “fat” into the area of interest [293]. 
The injected “fat” contains mature adipocytes as well as all the other cellular components present in 
adipose tissue (AT) including mainly ADSCs/preadipocytes and endothelial cells/endothelial 
progenitor cells [289]. The grafted fat, not only behave as a filler, but also improves surrounding 
tissues, bearing lesions such as scars, radiation damage and breast capsular contracture, into which 
the fat is placed [294]. In autologous fat transfer, ADSCs provide several benefits, they improve 
angiogenesis, graft vascularity and contribute actively to the adipocyte pool allowing fat grafts to 
maintain their volume [295]. However, as we talked before, the oncological safety of fat grafting 
problem need to be concerned. (For more detail information see review 2). 
 
In summary, on the one hand, mature adipocytes have moved from relatively inert lipid-storing cells 
to highly endocrine cells secreting growth factors, chemokines, inflammatory cytokines and extra-
cellular matrix (ECM) proteins, all secretions potentially susceptible to affect tumor behavior. In the 
other hand, the regenerative pluripotential of ADSCs has been clearly emphasized. Finally, obesity, 
where both the cellular composition and the normal balance of these adipose tissue secretory 
proteins are perturbed, has recently emerged as an independent negative prognosis factor for breast 
cancer independently of menopause status. These data suggest that clinicians should consider 
obesity and metabolic factors, not only in assessing cancer risk but also in the design of clinical 
trials in oncology. However, it is important to note that this is a field that is still in its infancy, with 
a solid foundation of epidemiological data, but only very limited direct mechanistic insights at this 
point. Specially, the metabolic interactions between adipocytes and cancer cells (mentioned in 
“obesity” part), are consistent with the “metabolic symbiosis” between cancer cells and host stromal 
cells (I will extend the discussion in the next part). 
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PART III: CANCER METABOLISM 
Cell metabolism describes the intracellular chemical reactions that convert nutrients and 
endogenous molecules into the energy and matter (proteins, nucleic acids and lipids) that sustain 
life. Adenosine triphosphate (ATP), the principal molecule that drives all energy-dependent cellular 
processes, is mainly generated by two metabolic pathways: glycolysis and oxidative 
phosphorylation (Figure 15). Multiple molecular mechanisms, both intrinsic and extrinsic, converge 
to alter the cellular metabolism of cancer cells and provide support to the three basic needs of 
dividing cells: rapid ATP generation to maintain cellular energy status, increased biosynthesis of 
macromolecules and tightened maintenance of appropriate cellular redox status [296]. To meet 
these demands, both cancer cells and stromal cells undergo metabolic changes. In addition to the 
genetic changes that alter tumor cell metabolism, the tumor microenvironment has a major role in 
determining the metabolic phenotype of tumor cells. Given that adipocytes are a major source of 
adipokines and energy for the cancer cell, understanding the mechanisms of metabolic symbiosis 
between cancer cells and adipocytes should reveal new therapeutic possibilities.  
 
1. A famous concept of cancer metabolism: The Warburg Effect 
Tumors are metabolic entities. They draw nutrients from the bloodstream, consume them through 
biochemical pathways, and secrete waste products which then become substrates for metabolism 
elsewhere in the body. The concept of dysregulated metabolism of cancer was first enunciated by 
the great German biochemist/cell biologist Otto Warburg over 80 years ago. Otto Warburg received 
the Nobel Prize in 1931 for the discovery of cytochrome oxidase but he also showed that tumor 
cells exhibit high rates of aerobic glycolysis, a phenomenon which became known as the Warburg 
Effect. The Warburg effect is defined by an increased utilization of glucose via glycolysis as a 
cellular resource even oxygen is abundant, and is a common phenotype of cancerous cells [297]. 
Without direct evidence, Warburg claimed that the respiratory machinery of cancer cells, 
mitochondria, must be damaged, thereby causing an increased reliance upon fermentation. In 
Warburg`s perspective, cancer arose in two phases. First, the respiratory system was damaged 
irreversibly. The second phase took place as injured cells struggled to obtain sufficient energy from 
fermentation. The characteristic enhanced glucose uptake observed in cancer cells has been used to 
detect and image cancers via PET detection of 2-
18
F-2-deoxylgucose, which preferentially 
concentrates within tumors as a result of their rapid uptake of glucose.  
In normal cells, the mitochondria can completely oxidize the pyruvate and NADH from glycolysis, 
resulting in the production of up to a further 36 moles of ATP per mole of glucose in the presence 
of oxygen, while cancer cells catabolize glucose to lactate only generates 2 ATP per mole of 
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glucose (Lehninger AL, Nelson DL, Cox MM. Principles of Biochemistry.2. Worth; New York: 
1993). How do cancer cells benefit from their abnormal metabolism? Breaking these resources 
down via glycolysis is more to feed and protect the cell as it grows than provide energy to maintain 
cellular functions. Intermediates produced through glycolysis are diverted to biosynthetic pathways 
that are necessary to produce the basic building blocks of cellular growth. Carbon from glucose fuel 
nucleoside synthesis, whereas pyruvate feeds the citric acid cycle supporting continued fatty acid 
synthesis by supplying acetyl- and malonyl-CoA. The metabolic changes such as the Warburg 
effect, observed in cancer allow readily available resources to be converted into biomass in an 
efficient manner. This metabolic shift releases cells from the typical restraints on growth, and 
provides a potential way to distinguish them from healthy cells – allowing for treatments that may 
be selective for cancerous cells [298]. 
One compelling idea to explain the Warburg effect is that the altered metabolism of cancer cells 
confers a selective advantage for survival and proliferation in the unique tumor microenvironment. 
As the early tumor expands, it outgrows the diffusion limits of its local blood supply, leading to 
hypoxia and stabilization of the hypoxia-inducible transcription factor, HIF. HIF initiates a 
transcriptional program that provides multiple solutions to hypoxia stress [299]. Because a 
decreased dependence on aerobic respiration becomes advantageous, cell metabolism is shifted 
toward glycolysis by the increased expression of glycolytic enzymes, glucose transporters and also 
suppresses the glucose oxidation activity of the mitochondria by transactivating the pyruvate 
dehydrogenase (PDH) kinase enzyme (PDK), which phosphorylates and inhibits the PDH complex 
[300]. PDH is a key enzyme in controlling the rate of glucose oxidative metabolism in that it 
catalyzes the irreversible oxidation of pyruvate, yielding acetyl-CoA and CO2 and, therefore its 
inhibition creates a glycolytic shift of glucose metabolism. And this phenomenon is associated with 
attenuates hypoxic ROS generation and rescues cells from hypoxia induced apoptosis (Alda H, 
2011) (Figure 15).   
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Figure 15. Metabolic transformation of cancer cells. Hypoxia induced factor-1α (HIF-1α) causes a 
pathological activation of pyruvate dehydrogenase (PDH) kinase (PDK), which in turn inhibits PDH activity, 
therefore limiting oxidation of pyruvate, which is shifted towards lactate production (Alda Huqi, 2011, Heart 
and Metabolism). 
 
 
In addition, HIF stimulates angiogenesis by upregulating several factors, including most 
prominently vascular endothelial growth factor (VEGF). However, some studies demonstrated that 
the Warburg effect – that is, an uncoupling of glycolysis from oxygen levels – cannot be explained 
solely by upregulation of HIF. Moreover, cancer cells appear to use glycolytic metabolism before 
exposure to hypoxic conditions. For example, leukemic cells are highly glycolytic [301]; [298], yet 
these cells reside within the bloodstream at higher oxygen tensions than cells in most normal 
tissues. Similarly, lung tumors arising in the airways exhibit aerobic glycolysis even though these 
tumor cells are exposed to oxygen during tumorigenesis [302]. Thus, although tumor hypoxia is 
clearly important for other aspects of cancer biology, the available evidence suggests that it is a 
late-occurring event that may not be a major contributor in the switch to aerobic glycolysis by 
cancer cells. 
Other molecular mechanisms are likely to be important, such as the metabolic changes induced by 
oncogene activation and tumor suppressor loss. The signaling molecule Ras, a powerful oncogene 
when mutated, promotes glycolysis [303]; [304]. Akt kinase, a well-characterized downstream 
effector of insulin signaling, reprises its role in glucose uptake and utilization in the cancer setting 
[305], whereas the Myc transcription factor upregulates the expression of various metabolic genes 
[306]. The most parsimonious route to tumorigenesis may be activation of key oncogenic nodes that 
execute a proliferative program, of which metabolism may be one important arm. Moreover, 
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regulation of metabolism is not exclusive to oncogenes. Loss of the tumor suppressor protein p53 
prevents expression of the gene encoding SCO2 (Synthesis of Cytochrome C Oxidase Protein), 
which interferes with the function of the mitochondrial respiratory chain [307]. A second p53 
effector, TIGAR (TP53-Induced Glycolysis and Apoptosis Regulator), inhibits glycolysis by 
decreasing levels of fructose-2, 6-bisphosphate, a potent stimulator of glycolysis and inhibitor of 
gluconeogenesis [308]. Another work also suggests that p53-deficiency mediated increase in the 
rate of aerobic glycolysis may be dependent on the activation of transcription factor NF-κB [309]. 
Regardless of whether the tumor microenvironment or oncogene activation plays a more important 
role in driving the development of a distinct cancer metabolism, it is likely that the resulting 
alterations confer adaptive, proliferative, and survival advantages on the cancer cell. 
                
2. Diversity of energy production pathways of cancer cells 
2.1 Glutamine metabolism 
Having originated from Warburg`s seminal observation of aerobic glycolysis in tumor cells, most of 
this attention has focused on glucose metabolism. However, people realized that aerobic glycolysis 
is not a universal feature of all cancers in humans [310]. Both clinical FDG-PET data, as well as in 
vitro and in vivo experiment studies showed that tumor cells are capable of using alternative fuel 
sources. In fact, amino acids, fatty acids and even lactate have been shown to function as fuels for 
tumor cells in a subset of micro-environmental settings [311]; [312]. 1950s cancer biologists have 
recognized the importance of glutamine as a tumor nutrient. It has been suggested that it participates 
in bioenergetics, supports cell defenses against oxidative stress, and complements glucose 
metabolism in the production of macromolecules. These observations are stimulating a renewed 
effort to understand the regulation of glutamine metabolism in tumors and to develop strategies to 
target glutamine metabolism in cancer. 
Glutamine is a nonessential amino acid, more than 90% of the body`s glutamine stores are in the 
muscle, and is the major amino acid exported from the muscle during catabolic stress. The 
metabolic fates of glutamine can roughly be divided into reactions that use glutamine for its γ-
nitrogen (nucleotide synthesis and hexosamine synthesis) and those that utilize either the α-nitrogen 
or the carbon skeleton. The reactions in the first category, glutamine is required for the de novo 
synthesis of both purines and pyrimidines and is therefore essential for the net production of 
nucleotides during cell proliferation. The rate-limiting step in the formation of hexosamine is 
catalyzed by glutamine: fructose-6-phosphate amidotransferase (GFAT), which transfers 
glutamine`s group to fructose-6-phosphate to form glucosamine-6-phosphate, a precursor for N-
linked and O-linked glycolsylation reactions. These reactions are necessary to modify proteins and 
lipids for their participation in signal transduction, trafficking/secretion and other processes [313]. 
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The reactions in the second category use glutamate, not glutamine, as the substrate. The 
mitochondrial enzyme glutaminase (GLS) catalyzes the conversion of glutamine to glutamate, then 
it can be channeled into the TCA cycle. Increased expression of glutaminase is often observed in 
tumor and rapidly dividing cells [314]. Classical experiments demonstrated that glutaminase 
activity correlates with tumor growth rates in vivo [315]; [316], and experimental models to limit 
glutaminase activity resulted in decreased growth rates of tumor cells and xenografts [317]. 
Interestingly, a recent study demonstrated that c-Myc enhanced GLS expression through 
suppression of miR-23a/b, thus providing a molecular link between oncogenic signal and glutamine 
metabolism [317]. Furthermore, Wang et al report the identification of another class of oncogenic 
molecules, Rho GTPases, which can promote glutamine metabolism through activation of GLS in a 
NF-κB-dependent manner [318].  
Glumate may also be converted into α-ketoglutarate (α-KG) and enters the TCA cycle to supply 
intermediates and energy for cell growth. Complete oxidation of glutamine carbon involves exit 
from the TCA cycle as malate, conversion to pyruvate and then acetyl-CoA, and finally re-entry 
into the cycle (Figure 16). It is particularly useful in the truncated TCA cycle which cannot 
efficiently use glucose to generate energy [319]. This process provides fuel for the passive TCA 
cycle due to a lack of isocitrate [320]; [319]. Therefore, it also demonstrates that cancer cells are 
able to use OXPHOS for ATP production.  Pike et al found that when glutamine was eliminated 
from the growth medium (glucose only), the oxygen consumption rate of the cells was significantly 
lower compared to that of the cells grown in control medium (Glucose and Glutamine). Moreover, 
the oxygen consumption rate of cells grown in medium containing no glucose did not differ 
significantly from the control cells suggesting that glucose may not contribute significantly to the 
intracellular fatty acids that flux into mitochondria for oxidation and/or that the presence of glucose 
inhibits oxidative phosphorylation (the Crabtree effect). They suggested that glutamine is involved 
in the de novo synthesis of fatty acids which feed into mitochondrial β-oxidation in Glioblastoma 
cells [321]. 
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Figure 16. Biochemistry of cancer-cell metabolism. On entering the cell, glucose is converted to pyruvate 
by glycolysis. In normal cells, if oxygen is available, pyruvate undergoes oxidative phosphorylation in 
mitochondria, through the TCA cycle. If oxygen levels are low, however, pyruvate is converted to lactate in 
the cytoplasm. Cancer cells drive pyruvate conversion to lactate even in the presence of oxygen. Metabolism 
of the nutrient glutamine is also modified in cancer. The transcription factors HIF (yellow) and MYC (green) 
seem to affect these metabolic pathways at various steps. For simplicity, only some chemical reactions and 
enzymes (purple) are shown. GLUT, glucose transporter; MCT, monocarboxylate transporter. (Kaelin WG Jr, 
Thompson CB, 2010, Nature). 
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2.2 Mitochondrial oxidative phosphorylation (OXPHOS) 
Cancer cells are different from most normal tissues in the energy metabolism and they take up 
glucose and glutamine at a high rate for aerobic glycolysis. In addition, cancers are extremely 
heterogeneous and each cancer is different in tissue origin and metabolic phenotype [322]. Even in 
a single cancer, its constituent cells vary in metabolic phenotype [323]. It is worth mentioning that 
metabolic phenotypes in cancer are plastic, and cancer tissues exhibit greater plasticity than normal 
tissues [324]. Cancer cells may change their metabolic phenotypes to adapt to microenvironmental 
changes and the results of these changes give a selective advantage to cancer cells under the 
unfavorable environment [325]. Warburg originally proposed that the aerobic glycolysis in cancer 
cells was due to a permanent impairment of mitochondrial OXPHOS. However, recent 
investigations found that defects of mitochondrial OXPHOS are not common in spontaneous 
tumors and that the function of mitochondrial OXPHOS in most cancers is intact [326]; [319]. 
Certain authors consider that the Warburg effect in cancer is due to enhanced glycolysis suppressing 
OXPHOS rather than defects in mitochondrial OXPHOS. If glycolysis is inhibited in cancer cells, 
the function of mitochondrial OXPHOS can be restored. For example, Fantin et al observed that 
when LDH-A (lactate dehydrogenase A) was suppressed in cancer cells, OXPHOS function could 
be enhanced to compensate for reduced ATP by inhibited glycolysis. This observation suggests that 
most cancer cells reserve the capacity to produce ATP by OXPHOS. Furthermore, they also found 
that proliferation and tumorigenicity of cancer cells were inhibited when LDH-A activity was 
suppressed, suggesting that enhanced OXPHOS is still not sufficient to meet the requirement of 
cancer growth and that LDH-A is a target of cancer therapy [327]. 
An emerging hypothesis of the so-called “reverse Warburg effect” also supports the function of 
OXPHOS in cancer cells [328]. Previously, we have mentioned that the behavior of cancer was 
determined not only by cancer cells but also by stromal cells. This is possible due to the co-
evolution between cancer cells and stromal cells in tumorigenesis. For example, under the 
‘education’ of cancer cells and inflammatory cytokines, stromal fibroblasts become carcinoma-
associated fibroblasts (CAFs), macrophages become tumor-associated macrophages (TAMs) and 
neutrophils become tumor-associated neutrophils (TANs) and adipocytes become cancer-associated 
adipocytes (CAAs). In fact, these tumor-associated stromal cells are already different from their 
original cells and have genetic and epigenetic changes which led to alterations in gene expression 
and metabolic profiles. Therefore, tumor cells and stromal cells not only influence each other in 
cytokines and growth factors, but also in energy metabolites. In the reverse Warburg effect, 
epithelial cancer cells induce aerobic glycolysis in CAFs which produce lactate, ketones and 
pyruvate that enter the TCA cycle in cancer cells for OXPHOS [328]; [329]. 
68 
 
An increasing number of recent studies showed that lactate released by glycolysis in hypoxic tumor 
cells and/or stromal cells is not discharged as a waste product, but can be taken up by oxygenated 
tumor cells as energy fuel. Lactate is converted to pyruvate by LDH-B and then enters the 
mitochondria for OXPHOS to generate ATP [330]; [331]. Metabolic symbiosis is not cancer-
specific. In fact, the cooperation between different cells in energy production is also observed in 
normal tissues. For example, neurons rely on OXPHOS to meet their energy demands, whereas 
astrocytes rely on glycolysis to meet their energy needs. Lactate released by astrocytes can be taken 
up by neurons, used as energy fuel and form the so-called astrocyte-neuron shuttle (ANLS) [332]. 
As such, it is perhaps not surprising that tumors may have also developed a form of metabolic 
coupling, specifically involving tumor-stromal interactions. In further support of the existence of a 
‘lactate shuttle’ in human tumors, Sotgia et al have shown that CAFs express MCT4 (for lactate 
extrusion), while breast cancer cells express MCT1 (for lactate uptake). Interestingly, MCT4 
expression in CAFs is induced by oxidative stress, and MCT4 is a known HIF1 target gene [312]. 
Co-cultures of normal human fibroblasts and MCF7 cells indicate that cancer cells use oxidative 
stress as a weapon to trigger the conversion of adjacent fibroblasts into myo-fibroblasts [333]. 
Cancer cell-induced oxidative stress potently perturbs the behavior of adjacent fibroblasts, induces 
the lysosomal-mediated degradation of Caveolin-1, and promotes mitochondrial dysfunction, 
resulting in increased aerobic glycolysis [334]. In turn, these glycolytic fibroblasts support tumor 
cell mitochondrial respiration and growth by actively transferring high-energy nutrients (such as 
lactate and pyruvate) to cancer cells. These studies suggest that tumor cells have a high degree of 
metabolic flexibility and given ample oxygen supply, utilize mitochondria to generate energy and 
important metabolic intermediates [335].  
Considering the possible target for cancer therapy, stimulation of glucose oxidation through 
pharmacological inhibition of PDK with Dichloroacetate (DCA) was tested. Besides metabolic 
changes, DCA restores mitochondrial ROS production capacity, releases pro-apototic factors and, 
ultimately, decreases cell survival and increases apoptosis rates (Figure 15) [300]. However, despite 
these promising cytological effects, the adverse effects such as hepatotoxicity and neurotoxicity has 
been reported [336]. Bonnet et al proposed that the effects of DCA to increase glucose oxidation 
rates can be achieved by inhibiting mitochondrial fatty acid oxidation rates [337]. The reciprocal 
relationship between glucose and fatty acid metabolism is part of a phenomenon known as the 
“Randle cycle”. Since glucose oxidation and fatty acid oxidation both produce mitochondrial 
acetyl-CoA, the rate of each other`s activity has a direct reciprocal effect on the rates of others 
pathway. Therefore stimulation of glucose oxidation through direct inhibition of PDK activity can 
similarly be obtained by inhibiting fatty acid oxidation. This has been the rationale for the 
development and use of fatty acid oxidation inhibitors. However, at this point one may argue: even 
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there is compelling evidence supporting the function of oxidation in cancer cells, how can we 
determine the fatty acid oxidation also involved in it? 
 
3. Fatty acid metabolism in the limelight 
In addition to glucose and glutamine, fatty acids (FFAs) are an extremely relevant energy source. 
They can be incorporated from the extracellular media, or can be potentially obtained from 
hydrolysed triglycerides by neutral hydrolases in the cytoplasm or acid hydrolases through a novel 
autophagic pathway: lipophagy [159]. FFAs are critically important in cellular homeostasis as they 
are involved in a wide variety of processes including phospholipid synthesis, protein post-
translational modifications, cell signaling, membrane permeability, and transcription control [338]. 
Furthermore, accumulating evidence suggested that some cancer can use adipocyte derived fatty 
acid for β-oxidation as an important energy source for tumor survival and proliferation [339]; [71]. 
Although vast majority of the research into cancer metabolism has been limited to glycolysis, 
glutaminolysis and fatty acid synthesis, the relevance of fatty acid β-oxidation (FAO) for cancer cell 
function have remained in the dark. Studies in the past 4 years have started to bring to light a 
relevant role for this metabolic pathway in cancer, a brief overview from fatty acid synthesis to their 
utilization is given below to help us better understanding the intricate metabolic systems in cancer. 
 
3.1 De novo fatty acid synthesis and the relationship with cancer 
Fatty acid synthesis is an anabolic process that starts from the conversion of acetyl CoA to malonyl 
CoA by acetyl CoA carboxylase (ACC). Malonyl CoA is then committed to fatty acid synthesis 
(FAS) and is involved in the elongation of fatty acids through fatty acid synthase (FASN). 
Additional modifications of fatty acids can be carried out by elongases and desaturases.  
Most normal human tissues preferentially use dietary (exogenous) lipid for synthesis of new 
structural lipids, whereas de novo (endogenous) fatty acid synthesis is usually suppressed, and 
FASN (fatty-acid synthase) expression is maintained at low levels. By contrast, tumor cells 
catabolize glucose at a rate that exceeds bioenergetics need by shifting from oxidative to glycolytic 
metabolism. In this scenario, tumor cells can redirect the excess glycolytic end product pyruvate 
toward de novo synthesis which is necessary to maintain a constant supply of lipids and lipid 
precursors to fuel membrane production and lipid based post-translational modification of proteins 
in a highly-proliferating cell population. In the mitochondria pyruvate is converted to acetyl-CoA, 
which enters the citric acid cycle. Depending on the oxygen tension, citrate can be oxidized to 
carbon dioxide and oxaloacetate, thereby generating ATP via oxidative phosphorylation, or it can 
be transported to the cytosol, where it is converted by ATP citrate lyase (ACL) to oxaloacetate and 
acetyl-CoA.  Acetyl-CoA is metabolized by acetyl-CoA carboxylase (ACC) to yield malonyl-CoA, 
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the first committed precursor of saturated long-chain fatty acids (LCFA) biosynthesis. Malonyl-
CoA is subsequently metabolized to LCFAs, such as palmitic acid, which is the most abundant 
LCFA in cancer cells, by the NADPH-dependent enzyme – fatty acid synthase (FASN) (Figure 17). 
LCFAs can be subsequently desaturated to monounsaturated fatty acids (MUFAs) by stearoyl-CoA 
desaturase (SCD)-1 [340]; [341]. It has been reported that MUFAs are important constituents of the 
phospholipid cell membrane and are thought to affect its biomechanical integrity, so they are 
important for tumorigenesis. Inhibition  of MUFA synthesis by SCD-1 inhibitors, such as 
CVT11127, has been proposed as a strategy for reducing tumor growth by attenuating cell 
proliferation at the G1/S cell cycle phase and initiating apoptosis, although concomitant inhibition of 
ACC in lung cancer cells does not augment the suppression of cell proliferation by SCD-1 
inhibition alone [342]; [343].  
Markedly increased ACL expression and activity have been reported in cancer cells [344]; [345]. 
RNA interference (RNAi) – directed and pharmacological inhibition of tumor-associated ACL 
drastically limits the in vitro proliferation and survival of cancer cells displaying aerobic glycolysis 
[345]. The relevance of ACL-driven channeling of glucose into de novo lipid synthesis as an 
important component of cell growth and transformation is further supported by the fact that ACL 
inhibition also reduces tumorigenesis in vivo [344]. 
The second rate-limiting enzyme for FA synthesis is ACC, it has been shown to be overexpressed 
both at the mRNA and protein levels, not only in advanced breast carcinomas but also in 
preneoplastic lesions associated with increased risk for the development of infiltrating breast cancer 
[346].  
Numerous studies have shown overexpression of FASN in various human epithelial cancers, 
including prostate, ovary, colon, lung, endometrium and stomach cancers [347]. Moreover, several 
reports have shown that FASN and related lipogenic enzymes play important roles in tumor cell 
survival at multiple levels. In cancer cells, transcriptional regulation of FASN gene is one of the 
important mechanisms of FASN overexpression [348];[349]. The FASN expression is regulated by 
growth factors – growth factor receptors, including epidermal growth factor receptor (EGFR) and 
HER2, and steroid hormone – steroid hormone receptors, such as estrogen receptor (ER), androgen 
receptor (AR) and progesterone receptor (PR). Downstream of the receptors, the 
phosphatidylinositol-3-kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK) are 
candidate signaling pathway that mediate FASN expression through the sterol regulatory element-
binding protein 1c (SREBP-1c). Recent reports have further shown that the FASN expression is not 
only controlled by SREBP-1c, but also by other transcription factors, such as the p53 family 
proteins and the lipogenesis-related nuclear protein, SPOT14, which is overexpressed in breast 
tumors [350]. 
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Figure 17. De novo synthesis of fatty acids from carbohydrate precursors. Upon cellular uptake by 
glucose transporters, glucose is phosphorylated by hexokinases (HK) to glucose-6-phosphate, most of which 
enters the glycolytic pathway generating pyruvate and ATP. In the mitochondria pyruvate is converted to 
acetyl-CoA, which enters the citric acid cycle. Depending on the oxygen tension citrate can be oxidized to 
carbon dioxide and oxaloacetate, thereby generating ATP via oxidative phosphorylation, or it can be 
transported to the cytosol, where it is converted by ATP citrate lyase (ACL) to oxaloacetate and acetyl-CoA. 
Acetyl-CoA is the requisite building block for fatty acid synthesis, but it also functions as a precursor of 
mevalonate, which is used for the synthesis of both cholesterol and isoprenoids. Acetyl-CoA carboxylase-α 
(ACC) carboxylates acetyl-CoA to malonyl-CoA. To produce fatty acids such as palmitic acid by fatty acid 
synthase (FAS). Saturated long-chain FAs can be further modified by elongases or desaturases to form more 
complex FAs (Swinnen JV, 2006, Curr Opin Clin Nutr Metab Care). 
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As with these intracellular signaling molecules, extracellular tumor microenvironmental stresses 
play an important role in tumor-related FASN expression. Hypoxia and low pH stress induce the 
FASN expression in cancer cells [351]; [352]. Hypoxia upregulates SREBP-1, the major 
transcriptional regulator of the FASN gene, through phosphorylation of Akt. 
Apart from the transcriptional regulation of FASN, it is also controlled at the posttranslational 
levels. Graner et al showed that the isopeptidase USP2a (ubiquitin-specific protease-2a) interacts 
with and stabilizes FASN protein in prostate cancer [353]. These observations suggest that tumor-
related FASN overexpression could be regulated at multiple levels [354].  
In cancer cells, LCFAs which are not metabolized to MUFAs are destined for two fates – 
cytoplasmic storage as glycerolipids or mitochondrial import for β-oxidation. The former involves 
the transient storage of palmitic acid as mainly cytoplasmic glycerolipid monoacylglycerol (MAG). 
MAG seems to be part of an important cellular homeostatic mechanism that prevents lipotoxicity 
within cancer cells with high levels of FA synthesis since palmitic acid can have both mitochondrial 
and endoplasmic reticulum-mediated proapoptotic effects which are probably cell type dependent. 
Three FAs are then esterified to a single glycerol molecule to create a molecule of TAG and stored 
as an energy reserve in lipid droplet.  
 
3.2 Cellular uptake and transport of long-chain fatty acids 
Long-chain fatty acids (LCFA) are critically important in cellular homeostasis as they are involved 
in a wide variety of processes. The physiological response to fasting is linked to the endocrine-
mediated utilization of stored hepatic and muscle glycogen to maintain normoglycemia. When 
glycogen reserves are depleted, triglycerides are mobilized from lipid stores, and fatty acids are 
released at the endothelial walls of capillaries and at the hepatocyte surface by the action of 
lipoprotein lipase and hepatic lipase, respectively. The physiologically available fatty acids are 
mostly C16 and C18 species and include saturated and both mono- and di- unsaturated species. The 
free fatty acids (FFAs) released by lipolysis are transported bound to albumin in blood and taken up 
by tissues in a process mediated by transport proteins present in the plasma membrane. Once within 
the cell, FFAs are bound to fatty acid binding proteins which are present in the cytosol in high 
amounts [355].  
Fatty acid-binding proteins are widely expressed throughout the tissues of the body (Table 4). Nine 
members of the FABP family have been identified as products of separate genes, yet they all appear 
to have a similar tertiary structure and demonstrate a high affinity for similar substrates [356]. Each 
FABP has a common 10-stranded antiparallel -barrel, which contains the ligand binding site, and 
an N-terminal helix-loop-helix motif [357]. Though they all bind single long-chain fatty acids, their 
individual levels of expression and specific cellular function appear to vary from tissue to tissue. As 
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lipid chaperones, FABPs may actively facilitate the transport of lipids to specific compartments in 
the cells, such as to the lipid droplet for storage; to the endoplasmic reticulum for signaling, 
trafficking and membrane synthesis; to the mitochondria or peroxisome for oxidation; to cytosolic 
or other enzymes to regulate their activity; to the nucleus for lipid-mediated transcriptional 
regulation; or even outside the cell to signal in an autocrine or paracrine manner [358].  
FABP4, also known as ALBP or aP2, is expressed almost exclusively in adipocytes and 
macrophages. FABP5 (keratinocyte type FABP) is also found in adipocytes, as well as other cell 
types, though usually at much lower levels. Both proteins are generally implicated in the storage 
and transport of intracellular lipids, as well as in the regulation of metabolism and lipid mediated 
gene expression [359]. So they may involve in obesity and cancer as well. One study revealed that 
serum FABP4 levles were significantly higher in obese (41.16 ng/ml) than in non-obese women 
(24.95 ng/ml). Independent of obesity, the serum FABP4 levels were significantly higher in brease 
cancer patients (34.65 ng/ml) than in healthy controls (24.47 ng/ml) showed a significant 
association of FABP4 with breast cancer risk [360]. Through the use of a protein array, Nieman et 
al [71] identified an upregulation of FABP4 in metastatic tumour cells (compared with primary 
ovarian cancer cells) and, in vivo, they observed a significantly lower rate of tumour growth in 
FABP4 -/- knockout mice than in wild type – further implicating FABP4’s participation. They went 
on to identify FABP4 as a potential therapeutic target in cancer, particularly highlighting the 
potential for inhibition of FABP4 to prevent lipolysis in adipocytes and lipid accumulation in 
tumour cells. Pharmaceutical companies have since begun to explore the potential for FABP4 
inhibition in oncology [358]. In an in vitro study of adipocytes treated with BMS309403, decrease 
fatty acids uptake [361] and inhibit the lipolysis ability [362], which may suggest that inhibition of 
FABP4 inhibit the liberation of FFAs by adipocytes and prevent their uptake by tumor cells. 
However, in general, the interacting molecular partners for FABPs are poorly understood, and the 
searches for such proteins with conventional approaches have not been fruitful. Little is known 
regarding how lipids regulate subcellular localization of FABPs. Further and clear evidence on the 
specific impact of FABPs on cell biology and lipid metabolism need to be created. 
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Table 4. family of fatty acid-binding proteins (FABPs) (Furuhashi M, 2008, Nat Rev Drug Discov). 
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3.3 Fatty acid β-oxidation 
3.3.1 Peroxisome fatty acid β-oxidation 
β-oxidation is a major process by which fatty acids are oxidized, and this oxidation occurs both in 
mitochondria and in peroxisomes [363]; [364]; [365]. Fatty acids are also oxidized by ω-oxidation 
by a cytochrome P450 CYP4A subfamily, this oxidation occurs almost exclusively in smooth 
endoplasmic reticulum [366]; [367]. Fatty acid synthesis is enhanced and β-oxidation is lowered 
when glucose supply is plenty so that excess energy can be stored in the form of triacylglycerol. 
When glucose availability is diminished, however, the synthesis of FAs is depressed and β-
oxidation is enhanced in liver so as to generate ketone bodies for export to serve as fuels for other 
tissue, such as the skeletal and cardiac muscle [368]. 
Peroxisomes are cell organelles present in virtually all eukaryotic cells. Currently, more than 60 
proteins have been found and more than half of these proteins participating in lipid metabolism in 
mammalian peroxisomes [369]. By virtue of this advantage, peroxisomes play a critical role in 
metabolic systems and physiological processes influencing alternate use of carbohydrate and fatty 
acids to generate ATP. It is clear that in animals both the mitochondrial and the peroxisomal FAO 
systems are present in the same cell; they are catalyzed by different enzymes encoded by different 
genes and they play functionally complementary but different roles [370]; [371]. Short- (C4-C6) 
medium-chain (C8-C12) of fatty acids are exclusively β-oxidized and Long-chain fatty acids 
(LCFAs) (C14-C20) are predominantly β-oxidized in mitochondria, while Very Long-chain fatty 
acids (VLCFAs) (>C20) are almost exclusively β-oxidized in peroxisomes because mitochondria are 
devoid of very-long-chain acyl-CoA synthetase [372]; [371]. 
The classical Peroxisomal β-oxidation pathway is catalyzed by three enzymes: fatty acyl-CoA 
oxidase (AOX), enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase bifunctional protein 
(L-PBE) and 3-ketoacyl-CoA thiolase [370]; [372], and all three enzymes are transcriptionally 
activated by PPARα ligands [373]. AOX is the first and rate-limiting enzymes which reflect 
distinctive differences between peroxisomal and mitochondrial oxidation pathways [374]. Unlike 
the mitochondrial system, peroxisomal β-oxidation is carnitine independent, after 4 steps of 
reaction, they release acetyl-CoAs and an acyl-CoA that is two carbon atoms shorter than the 
original molecule and that can reenter the spiral for the next round of β-oxidation [370]. Then, it 
does not go to completion, as the chain-shortened acyl-CoAs are exported to mitochondria for the 
completion of β-oxidation. The brief comparison of mitochondrial and peroxisomal fatty acids β-
oxidation is shown in Figure 18.  
As mitochondrial β-oxidation is primarily involved in the catabolism of short-, medium-, and long-
chain fatty acids, we will describe it more carefully. 
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Figure 18. Enzymology of mitochondrial inner-membrane-bound long-chain fatty acid β-oxidation system 
involving trifunctional protein, and the peroxisomal-inducible classical straight-chain and the noninducible 
branched-chain fatty acid β-oxidation systems in humans (Reddy JK, 2001, Annu Rev Nutr). 
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3.3.2 Mitochondrial Transport of Fatty Acids 
Mitochondria are not only the seat for the electron transport chain but they are also the site for the 
tricarboxylic acid (TCA; Kreb`s) cycle. The TCA cycle is the cancer cell`s principal “biochemical 
hub” where different carbon sources are substrates for both OXPHOS and cellular biosynthesis such 
as nucleotide production for DNA synthesis and cellular membrane synthesis [375]. Lots of enzyme 
involved during these process. 
Carnitine (β-hydroxy γ-trimethylaminobutyric acid) is a critical factor for LCFA intramitochondrial 
transport. The first β-oxidation reaction is the cytoplasmic metabolism of LCFA to their respective 
acyl-CoA derivatives by acyl-CoA synthase (ACS) isoforms. Long-chain acyl-CoAs are 
subsequently esterified to their L-carnitine derivatives by Carnitine palmitoyltransferase I (CPT-I) 
on the surface of the outer mitochondrial membrane before mitochondrial import for β-oxidation, 
such that the principal long-chain acyl-CoA, palmitoyl-CoA (PALMCoA), is metabolized by CPT-I 
to palmitoylcarnitine. The resulting long-chain acyl-carnitine is transported across the inner 
mitochondrial membrane by carnitine: acylcarnitine translocase (CACT). Once inside the 
mitochondrial matrix, the acyl-CoA is reformed by the action of the inner mitochondrial membrane-
bound CPT II using free CoA. The carnitine released by this reaction is recycled for subsequent 
reutilization via CACT [376]. 
The step catalyzed by CPT-I is rate limiting for entry of fatty acids into the mitochondria. During 
energy starvation, when ATP levels are low and AMPK is activated, ACC-dependent malonyl-CoA 
levels fall, releasing the inhibition on the CPT-I (malonyl-CoA inhibit CPT-I) which thus facilitates 
the mitochondrial entry of LCFAs for β-oxidation [365]. PALMCoA is subsequently metabolized 
by four enzymatic reactions to produce acetyl-CoA. This utilizes a quartet of cornerstone β-
oxidation enzymes that reside on different mitochondrial substructures [377], which in toto 
suppresses glucose oxidation by repressing PDH activity, thus preventing the mitochondrial 
metabolism of pyruvate. Medium- and short-chain fatty acids (chain length 12 and lower) enter the 
mitochondria independently of the carnitine shuttle and are presumably activated within the 
mitochondrial matrix by different acyl-CoA synthetases. 
CPT-I was the first enzyme of FAO shown to exist in distinct tissue-specific isoforms. CPTIA was 
first identified in the liver but is in fact broadly expressed. Mutations of the CPTIA gene have been 
implicated in hereditary disorders. In contrast, CPT1B expression is restricted to muscles, and 
CPT1C is a brain-specific isoform [378]. These enzymes are present on the cytosolic surface of 
mitochondria and catalyze the production of acyl carnitine from acyl-CoA, thereby facilitating lipid 
transport through the mitochondrial membranes.  
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3.3.3 Mitochondrial fatty acid β-oxidation reaction process 
The β-oxidation process involves the concerted action of a series of chain-length specific enzymes, 
which sequentially remove a molecule of acetyl-CoA per cycle from the initial fatty acid substrate. 
The first reaction involves a member of the acyl-CoA dehydrogenase family of FAD-requiring 
oxidoreductases. Very long-chain acyl CoA dehydrogenase (VLCAD) is a membrane-associated 
enzyme responsible for reduction across the 2, 3 position of the acyl-CoA moiety to produce a 2, 3-
enoyl-CoA [379]. VLCAD is responsible for reducing acyl-CoAs of chain lengths C12 - C18. Two 
additional members of the acyl-CoA dehydrogenase family, medium-chain and short-chain acyl-
CoA dehydrogenases, respectively (MCAD, SCAD), are found in the mitochondrial matrix. MCAD 
is responsible for the metabolism of acyl-CoAs of chain lengths C6 - C10, and SCAD is specific for 
C4 and C6 substrates in the two final rounds of the β-oxidation cycle in the mitochondrial matrix 
(Figure 19). MCAD and SCAD are catalytically active as homotetramers of 44-kDa polypeptides 
[380]. Long chain acyl-CoA dehydrogenase (LCAD) is also a member of this family of enzymes 
and has substrate chain length specificity between VLCAD and MCAD. Although no human case 
of LCAD deficiency has been described, a mouse model of this disorder results in gestational loss, 
lipidosis, hypoglycemia, and myocardial degeneration, a biochemical phenotype similar to human 
VLCAD deficiency [381]. 
The second reaction involves hydration of the double bond in the 2, 3 position to produce a stereo-
specific L-3-hydroxyacyl-CoA species. Two enzymes able to carry out this reaction have been 
described to date: long-chain enoyl-CoA hydratase (LHYD) is responsible for hydrating long-chain 
species and is part of a membrane-associated trifunctional enzyme complex called the 
mitochondrial trifunctional protein (TFP). Active TFP is a heterooctamer of α4β4 subunits [382]; 
[383]. The α-subunit encodes LHYD activity and the subsequent enzyme in the sequence, long-
chain L-3-hydroxyacyl-CoA dehydrogenase (LCHAD). The β-subunit has long-chain 3-ketoacyl-
CoA thiolase (LKAT) activity, the fourth enzyme in the cycle. Association of the complex is 
necessary for membrane translocation and for catalytic stability of the individual enzymes [384]; 
[385]. The second hydratase is crotonase (short-chain enoyl-CoA hydratase), which is responsible 
for the hydration of medium- and short-chain enoyl-CoA species.  
The third step of FAO involves the reduction at the L-3-hydroxy position to yield a 3-ketoacyl-CoA 
species. In this reaction, NAD
+
 is reduced to NADH. LCHAD is an integral part of the TFP and is 
responsible for the reduction of long-chain substrates, while a medium- short-chain L-3-
hydroxyacyl-CoA dehydrogenase (M/SCHAD) with broad-chain-length specificity is responsible 
for medium- and short-chain species [386]. 
The final step of β-oxidation involves thiolytic cleavage of the 3-ketoacyl-CoA to yield acetyl-CoA 
and a two-carbon chain-shortened acyl-CoA. The enzyme responsible for long-chain species is 
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LKAT, which is also part of the TFP. Finally the generated acyl-CoA by this process is targeted 
toward steroidogenesis, ketogenesis or TCA cycle for complete oxidation to yield CO2. 
Mitochondrial FAO represents the major route of acyl-CoA oxidative metabolism via β-oxidation to 
produce acetyl-CoA and chain-shortened acyl-CoAs, with the produced acetyl-CoA potentially 
entering the TCA cycle, culminating in complete oxidation of the carbon to CO2 (complete FAO). 
However, a portion of lipids are incompletely oxidized, a process that leads to the production of 
acid-soluble metabolites (ketone bodies, acyl-CoAs, and acylcarnitines). It has been suggested that 
an increase in the relative proportion of complete FAO to CO2 may be physiologically beneficial 
[387]. The percentage of complete FAO to CO2 relative to total FAO can be viewed as a marker of 
FAO efficiency by estimation of the coupling of acetyl-CoA production by β-oxidation to the flux 
of acetyl-CoA through the TCA cycle. Recently, some studies reported that elevated liver FAO 
efficiency was associated with increases in hepatic mitochondrial protein expression and/or function 
and decreased steatosis [388]; [389]. Peroxisome proliferator-activated receptor-γ coactivator 
(PGC-1α) is a member of a family of transcription coactivators that plays a central role in the 
regulation of cellular energy metabolism. It has been observed to functionally control FAO 
efficiency in skeletal muscle. The mitochondrion is unique among mammalian organelles, in that it 
contains DNA that encodes proteins required for appropriate function [390]; as such, the relative 
mitochondrial DNA copy number in cells can serve as an index for mitochondrial content under 
differing environmental or metabolic conditions. In skeletal muscle, PGC-1α increases mtDNA 
content through upregulation of the nuclear-encoded mtTFA via coactivation of nuclear respiratory 
factors 1 and 2 [391]. Several studies suggested that increased PGC-1α expression produced 
coordinated increase in fatty acid β-oxidation and downstream mitochondrial pathways, resulting in 
elevated FAO to CO2 [392]; [393]. 
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Figure 19. Pathway of fatty acid metabolism from the transport of long-chain fatty acids and carnitine 
across the plasma membrane to the production of acetyl-CoA. Medium- and short-chain fatty acids do 
not require an active transport mechanism to reach to mitochondrial matrix. Enzymes of the carnitine cycle 
(CPTI, CACT, and CPTII) shuttle long-chain fatty acids across the mitochondrial membranes. The fatty acid 
β-oxidation spiral includes an FAD-dependent acyl-CoA dehydrogenase step (1) followed by a 2, 3-enoyl-
CoA hydratase reaction (2), the NAD-dependent 3-hydroxyacyl-CoA dehydrogenase step (3), and the 
thiolase cleavage reaction (4). (Rinaldo P et al, 2002, Annu Rev Physiol) 
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3.4 Mitochondrial fatty acid β-oxidation in cancer 
There are a number of studies that link β-oxidation with cancer. Several enzymes involved in the 
metabolism of fatty acids have been determined to be altered in prostate cancer relative to normal 
prostate, which is indicative of an enhanced β-oxidation pathway in prostate cancer [394]. Another 
study provided significant evidence that increased mitochondrial β-oxidation of fatty acids has been 
linked to tumor promotion in pancreatic cancer [395]. The group of Nika Danial found that diffuse 
large B cell lymphoma (DLBCL) have an OXPHOS gene expression signature and are highly 
dependent on mitochondrial FAO for growth and survival that do not require the activation of the B 
cell receptor [396]; [397]. Linher-Melville K et al., revealed that Prolactin enhances FAO by 
stimulating CPT1a expression in breast cancer cells and these effects are partially dependent on the 
LKB1-AMPK pathway [398]. Pharmacological activation of β-oxidation can also rescue the 
glucose dependency of Akt-transformed cells [399], suggesting that this pathway can provide 
important metabolites for cancer-cell survival. 
FAO is controlled at the step of FA import into the mitochondria, a process executed by tissue-
specific isoforms of CPT1. Pharmacologic inhibition of FAO with etomoxir, which inhibits the 
activity of CPT1, has yielded therapeutic benefits for the treatment of heart failure by shifting the 
failing heart`s energy supply from fatty acids to the energetically more efficient pyruvate [400]. 
Samudio et al., have demonstrated that etomoxir inhibited proliferation and sensitized human 
leukemia cells to apoptosis induction by ABT-737 (a molecule that releases proapoptotic Bcl-2 
proteins). Importantly, etomoxir decreased the number of quiescent leukemia progenitor cells in 
approximately 50% of primary human acute myeloid leukemia samples, provided substantial 
therapeutic benefit in a murine model of leukemia [401]. Pike et al., reported that human 
glioblastoma SF188 cells oxidize fatty acids and that inhibition of FAO by etomoxir markedly 
reduces cellular ATP levels and viability. They also found that inhibition of FAO decreases 
NADPH levels and the reduced glutathione (GSH) content and elevates intracellular reactive 
oxygen species which suggested that mitochondrial fatty acid oxidation may provide NADPH for 
defense against oxidative stress and prevent ATP loss and cell death [321].  
The requirement of FAO for ATP production in conditions of metabolic stress is recapitulated in 
other cancer types and conditions. The group of Tak W.Mak identified an atypical carnitine 
palmitoyltransferase 1 (CPT1) isoform—CPT1C—as a potential oncogene that is frequently 
expressed in tumors and up-regulated in response to metabolic stress. They showed that CPT1C 
expression in tumor cells correlates inversely with both mTOR pathway activation and sensitivity to 
the mTOR inhibitor rapamycin. Enhanced CPT1C expression increases FAO and ATP production 
and protects cells from death induced by glucose deprivation or hypoxia. Conversely, cells deficient 
in CPT1C show reduced ATP production, enhanced apoptosis: increased caspase-3 and -9 
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activation, and impaired mitochondrial membrane potential: swollen mitochondria exhibiting 
abnormal internal membrane structure and loss of internal cristae density. There is dramatic 
difference in lipid composition: in CPT1C deficiency cells, there is increased levels of linoleic, 
arachidonic, and docosotetraenoic acids, and decreased levels of oleic acid. Collectively, these 
results demonstrate that tumor cells constitutively expressing CPTIC show increased fatty acid 
oxidation, ATP production, and resistance to glucose deprivation or hypoxia. These data indicate 
that cells can use a novel mechanism involving CPTIC and FA metabolism to protect against 
metabolic stress [402]. Schafer and co-workers showed that antioxidants counteract ROS 
accumulation and can reactivate FAO, increase ATP levels and prevent loss of attachment (LOA)-
induced anoikis [403]. Pandolfi et al described a novel mechanism in which FAO is regulated by 
the promyelocytic leukaemia (PML) protein, and this regulation is dependent on peroxisome 
proliferator-activated receptors (PPARs) [404]. In agreement with the study from Joan Brugge`s 
group, the ability of PML to increase FAO activity promoted cell survival on LOA [403]. This 
mechanism of action provides an explanation for the upregulation of PML that is observed in a 
subset of aggressive breast cancers with increased PPAR activity and a poor prognosis [404].  
 
Accordingly, the hallmarks of cancer metabolism are much more nuanced than can be explained by 
a single metabolic phenotype and recent evidence highlights an unexpected complexity of 
alterations in metabolic pathways within tumors. These recent studies also highlight the importance 
of “metabolic coupling” between cancer and stromal cells. They suggest that tumor cells promote 
their own growth and survival by behaving as a “parasitic organism”. Hence, the term “parasitic 
cancer metabolism” to describe this type of metabolic-coupling in tumors has been proposed. 
 
3.4.1 Cancer cells behave as Metabolic Parasites: lactate and FFAs from stromal cells promotes 
mitochondrial metabolism in cancer cells, fueling tumor growth 
 
According to the “Reverse Warburg Effect” (discussed above), epithelial cancer cells induce 
oxidative stress in adjacent stromal fibroblasts, by secreting hydrogen peroxide and activating NF-
κB, these cause stromal fibroblast activation, with the upregulation of HIF1 activity driving 
autophagy, mitophagy, aerobic glycolysis and local inflammation state in the tumor stroma [328]; 
[334]; [333];  [335]; [329]; [405]. As such, the stroma provides catabolized nutrients to “fuel” the 
anabolic growth of tumor cells by enhancing their mitochondrial activity. L-lactate derived from 
glycolytic fibroblasts is transferred to cancer cells and is used to generate energy. Similarly, ketone 
bodies and glutamine derived from host cell catabolism can also fuel the mitochondrial activity of 
adjacent epithelial cancer cells (Figure 20).  
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Figure 20. Energy transfer in cancer metabolism. Cancer cells induce oxidative stress in adjacent stromal 
cells by secreting hydrogen peroxide, activating NF-κB and upregluating HIF-1 to drive autophagy, 
mitophagy, aerobic glycolysis and local inflammation state in the tumor stroma. Thus, the stroma provides 
catabolized nutrients: lactate, ketones, Glutamine and fatty acid to “fuel” the anabolic growth of tumor cells. 
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In the obese, an increased rate of lipolysis is observed in adipocytes. In line with this concept, 
enhanced lipolysis in host tissues can potentially fuel tumor growth by releasing free fatty acids 
(FFAs) from host adipocytes to be recycled via β-oxidation in cancer cell mitochondria.  
Over 80% of ovarian cancers are metastatic to the omental fat. Currently, it is unclear why ovarian 
cancer cells preferentially seed the omentum as compared to other sites. To address this issue, 
Nieman et al., showed that human omental adipocytes promote homing, migration and invasion of 
ovarian cancer cells, and that adipokines including IL-8 mediate these activities; a co-culture model 
of adipocytes with ovarian cancer cells suggested that, in the presence of ovarian cancer cells, 
adipocytes released significantly higher levels of FFAs and glycerol than adipocytes cultured in the 
absence of cancer cells; coculture led to the direct transfer of lipids from adipocytes to ovarian 
cancer cells and promoted in vitro and in vivo tumor growth. Moreover, they demonstrate that 
ovarian cancer cells have higher mitochondrial metabolic activity, specifically fatty acid β-
oxidation, when cocultured with adipocytes compare to cancer cells alone. The adipocyte fatty acid 
binding protein FABP4 was identified as a key mediator of ovarian cancer cell-adipocyte 
interaction [71]. These results suggested high-energy nutrients provided by host cells may bolster 
mitochondrial metabolism in cancer cells, but how these adipocyte-derived fatty acids are stored as 
TG in cancer cells and liberated as free fatty acid, whether  mitochondria β-oxidation is important 
for tumor progression,  was not demonstrated. 
 
3.4.2 Adipocyte lipolysis promotes Cancer-Associated Cachexia driving tumor growth and tumor 
may possess this lipolytic activity supporting their malignant behavior 
 
Cancer associated cachexia (CAC) is a multi-factorial wasting syndrome, accounting for about 20% 
of cancer death, characterized by the loss of adipose tissue and skeletal muscle mass, which lead to 
physical impairment [406]. The severity of cachexia varies depending on the tumor type, site, and 
stage [407]. CAC is prevalent in patients suffering from gastrointestinal and pancreatic 
adenocarcinoma, occurring in 80-90% of patients. It also arises in patients suffering from other 
carcinomas, although to a lesser extent [408]. Patients suffering from CAC lose on average 32% of 
their body weight, 75% of their skeletal muscle, as well as 85% of total body fat [409]. The 
mechanism underlying CAC are poorly understood. Indeed, nutritional supplementation has largely 
failed to reverse the wasting process, thus, anorexia is unlikely to be solely responsible for the loss 
of weight in CAC [410]. The loss of muscle mass might be a result of decreased protein synthesis, 
increased protein catabolism, or both depending on the tumor or stage of CAC. Recent reports 
recognize a prominent role for lipid metabolism and triglyceride lipases in the initiation and/or 
progression of CAC [411]; [412];  [413].  
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Triacylglycerol (TAG) stored in WAT is broken down into FFAs and glycerol by a highly regulated 
process known as lipolysis, a process of three subsequent steps catalyzed by three essential lipases. 
ATGL catalyzes the rate-limiting first step, converting TAG into diacylglycerol (DAG) and a free 
FA. DAG is then acted upon by HSL to remove the second FA to form monoacylglycerol (MAG). 
The third and final enzyme, monoglyceride lipase (MGL) converts MAG into glycerol and a third 
free FA. Thus three molecules of FA are released in this process that are then either re-esterified to 
form new TAG or shuttled to metabolically active tissues where they undergo fatty acid oxidation 
to generate energy or might be used for anabolic process. Lipolysis is influenced by several 
additional factors that regulate the activities of these essential lipases, and both lipolysis and 
lipogenesis not only regulate the homeostasis of WAT but also direct systemic energy production 
(described in the second part). 
The processes leading to the depletion of TAG reserves involve decreased lipogenesis, like the 
activity of FA synthase are reduced in WAT adjacent to the tumor, compared with distant WAT, in 
samples from 32 colorectal cancer patients [414]; [415] and most prominently, increased lipolysis 
[416]. Tisdale et al., has observed there is elevated levels of serum TAG and cholesterol in patients 
suffering from CAC and a marked increase in FA and glycerol concentrations in CAC patients as 
compared to weight-stable cancer patients. There is twofold increase in HSL expression in WAT 
and a similar elevation of free FAs in serum from cancer patients and patients in the early phases of 
CAC, compared with normal controls [417]; [418]; [419]. ATGL expression is somewhat enhanced 
in WAT of cachectic cancer patients; however, the increase was not significant [419]. Suman et al., 
used two different cachexia models in mice lacking either Atgl or Hsl. They observed that ATGL 
activity increases in parallel with tumor growth and WAT mobilization, the induction of lipolysis is 
not observed in the absence of ATGL and significantly reduced in the absence of HSL. Thus, lipase 
deficiency blocks tumor-induced WAT loss. Moreover, they also found that in gastrocnemius 
muscle samples of WT mice with Lewis lung carcinoma (LLC), there is 1.8- to 2.5- fold increased 
mRNA expression levels of genes involved in the regulation of cellular FA uptake (CD36 and fatty 
acid transport protein-1, Fatp-1), CPT-1β, and mitochondrial function (PGC-1α), no changement in 
Atgl
-/-
mice in response to LLC which suggested the increased FA oxidation in skeletal muscle of 
CAC patients [412]; [420]. Based on this work, it is tempting to speculate that drugs targeting 
adipose tissue lipases may represent a therapeutic strategy to avoid the devastating conditions of 
CAC. These data provide additional support for the intense metabolic-coupling between cancer and 
host cells.  
As we know that tumor cells display progressive changes in metabolism that correlate with 
malignancy, including storage of FFAs from surrounding adipocytes as TG or development of a 
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lipogenic phenotype. However, how stored fats are liberated and remodeled to support cancer 
pathogenesis, do they also possess these lipases that favor their own metabolic transformation? 
Nomura et al., used functional proteomic methods to discover MAGL highly elevated in aggressive 
cancer cells from multiple tissues of origin. They showed that MAGL, through hydrolysis of MAG, 
controls FFA levels in cancer cells. The resulting MAGL-FFA pathway feeds into a diverse lipid 
network enriched in protumorigenic signaling molecules and promotes migration, survival, and in 
vivo tumor growth. shMAGL melanoma, ovarian and breast cancer cells exhibited significantly 
reduced in vitro migration, invasion and cell survival under serum-starvation conditions. Thus, 
aggressive cancer cells possess high lipolytic activity to generate an array of protumorigenic signals 
that support their malignant behavior [421]. This is consistent with further observation indicating 
that MAGL is elevated in androgen-independent versus androgen-dependent human prostate cancer 
cell lines, and that pharmacological or RNA-interference disruption of this enzyme impairs prostate 
cancer aggressiveness. Furthermore, they showed that MAGL is part of a gene signature correlated 
with epithelial-to-mesenchymal transition and the stem-like properties of cancer cells that may 
support their progression to a high-malignancy state [422]. Another study demonstrated colorectal 
cancer cells growth can be inhibited via knockdown of MAGL through repress Cyclin D1 and Bcl-2 
to reduce cell proliferation and increase apoptosis [423].  
Although the relationship between the synthesis, storage and the use of FFAs in tumor cells is still 
poorly understood, it becomes clear that lipid metabolites, supplied either by exogenous sources—
such as adipose tissue, or by intracellular de novo synthesis, are required for promoting tumor 
growth and metastasis. 
 
Taken together, over the past three decades, ground-breaking work has been performed on 
expanding our knowledge of the altered cellular signaling mechanisms responsible for the 
progression from healthy cells to transformed, aggressively growing tissues. Two new areas have 
received more attention in the more recent past. One is the increased realization that the stromal 
microenvironment surrounding the tumor cells plays a critical role for tumor progression and 
metastasis. Growing evidence from epidemiologic and preclinical studies highlights the link 
between obesity and cancer. The molecular mechanisms responsible for this adipocyte-cancer cell 
heterotypic crosstalk have remained largely unknown. However, it is likely that this interplay 
between adipocytes and tumor cells may lead to adipose tissue remodeling, including acquisition of 
the adipocytes of a fibroblast-like phenotype, altered adipokine production, thereby affecting the 
remodeling of the local ECM as well as local and systemic inflammation, enhanced angiogenesis as 
well as altered lipids metabolism. And these molecular alterations would be amplified because of 
adipose tissue dysfunction in obese condition.  
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The second area of interest focus on tumor metabolism, reviving the original observations related to 
the Warburg effect. While the importance of the host microenvironment and energy transfer in 
cancer metabolism is highlighted. More studies on two compartment tumor metabolism will be 
necessary to understand and therapeutically exploit the metabolic coupling between “parasitic” 
tumor cells and their hosts. Uncoupling “parasitic” tumor cells should allow us to starve cancer cells 
and effectively treat advanced and metastatic cancers. With the fatty acid oxidation in the limelight, 
we further speculate that concurrent targeting of FA oxidation in tumor cells could be a highly 
effective anticancer approach. 
 
Therefore, to date, there is no literature report the “metabolic symbiosis” between breast cancer and 
their close neighborhood: adipocytes. The lipolytic activity in breast cancer to favor their metabolic 
transformation is also in dark. My work is to shed in light the crosstalk between adipocytes and 
breast cancer cells, specially the “metabolic part” and underscore the need to fully understand the 
role of this heterotypic signaling in modulating tumor behavior. 
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E-mail address: catherine.muller@ipbs.fr (C. MulleAmong the many different cell types surrounding breast cancer cells, the most abundant are those that
compose mammary adipose tissue, mainly mature adipocytes and progenitors. New accumulating recent
evidences bring the tumor-surrounding adipose tissue into the light as a key component of breast cancer
progression. The purpose of this review is to emphasize the role that adipose tissue might play by locally
affecting breast cancer cell behavior and subsequent clinical consequences arising from this dialog. Two
particular clinical aspects are addressed: obesity that was identified as an independent negative prognos-
tic factor in breast cancer and the oncological safety of autologous fat transfer used in reconstructive sur-
gery for breast cancer patients. This is preceded by the overall description of adipose tissue composition
and function with special emphasis on the specificity of adipose depots and the species differences, key
experimental aspects that need to be taken in account when cancer is considered.
 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
There is now cumulative evidence that cells immediately adja-
cent to a tumor are not only passive structural elements but also
active actors in tumor progression (for reviews [1–3]). The tumor
mass is undoubtedly a multifaceted show, where different cell
types, including neoplastic cells, fibroblasts, endothelial and
immune-competent cells, interact with one another continuously
to favor tumor progression [1,4]. The carcinoma stroma shares
many traits with conditions of chronic inflammation or wound
healing and accordingly, tumors have been described as ‘‘wounds
that never heals’’ [5]. Infiltration of inflammatory cells including
T cells, neutrophils and macrophages, among others, is a very com-
mon feature in breast cancer lesions [6,7]. In addition, it is becom-
ing increasingly clear that cancer-associated fibroblasts (CAFs) are
also prominent modifiers of breast cancer progression [2].
Among the many different cell types surrounding breast cancer
cells, the most abundant are those that compose mammary adi-
pose tissue (MAT) (see Fig. 1), mainly mature adipocytes and pro-
genitors (preadipocytes and Adipose-Derived Stem cells [ADSCs]).
For a long time, MAT has not been considered more than a casuald Ltd. All rights reserved.
ie et de Biologie Structurale,
31077 Toulouse, France. Tel.:
r).observer, and certainly not a disease modifying entity. However,
recent accumulating evidences bring the tumor-surrounding adi-
pose tissue into the light as a key component of breast cancer pro-
gression. Both progenitors and mature adipocytes are not passive
towards breast cancer cells and exhibit specific traits that begin
to be characterized, as their ability to contribute to local inflamma-
tion through IL-6 secretion [8,9]. The effect of MAT does not appear
to be limited to tumor progression but may also affect the early
stages of carcinogenesis and the response to treatment of estab-
lished tumors [10].
Studying the multifaceted role of MAT in breast cancer is of
major clinical importance. In fact, obesity has recently emerged
as an independent negative prognosis factor for breast cancer inde-
pendently of menopause status [11,12]. This relationship has major
consequences in public health since the prevalence of overweight
and obesity has been increasing worldwide over the past decades
and reaches alarming dimensions. According to the World Health
Organization (WHO), by 2015 there will be 3 billion overweight
and 700 million obese adults worldwide. Although not demon-
strated experimentally, one might reasonably speculate that the
positive contribution of MAT into tumor progression might be
amplified in obese women, therefore explaining in part the poor
prognosis observed in this subset of patients. The expected striking
increase in the incidence of these aggressive cancers in the near
future related to obesity turns the knowledge of this field of great
impact. Another clinical consequence of the experimental studies
Ad
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Fig. 1. In breast cancers, early local tumor invasion results in immediate proximity
of cancer cells to adipose tissue. Histological examination of an invasive breast
tumor after H&E staining (original magnification X 200). Ad, adipose tissue; IF,
invasive front; C, tumor center. Note that at the invasive front, the number and size
of adipocytes are reduced (indicated by arrows).
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autologous fat transfer, also defined as lipofilling procedures, used
to improve the results of the total or partial reconstruction in
breast cancer patients [13].
The purpose of this review is to emphasize the role that MAT
might play by locally affecting breast cancer cell behavior and sub-
sequent clinical consequences arising from this dialog. This will be
preceded by the overall description of adipose tissue (AT) compo-
sition and function with special emphasis on the specificity of adi-
pose depots and the species differences, key aspects that need to be
taken in account when cancer is considered. Of note, AT constitutes
an active endocrine organ that can have far-reaching effects on the
physiology of other tissues. To understand the endocrine effect of
adipose tissue on breast cancer the reader is referred to reviews
on that topic [14,15].2. White adipose tissues: common features and differences,
consequences on breast cancer studies
2.1. Characterization of white adipose tissues: common features and
depot-specific differences in obesity conditions
Mammals have two main types of adipose tissue: white adipose
tissue (WAT), and brown adipose tissue (BAT), each of which pos-
sesses unique cell autonomous properties. While WAT is special-
ized in storing energy and is an important endocrine organNormal Mammary Adipose Tissue
Fig. 2. Differences between in vivo mature adipocytes and in vitro differentiated cells.
staining (original magnification X 400). Note that mature white adipocytes have a single l
a reduced rim of cytoplasm. Right panel, phase contrast microscopy of preadipocytes cells
rounded shape with multiple lipid droplets in the cytoplasm.involved mainly in the control of weight regulation, the BAT is
the main tissue regulating thermogenesis in response to food in-
take and cold. WAT, which will be covered in this review, is mainly
comprised of adipocytes, although other cell types contained in the
so-called stroma vascular fraction (SVF) contribute to its growth
and function, including ADSCs, preadipocytes, lymphocytes, mac-
rophages, fibroblasts and vascular endothelial cells [16]. Mature
white adipocytes have a spherical shape and a single lipid droplet,
surrounded by a reduced rim of cytoplasm, which essentially occu-
pies the fat cell volume (see Fig. 2). Mature adipocytes, first
thought as energy-storing cells, have emerged this last decade as
highly endocrine cells which are able to secrete hormones, growth
factors, chemokines or pro-inflammatory molecules, an heteroge-
neous group of molecules termed «adipokines» [16]. Traditionally,
the two major adipose depots considered and the more extensively
studied are the visceral (VAT) and subcutaneous (SAT) adipose tis-
sues. Differences between adipocytes from visceral and subcutane-
ous depots have been recognized for many years including their
unique profile of adipokines production (for review see, [16]). In
addition, VAT adipocytes exhibit higher rates of fatty acid turnover
and lipolysis, and are less responsive to the anti-lipolytic effects of
insulin and catecholamines than SAT adipocytes [17]. There is
clearly a different impact on VAT versus SAT on human health. In-
crease in VAT is particularly linked to obesity-related complication
such as type 2 diabetes, cardiovascular diseases and dyslipidemias
whereas, storage of fat in subcutaneous adipose tissue (SAT) is
linked to a lower risk for such conditions [16]. Accumulating evi-
dence indicates that a state of chronic low-grade inflammation
has a crucial role in the pathogenesis of obesity-related metabolic
dysfunction in intra-abdominal adipose depots as opposed to sub-
cutaneous depots. Accordingly, obese subjects were found to har-
bor increased AT macrophage content mainly in visceral depots
[16,18].2.2. What are the specificities of mammary adipose tissue?
The different impact of visceral versus subcutaneous fat on
health during obesity conditions highlights an important concept
in adipose tissue biology, namely, that fat in different body loca-
tions exhibits distinct features and functional characteristics.
Regarding this later point, what is the specificity of MAT? The
mammary gland is comprised of myoepithelial and luminal epithe-
lial cells embedded in a complex stroma termed mammary fat pad
composed predominantly of fibroblasts and adipocytes, and cells of
both the interspersed vasculature and lymphatic systems [19]. AIn vitro differentiated preadipocytes 
Left panel, Histological examination of normal mammary adipose tissue after H&E
ipid droplet (in white), which essentially occupies the fat cell volume surrounded by
after differentiation into mature adipocytes. Note that the differentiated cells have a
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mammary fat pad is essential for the post-natal development of
mammary epithelium by providing signals mediating ductal mor-
phogenesis [19,20]. Adipocytes within the mammary fat pad spe-
cifically participate to the development of the normal mammary
gland. For example, it has been shown that the total absence of
breast fat in transgenic mice prevents normal mammary gland
development [21]. The mammary adipocytes are very active during
the transitions from pregnancy to lactation and into involution
(corresponding to the post-lactation regression of mammary epi-
thelium) underlying their responsiveness to local signals from
the epithelium [22]. Briefly, during lactation, mammary adipocytes
in close proximity to epithelial cells exhibit rapid depletion of their
lipid store due to enhanced lipolysis. By contrast, the involution
period is associated to a refilling of mammary adipocytes that is
completed approximately within 4 days. Intimate and bidirectional
interaction with adjacent epithelium is one of the hallmarks of
mammary adipocytes, suggesting that this dialog might persist in
physiopathological conditions such as cancer. It is also very impor-
tant to underline that there is undoubtedly species differences con-
cerning the composition and function of mammary fat pad
between humans and rodents that should be taken in account
when results obtained in rodents are extrapolated to humans. In
contrast to rodents where the mammary fat pad consists primarily
of adipocytes, human mammary adipose tissue is extensively
interlaced with a network of fibroblasts and associated connective
tissue [20]. Therefore, in murine mammary glands, the adipocytes
are immediately adjacent to the ductal epithelial cells, whereas in
human mammary glands, a fibrous layer separates the two cell
types. In addition, it has been clearly shown that human mammary
epithelium transplanted into the mammary fat pad of mice did not
grow out unless human stromal fibroblasts are incorporated into
the cleared fat pad [23].
2.3. Models used to study the AT/breast cancer crosstalk: from
established preadipose cell lines to freshly isolated cells
These specificities in terms of depots as well as species raise the
question of the source of adipose cells that should be used in
experimental studies to study the breast cancer/adipose tissue
connection. The detailed description of all the available human
and murine models can be found in the extensive review recently
written by Lafontan [24]. For feasibility reasons, the most common
in vitro models used are the murine preadipocyte cell lines 3T3-L1
and 3T3-F442A cells. These cell lines were clonally isolated from
Swiss 3T3 cells (derived from disaggregated 17- to 19-day mouse
embryos). This clonality circumvents donor-to-donor variability
of primary cells, providing standardized conditions [24,25]. They
exhibit a fibroblast-like morphology and are already committed
in the adipocyte lineage. Their differentiation into mature adipo-
cytes can be achieved in vitro by the addition to confluent cells,
in a serum-containing medium, of adipogenic stimuli, including
glucocorticoids (dexamethasone), drugs that increase cyclic AMP
levels (IBMX) and insulin for 3T3-L1 and insulin alone for
3T3-F442A, that are committed to a later stage of adipocyte
differentiation [24,25]. Although these in vitro models share many
similarities with primary adipocytes—including triglycerides stor-
age, expression of adipocyte-specific genes and responsiveness to
lipogenic and lipolytic factors, some differences persist. For exam-
ple, triglycerides are stored in multiple lipid droplets in in vitro dif-
ferentiated adipocytes in contrast to normal mature adipocytes
that exhibit a unique large lipid droplet (see Fig. 2). This ‘‘incom-
plete’’ differentiation might lead to a lower expression of some
genes and several adipocytes functions such as adipokines secre-
tion. This is the case for example of leptin [26], an adipokine
involved in the stimulation of the proliferative and migratoryproperties of cancer cells (see below). To circumvent these limits,
the use of long-term culture of 3T3-L1 differentiated on 3D poly-
meric scaffolds has been proposed [27]. In vivo transplantation
studies strongly reinforce the interest of these models, especially
the 3T3-F442A preadipose cell line. In fact, when implanted subcu-
taneously into athymic mice at an anatomic site devoid of adipose
tissue, the 3T3-F442A preadipocytes differentiate, and within few
weeks, fat pads morphologically similar to normal subcutaneous
adipose tissue developed at the site of injection [26]. An original
2D coculture system setup in our laboratory using human breast
cancer cell lines and in vitro differentiated 3T3-F442A adipocytes
mimics the adipocytes changes observed at the invasive front of
breast tumors [9], underscoring the validity of these mouse models
in cancer studies (see also below Section 3). More recently, a hu-
man multipotent adipose-derived stem cells (hMADS) cell line
was isolated from the adipose tissue of young donors and estab-
lished in culture. When differentiated into adipocytes, the cells
show a lipolytic system similar to that reported in human mature
adipocytes, therefore representing a promising tool in adipocyte
biology [24]. Finally, mature adipocytes can be obtained from the
in vitro differentiation of the SVF of adipose tissues (that contains
ADSCs) from human and rodents in defined culture conditions
either in 2D or 3D culture systems [24,28].
A clear limitation of the use of these human and murine prea-
dipocyte cell lines and primary precursors present in the SVF frac-
tion is that they are not suitable models to study obesity-related
condition due to their inability to undergo hypertrophy in vitro.
Therefore, the use of mature adipocytes isolated from AT of lean
and obese subjects should be considered. In fact, adipocytes iso-
lated from whole AT of either lean or obese (human or mouse) sub-
jects exhibit similar features in vitro than in situ as far as they are
maintained in appropriate culture conditions. From a structural
point of view, isolated fat cells from obese are hypertrophied while
those obtained from lean are smaller. Isolated adipocytes from lean
and obese subject exhibit also functional differences in terms of li-
pid mobilization and adipokines secretion [29,30]. The isolation of
adipocytes from the extracellular matrix and the SVF fraction is a
technique available in many laboratories whatever the AT consid-
ered including MAT [9]. Briefly, collagenase treatment of AT release
the fat cells from extracellular matrix. Fat cells, owing to their own
fat content are floating whether the SVF fraction remains in the
pellet [24]. Coculture system using this source of cells to obtain in-
sight into the crosstalk with tumor cell population is clearly lim-
ited by the fact that these isolated mature adipocytes cannot be
used for long terms culture. Isolated adipocytes in suspension in
an appropriate culture medium remain viable for approximately
24 h but after this period both survival and function are profoundly
altered [24]. Primary culture of AT explants represents a useful
alternative to both improve adipocyte viability and preserve the
entire tissue environment and structure. Several laboratories have
been using adipose tissue explants culture to study the influence of
various pharmacological or nutritional factors. Adipocytes can also
be isolated from the explants after the treatment in order to focus
on the fat cell itself [29]. However, such a tri-dimensional struc-
tures in vitro do not allow an accurate oxygen and nutrients supply
during long -term periods leading to hypoxia-induced alterations
of adipocyte function such as an increased anaerobic glycolysis
or TNF-a accumulation [31]. Therefore, adipose tissue explants
must be considered as useful over less than 48 h period after cul-
ture. Again, 3D culture of isolated adipocytes from lean and obese
subjects on various scaffolds remains the most promising alterna-
tive for long-term coculture, model which is currently largely un-
tapped with the exception of some studies using isolated
adipocytes from rat and mice AT [32,33]. Finally, to study the
in vivo cross-talk in both rodents and human breast tumors,
modifications of the tumor-surrounding adipose tissue could be
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isolated mature adipocytes and precursors [9] or a proteomic ap-
proach [36].
To conclude, as a first step, the use of human and murine prea-
dipocyte cell lines after in vitro differentiation represents highly
useful tools to study the crosstalk with breast cancer cells. Never-
theless, the results obtained should be validated in vitro using
mammary primary adipose cells in 2D (and ideally in 3D) coculture
systems and in vivo in human breast tumors to ensure their
relevance.3. Paracrine role of the different components of adipose tissue
in breast cancer progression
There are long standing arguments in the literature showing
that fat tissue is able to support and amplify breast cancer progres-
sion. In 1992, Eliott and colleagues showed that the murine carci-
noma SP1 cell line grew best when injected in the mesenteric and
ovarian fat pads and in the mammary gland, but very poorly in the
subcutis or peritoneal cavity [37]. Moreover, mammary tumors
cells transplanted into various adipose tissue depots subsequently
metastasize to different organs. Massive dissemination of tumors
from the ovarian and mesenteric sites occurs to the liver, spleen
and diaphragm whether metastases from the mammary site occur
primarily in the lung [37]. The positive influence of the local mam-
mary fat-rich microenvironment on breast cancer growth is also
sustained by the increase in xenograft success in mice when ortho-
topic, rather than subcutaneous, injections are employed [38]. In
humans, it has been proposed that the adipose tissue invasion
(ATI) at the tumor margin, as well as the invasive length of fat inva-
sion, are indicators of tumor aggressiveness in early stage breast
cancers [39]. It has been previously emphasized that adipose tissue
at close distance to breast tumors is a source of pro-inflammatory
cytokines such as IL-6, TNF-a, and reactive oxygen species [40]. A
detailed proteomic study of fresh fat tissue samples collected from
tumors of high risk breast cancer patients identified a large array of
proteins, including numerous signalling molecules, hormones,
cytokines, and growth factors, involved in a variety of biological
processes such as signal transduction and cell communication, en-
ergy metabolism, protein metabolism, cell growth and/or mainte-
nance, immune response and apoptosis [36]. As stated before, AT
is composed of different cell types. Accordingly, regarding the spe-
cific cellular components of this tissue, namely mature adipocytes
and preadipocytes/ADSCs, two important questions remain open:
do they both participate in breast tumor progression and what
are the signalling pathways involved?3.1. Mature adipocytes are key actors in breast cancer progression: the
concept of cancer-associated adipocytes (CAAs)
As mentioned before, mature adipocytes are highly active endo-
crine cells and are therefore excellent candidates to play a crucial
role in the control of tumor behavior through heterotypic signal-
ling processes. One of the first evidence of their role in breast can-
cer progression came from the study of Manabe et al. [41], showing
that the rat mature adipocytes, but not the preadipocytes, promote
the growth of several oestrogen-receptor (ER)-positive breast can-
cer cell types. The same year, the pioneering study of the group of
P. Scherer demonstrated that the full complement of adipokines,
represented by the conditioned-medium of mature 3T3-L1 murine
adipocytes, showed an unparalleled ability to promote the growth,
cell motility and invasion of ER-negative and positive breast cancer
cells in vitro [42]. Combined, these first studies shed in light the
crosstalk between adipocytes and breast cancer cells and under-score the need to fully understand the role of this heterotypic sig-
nalling in modulation of tumor behavior.
As stated in the introduction of this review, cancer cells usually
go about generating a supportive microenvironment by activating
the wound-healing response of the host. For example, resident
fibroblasts are capable of adapting to tissue injury (including can-
cer), and as a result change their phenotype to become ‘‘reactive.’’
In order to investigate if such phenotypic changes are observed in
tumor-surrounding adipocytes, a 2D coculture system in which
adipocytes and breast cancer cells were separated by an insert, that
allows the diffusion of soluble factors, was setup in our laboratory
to mimic the adipocyte-cancer cell crosstalk at the tumor invasive
front [9]. Using this original model, we extensively described tu-
mor-induced changes in adipocytes that are reproducibly dis-
played by both mouse and human mammary adipocytes.
Adipocytes cocultivated with various human and murine breast
cancer cell lines generally exhibit a loss of lipid content, a decrease
in late adipose markers expression, and over-expression of inflam-
matory cytokines (such as IL-6 and IL-1b) and proteases (such as
MMP-11 and PAI-1). We named these tumor-surrounding adipo-
cytes, ‘‘Cancer-Associated Adipocytes’’ (CAAs). Equally important,
using immunohistochemistry and quantitative PCR, we confirmed
the presence of these modified adipocytes in human breast tumors.
What are the effects of these CAAs on tumor progression? All mur-
ine and human tumor cells cocultivated with mature adipocytes
exhibited increased invasive, but not proliferative, capacities
in vitro and in vivo. In tumor cells, these increase invasive capaci-
ties were associated with incomplete epithelial to mesenchymal
transition (EMT). In the case of IL-6, we further showed that it
plays a key role in the acquired pro-invasive effect, and associated
EMT, by tumor cells. Interestingly, the human breast tumors of lar-
ger size and/or with lymph nodes involvement exhibit the higher
levels of IL-6 in tumor surrounding adipocytes [9]. Such an inflam-
matory state in the tumor-surrounding adipose tissue has also
been described for prostate cancer. High levels of IL-6 were found
in the periprostatic adipose tissue of tumor-bearing patients and
the levels of IL-6 correlated with the aggressiveness of the tumors,
highlighting the importance of this cytokine in the adipocyte/can-
cer cells crosstalk [43]. Another very important aspect of this cross-
talk concerns the remodelling of the ECM. Collagen VI (COLVI) is
abundantly expressed in tumor-surrounding adipocytes and adi-
pocyte-derived COLVI production is involved in mammary tumor
progression in vivo [35,42]. In the same way, adipocytes at the
invasive front of human tumors consistently exhibit increased
expression of metalloprotease 11 (MMP-11)/stromelysin 3 [34]. In-
crease local fibrosis and its permanent remodelling (generating
ECM components functioning as signalling molecules) have been
clearly implicated in tumor progression. This association seems
to justify prominently, the role of both COLVI and MMP-11 overex-
pression in a tumor context. In addition, these events might di-
rectly contribute to the occurrence of the CAAs phenotype since
adipocytes actively reorganize the ECM during differentiation pro-
cesses [44]. For example, it has been shown that MMP-11 is a po-
tent negative regulator of adipogenesis [34]. In fact, a relative
degree of ‘‘dedifferentiation’’ is one of the hallmarks of CAAs [9,34].
Supported by epidemiological evidence, animal models and
in vitro studies, two adipokines, leptin and adiponectin, have been
largely involved in breast cancer occurrence and progression
[15,45]. Schematically, leptin appears to promote tumor cells
growth by mainly stimulating the activity of signalling pathways
involved in proliferation process whereas adiponectin repressed
proliferation and induced apoptosis, in breast cancer cells
[15,45]. The paracrine local implication for these adipokines in
breast cancer cells appears to be weaker, or at least less character-
ized, than their endocrine effects. We found that CAAs exhibit a de-
crease in late adipose markers including leptin (Dirat et al.,
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ily involved in the negative crosstalk between adipocytes and
breast cancer cells at the invasive front. By contrast, adiponectin
expression is absent in CAAs suggesting that its negative effect
on tumor progression might be hampered in these tumor-modified
adipocytes [9]. CAAs derived-factors might also affect in turn the
secreted profile of tumor cells. For example, it has been shown that
adipocytes stimulate the expression of genes related to immune
function and wound-healing in tumor cells, such as the chemokine
CCL-20, the macrophage inhibitory cytokine 1 (MIC-1) or even IL-6
[10,46,47], contributing among others things, to increase tumor
invasiveness. Finally, one probably underestimated effect of adipo-
cyte/cancer crosstalk is its role in the response to antitumor ther-
apy. We have recently shown that CAAs contribute to the
occurrence of a radioresistant phenotype in breast tumor cells
[10]. In a different tumor model (i.e. acute lymphoblastic leukae-
mia) it has been demonstrated that adipocytes impairs leukaemia
treatment by Vinca alkaloids both in vitro and in vivo [48]. Taken
together, all these data strongly support the concept that an inti-
mate crosstalk is established between cancer cells and mature adi-
pocytes at the invasive front of the tumor, whose relevance has
been clearly demonstrated in human tumors [9,34,35]. Invading
tumor cells are able to modify adipocytes phenotype, which, in
turn, stimulate cancer cells aggressive behavior, the stimulation
of local tumor invasiveness being, to our point of view, one of
the key events resulting from this crosstalk. The molecular cir-
cuitry involved in these processes as well as the resulting pheno-
typic changes observed in both populations is summarized in
Fig. 3.Fig. 3. Invading tumor cells are able to modify adipocytes phenotype, which, in turn, sti
results in immediate proximity of cancer cells to mature adipocytes. In turns, matu
aggressiveness of tumor cells by increasing tumor growth, tumor invasiveness and resist
also affect the secreted profile of tumor cells.3.2. Contribution of ADSCs and pre-adipocytes to breast cancer
progression
Studies have provided compelling in vivo evidences that mesen-
chymal stem cells (MSCs) distally recruited from the bone marrow
contribute to breast cancer progression [49]. Even though adipose
tissue is the most abundant stromal constituent in the breast and a
rich source of mesenchymal stem-like cells, only recent studies ad-
dressed the question of the involvement of this resident stem cells
population in breast cancer progression [50]. Globally, these stud-
ies demonstrated that ADSCs also contribute to tumor progression.
ADSCs promote in vitro and in vivo the growth and survival of
breast cancer cells as well as their migratory and invasive capaci-
ties [8,51–55]. Several molecules have been involved in the pro-
invasive effects of ADSCs including IL-6 [8], IL-8 [52], CCL-5 [53]
and CXCL-12/SDF-1 [55]. More recently, it has been demonstrated
that ADSCs promote the expansion of cancer stem cells and induce
EMT in the cancer cells in a PDGF dependent manner [54]. As for
other components of the tumor stroma, a complex network is
established between tumor cells and ADSCs. Tumor cells, through
TGFb signalling, are able to «differentiate» ADSCs into CAF-like cells
expressing a-smooth muscle actin (a-SMA) and tenascin C [54,56].
Interestingly, ADSCs are themselves chemo-attracted towards
breast cancer cells [52,57]. Therefore, these compelling results sug-
gest that ADSCs could directly contribute to the dense network of
fibroblasts (the so-called desmoplastic reaction) frequently ob-
served in the center of breast tumors and, as such, be considered
as a subpopulation of CAFs. Of note most of these studies have been
performed using ADSCs from abdominal or subcutaneous sourcesmulate cancer cells aggressive behavior. In breast cancer, early local tumor invasion
re adipocytes exhibit profound changes. CAAs clearly contribute to increase the
ance to antitumor therapy including ionizing radiation. CAAs derived-factors might
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As stated before since adipose depots have different biochemical
profiles, it appears important to use breast-derived ADSCs when
investigating the effects of ‘‘resident’’ stem cells on breast cancer
cells. ADSCs obtained from reduction mammoplasty differentiate
along adipogenic, osteogenic and chondrogenic lineages in vitro
and exhibit similar gene expression profiles and an indistinguish-
able immunophenotype from ADSCs from abdominoplasty speci-
mens and bone marrow (BM)-MSCs [50]. However, notable gene
expression differences are observed between stem cells from dif-
ferent sources, with abdominal ADSCs being more similar to BM-
MSCs and breast-derived ADSCs being more similar amongst them
when compared to abdominal ADSCs. A comparison of the gene
expression profiles breast ADSCs with BM-MSCs demonstrated that
numerous genes implicated in cell growth, matrix deposition,
remodelling, and angiogenesis are expressed at significantly higher
levels in the local/breast ADSCs relative to BM-MSCs, suggesting
that these resident stem-like cells may play a unique role in breast
cancer progression [50]. More committed preadipose cells such as
preadipocytes can also interact with breast cancer cells. It has been
demonstrated that adipocyte differentiation is inhibited when pre-
adipocytes are cocultivated with various breast cancer cell lines or
in the presence of breast cancer cells conditioned media, this effect
being dependent of TNF-a and IL-11 secreted by breast tumor cells
[58]. Finally, it has been proposed that 3T3-L1 preadipocytes fa-
vored in vitro and in vivo fibronectin deposition and remodelling
within the breast tumor microenvironment [59]. Again, these data
favor the concept of ADSCs/preadipocytes as constituents of the
CAFs population surrounding the tumors. However, it is important
to note that most of these data were obtained in coculture systemsFig. 4. Crosstalk between tumor cells and adipose progenitors contribute to breast cance
growth factors and cytokines, adipose progenitors. These activated progenitors or Adipos
Their increased migratory/invasive abilities allow them to join the center of the tum
progression. Note however that all these results have been mostly obtained in in vitro
models and have not been fully validated in human tumors.using breast cancer cell lines and isolated adipose precursors. In a
series of 28 samples, we observed no modifications of inflamma-
tory or protease gene expressions between the SVF fractions of
adipose tissue obtained from tumorectomy or reduction mammo-
plasty [9]. These results obtained in human tumors suggest that
within the cellular complexity of the adipose tissue, the crosstalk
with tumor cells is rather established with mature adipose cells,
than with their precursors. However, we cannot exclude that
changes concern a minor subpopulation that does not affect the
overall level of gene expression of the SVF fraction, which remains
highly heterogeneous. Further experiments are clearly needed to
assess that the phenotypic changes observed with isolated adipose
precursors can also be observed in human tumors. The molecular
circuitry involved in adipose precursors/tumor cells crosstalk
described to date as well as the resulting phenotypic changes
observed in both populations are summarized in Fig. 4.
4. Adipocytes could also contribute to carcinogenesis in
addition to tumor progression
It has been proposed that the stroma cells do not contribute
only to the progression of existing tumors but can also contribute
to early events in carcinogenesis [4,60]. Key to this ‘‘tumor micro-
environment’’ perspective of malignancy is the idea that ‘‘initiated
‘‘ genetically primed resident cells within a tissue have a low pre-
disposition to develop as a tumor and will probably remain dor-
mant unless exogenous stimuli such as factors produced by
activated stroma promote the carcinogenic process. A functional
link between inflammation and cancer has long been recognized.
Individuals suffering from chronic inflammatory disorders harborr progression. Invasive breast cancer cells could locally activate, via diverse soluble
e-Progenitors Derived Fibroblasts (ADPFs) exhibit similar characteristics than CAFs.
or and to participate to the desmoplastic reaction. These ADPFs stimulate tumor
coculture studies (mostly using ADSCs from other sources than MAT) and animal
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the procarcinogenic environment generated by activated inflam-
matory cells [4,60]. Several studies have shown that fibroblasts
can also induce a tumorigenic process. For example, when CAFs ob-
tained from lesions of prostatic adenocarcinoma are engrafted with
initiated but non tumorigenic prostate epithelial cells in mice,
these later cells form tumors [61]. Senescent fibroblasts were also
shown to have protumorigenic activity, underscoring a relation-
ship between aging and cancer [62]. In mice, deleting the activity
of one of the TGF-b receptors only within the fibroblasts leads to
epithelial tumors in the prostate and forestomach [63].
Is there a role for adipocytes in this ‘‘tissue-integrated’’ view of
carcinogenesis? Although not directly demonstrated, several stud-
ies argue in the favor of the later hypothesis. In mice, injection of
unirradiated mammary epithelial cells into irradiated epithelial-
cell-free (cleared) mammary fat pads resulted in neoplastic
transformation of the epithelial cells [64]. Interestingly, this effect
appears to be independent of the systemic radiation effects since
tumor incidence was restricted to the irradiated site as tested by
hemi-body irradiation [64]. Of note, adipocytes by themselves have
been described to be highly resistant to ionizing radiation [65]. Sim-
ilarly, Maffini and co-workers [66] demonstrated that treatment of
cleared mammary fat pads with the carcinogen N-nitroso-methyl
urea (NMU) generated a stroma environment that allowed the
development of epithelial tumors from transplanted normal epithe-
lial cells. They even showed that treatment of the epithelial cells
with NMU was not sufficient to induce tumor in untreated stromal
background, but rather, required the grafting onto NMU-treated
stroma [66]. Themechanisms bywhich this ‘‘activated’’ fat pad con-
tributes to carcinogenesis and the signalling events involved are
poorly understood. The fat pad consists, in addition to adipocytes,
of various cell types. However, while in the human mammary
gland, the developing mammary epithelium is closely sheathed
by stromal fibroblasts in addition to adipocytes, the mouse mam-
mary fat pad consists primarily of adipocytes [22]. Therefore, adipo-
cytes are probably key targets of the genotoxic compounds leading
to the stroma-dependent carcinogenesis models described above.
Also as part of this concept, it is important to note that many envi-
ronmental chemical carcinogens are indeed lipophilic, so they can
bio-accumulate into adipocytes lipid droplets [67]. The local release
of carcinogens from adipocytesmight directly initiate, or contribute
to the carcinogenesis process in adjacent epithelial cells. All of these
studies, though still preliminary and mostly conducted in mouse
models, open very interesting perspectives for the prevention,
detection and treatment of breast cancer in humans.5. Direct clinical consequences of the epithelial adipose tissue/
crosstalk
5.1. Obesity and breast cancer prognosis
One of the main clinical consequences of the intimate crosstalk
between adipose tissue and breast cancer concerns the prognosis
of breast cancer in obese patients. In fact, overweight (defined as
a body mass index [BMI] of 25–29.9 kg/m2) and obesity
(BMIP 30 kg/m2) are now established risk factors for cancer and
cancer-related mortality (for reviews see [11,12,68]). Concerning
breast cancer, early studies have clearly established that obese wo-
men have an increased risk of developing postmenopausal, but not
premenopausal, breast cancer [68]. Interestingly, the level of asso-
ciation with increasing adiposity becomes stronger with increasing
time since the menopause [69]. One of the major mechanism con-
tributing to the increased risk of post-menopausal breast cancer, as
well as endometrial cancer, associated to obesity is the increase in
circulating levels of estrogens since after the menopause theprincipal site of estrogens production is in the adipose tissue
[69]. Noteworthy, excess bodyweight is not only associated to in-
creased incidence of breast cancer, but is also an independent neg-
ative prognosis factor independently of menopause status (for
reviews see [11,12]). As already discussed before [12,70], multiple
factors might contribute to the poorer survival rates in obese pa-
tients with breast cancer including a higher likelihood of co-mor-
bid conditions and other ‘‘non-biological’’ effects. However, there
is now clear evidences that host factors contribute to the occur-
rence in obese women of tumors exhibiting at diagnosis an aggres-
sive biology defined by an increase in lymph nodes involvement
and a higher propensity to distant metastasis (reviewed in [12]).
In the largest retrospective clinical study published to date, Ewertz
et al. report that obesity is an independent prognosis factor for the
development of distant metastases and death after the diagnosis of
breast cancer [71]. The increased risk for obese women of develop-
ing distant metastases after 10 years, increased by almost 50% [71].
Obesity is associated with elevated levels of pro-inflammatory
cytokines in VAT and in the circulation, which generates a low-
grade, chronic inflammatory state [72]. One hallmark of obesity-
associated inflammation is the recruitment of macrophages into
adipose tissue, where they form characteristic ‘‘crown-like’’ struc-
tures (CLS) around apoptotic adipocytes [72]. Interestingly, we have
demonstrated that obesity and the defined profile of CAAs share
inflammation as common traits [9]. Furthermore, in breast human
tumors, the association of high levels of IL-6 in CAAs with high tu-
mor size and enhanced local invasion reflect those traits present
in obese patients [9]. Therefore, it is tempting to speculate that CAAs
within a context of obesity should bemore prone to amplify the neg-
ative crosstalk with tumor cells. Therefore, this assumption under-
lies that such an inflammatory condition also exists in breast
adipose tissue. In opposition to VAT, very little is known about
MAT and inflammation in obese subjects. Nevertheless, Subbarama-
iah et al. has recently shown that obesemice (involving both dietary
and genetics models of obesity) exhibit necrotic adipocytes sur-
rounded by macrophages forming CLS in both the mammary gland
and visceral fat [73]. Moreover, the presence of CLS was associated
with activation of NF-jB and increased levels of pro-inflammatory
mediators in the MAT of obese versus lean mice. The same team
has shown that these findings can be translated into women since
CLSwere founded in nearly 50% of breast tissue fromwomenunder-
goingmastectomy and the severity of breast inflammationwas cor-
relatedwith both BMI and breast adipocytes size [74]. Similarly, Sun
et al. has recently shown that normal breast tissue, obtained from
reduction mammoplasty of obese women, exhibit macrophages
infiltration and a significant enrichment for pathways involving
IL-6, IL-8, CCR5 signalling, consistent with a local pro-inflammatory
state [75]. Therefore, these compelling very recent results demon-
strate that obesity is associated with a sub-inflammatory state of
the MAT reinforcing the hypothesis of an amplified paracrine nega-
tive crosstalk between adipose tissue and tumor cells to explain the
poor prognosis observed in obese patients. However, this is still a
hypothesis that remains to be validated both in vitro and in vivo. In
mouse models, preliminary results have been obtained that links
obesity and the occurrence of high-grade adenocarcinomas, in-
creased tumor growth, as well as angiogenesis and distantmetasta-
sis [76,77]. These mouse models will be very helpful to identify the
paracrine mechanisms involved in the stimulation of tumor pro-
gression in order to setup specific strategies for the treatment of ob-
ese patients exhibiting aggressive diseases.
5.2. Safety concerns between autologous fat grafting and breast cancer
occurrence and recurrence
In plastic and reconstructive surgery, autologous fat grating
enables soft tissue augmentation and is increasingly used for
Y.-Y. Wang et al. / Cancer Letters 324 (2012) 142–151 149cosmetic indications but also for correction of defect following
breast cancer treatment. Schematically, this procedure first pro-
posed by Coleman, known as the Coleman technique, consists of
the harvesting of subcutaneous fat usually from the abdominal
wall or the thighs by a blunt liposuction cannula connected to a
syringe, followed by a short centrifugation and injection of the cel-
lular ‘‘fat’’ into the area of interest [78]. To maximize survival, fat is
generally injected in small parcels and thin strips at different levels
in the sub-cutis region of the breast [79]. Therefore, the injected
preparation contains mature adipocytes as well as all the cellular
components of the SVF including ADSCs/preadipocytes, endothelial
cells and progenitors, fibroblasts and macrophages. Because the
lipoaspirate contains at least two populations of cells, adipose pre-
cursors and mature adipocytes, which are involved in tumor–stro-
mal interaction as we discussed before, the potential risk of this
approach in increasing breast cancer recurrence (and even induc-
tion) needs to be addressed. To date, very few, if any, translational
studies to evaluate the risk of fat grafting using the lipofilling tech-
nique described above are available. In our hands, the coinjection
of fat used for lipofilling with human breast cancer cells dramati-
cally increases the tumor growth in mice (I. Garrido, unpublished
results). However, the design of the study was different from the
clinical situation since in human, autologous fat transfer is used
in treated patients and is expected to interact with dormant and
not actively growing tumor cells. At clinical levels, available series
addressing the oncological risk of lipotransfer in breast cancer pa-
tients are also limited [80]. Only one series using a retrospective
control group has been published to date [81]. For each of the
321 patients operated for a primary breast cancer between 1997
and 2008 who subsequently underwent lipofilling for reconstruc-
tive purpose, two matched patients with similar characteristics
who did not undergo a lipofilling were used as a control. This study
concludes that the lipofilling transfer for breast cancer patients
was a safe procedure. However, it is interesting to note that when
the analysis was limited to intra-epithelial neoplasia (37 patients),
the lipofilling group resulted at higher risk of local events [81].
Accordingly, prospective control protocols are clearly needed to
definitively assess the safety of the procedure. In addition, recent
fat transfer and lipoinjection protocols have focused on the addi-
tion of autologous ADSCs or freshly isolated adipose stromal vascu-
lar cells to promote graft volume retention [82]. This type of
procedures should be considered with even greater caution with
respect to conventional technique. In fact, a recent study demon-
strated that the coinjection of human WAT-CD34(+) endothelial
precursors cells (EPCs) from lipotransfer procedures contributed
to tumor vascularisation and significantly increased tumor growth
and metastases in several orthotopic models of human breast can-
cer in immunodeficient mice compared with coinjection with
CD34 EPCs or breast cancer cells alone [83]. Interestingly in this
study, the increase in axillary and lung metastases in mice injected
with CD34+ WAT cells was even observed when these cells are in-
jected after surgical removal of the initially transplanted tumor.
Therefore, this first translational study designed to address the
question of the safety of fat grafting highlights the urgent need
of controlled clinical trials when ‘‘enriched’’ fat sources are used
for lipofilling.6. Conclusion and perspectives
The AT has emerged these last 5 years as an integral and active
component of breast cancer microenvironment. The role of the var-
ious cellular actors of AT begins to be addressed and it is important
to underline that, to date, only the tumor-induced changes of
mature adipocytes, the so-called CAAs, have been demonstrated
in both in vitro studies, animal models and human tumors. Sincepopulation of obese people is constantly increasing, it is of funda-
mental and of clinical interest to further study the relationship
existing between adipocytes and breast cancer cells in order to
prevent and treat this subset of aggressive diseases. As found in ob-
ese patients exhibiting an increase in both local and distant inva-
sion, one of the principal hallmarks of the adipose tissue/cancer
crosstalk appears to imply the invasive properties of tumor cells.
Interestingly, it is suggested from several studies that tumor-sur-
rounding adipose tissue, by its ability to secrete pro-inflammatory
cytokines such as IL-6, contributes to local inflammation that con-
tribute to promote an aggressive phenotype in breast cancer.
Therefore, limiting inflammation through inhibition of IL-6 signal-
ling might represent an interesting strategy to block disease pro-
gression, a strategy that need to be tested in in vitro 3D coculture
models as well as in lean and obese conditions in vivo. CAAs appear
to promote tumor progression by acting at least directly on the tar-
get tumor cells. However, these stromal cells might also mediate
disease progression by secreting factors promoting angiogenesis
and/or by creating an immunosuppressive microenvironment,
hypothesis that remains to be explored. It is likely that the contin-
ued characterization of these interactions, and the molecular iden-
tification of key mediators, will provide new insights into tumor
biology and suggest further novel therapeutic options.Acknowledgements
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Oncological Risk After Autologous Lipoaspirate
Grafting in Breast Cancer Patients: From the Bench
to the Clinic and Back
Yuan Yuan Wang, MD,* Guo Sheng Ren, MD, PhD,Þ Jean-Yves Petit, MD,þ
and Catherine Muller, MD, PhD§
Restoring acceptable human appearance after cancer resection isan important part of the treatment process. Increasingly, autolo-
gous fat transfer is used by breast reconstructive surgeons following
cancer treatment, particularly in the realms of breast-conserving
surgery.1,2 Compared with other techniques, use of autologous fat
has several advantages, including biocompatibility, versatility, nat-
ural appearance, and low donor-site morbidity. Schematically, the
procedure used by the majority of surgeons, known as the Coleman
technique, consists of the harvesting of subcutaneous fat usually
from the abdominal wall or the thighs, followed by a short centri-
fugation and injection of the cellular ‘‘fat’’ into the area of interest.3
Therefore, the injected ‘‘fat’’ contains mature adipocytes as well as
all the other cellular components present in adipose tissue (AT)
including mainly adipose-derived stem cells (ADSCs)/preadipocytes
and endothelial cells/endothelial progenitor cells.4 The grafted fat
not only behaves as a filler, but also improves surrounding tissues,
bearing lesions such as scars, radiation damage, and breast capsular
contracture, into which the fat is placed.5 These effects clearly in-
dicate a modification of the local physiology at the recipient site
upon fat transfer.
Unfortunately, accumulating experimental evidence has revealed
that the factors accompanying tissue regeneration and revasculari-
zation are also critical to cancer growth and metastasis.6 In fact,
cancer cells usually go about generating a supportive microenvi-
ronment by activating the wound-healing response of the host, and
accordingly, tumors have been described as ‘‘wounds that never
heal.’’7 Therefore, this concept of tumor-stroma interaction in cancer
progression raises questions over the oncological safety of fat
transfer in cancer patients and indicates that this needs to be
addressed at both experimental and clinical levels. In considering
this question, we must first confirm whether AT, among other cel-
lular components of the stroma, is an active player in the mammary
tumor progression.
CELLULAR COMPONENTS OF THE ADIPOSE
TISSUE CONTRIBUTE TO BREAST
CANCER GROWTH
In fact, if we consider the ‘‘normal’’ cells surrounding a breast
tumor, the cells that compose the AT are clearly the most abundant.
In addition, in the case of invasive breast cancer, tumor cells come in
close contact with AT ( F1Fig. 1). Regarding the role of stromal cells in
breast cancer progression, earlier studies have emphasized the im-
portance of fibroblasts and macrophages,8 but an increasing curi-
osity has emerged these past few years concerning the role of AT.9
This growing interest is due to several reasons. On the one hand,
mature adipocytes have moved from relatively inert lipid-storing
cells to highly endocrine cellYsecreting growth factors, chemokines,
inflammatory cytokines, and extracellular matrix (ECM) proteinsV
all secretions capable of affecting tumor behavior.10 On the other
hand, the regenerative pluripotential of ADSCs has been clearly
demonstrated.11 Finally, obesity, where both the cellular composi-
tion and the normal balance of these AT secretory proteins are per-
FIGURE 1. Breast cancers are surrounded by AT. Histological examination
of an invasive breast tumor after hematoxylin-eosin staining (original
magnification 200). Ad indicates adipose tissue; IF, invasive front; C,
tumor centre. Note that at the invasive front the breast cancer cells become
in very close contact to adipocytes (indicated by arrows).
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turbed, has recently emerged as a negative prognosis factor for breast
cancerVindependent of menopausal status.12
Both major cellular components of AT, namely, mature adipo-
cytes and ADSCs, contribute to breast cancer progression (for recent
reviews from our laboratories, see Bertolini et al4 and Wang et al9).
We have recently demonstrated that tumor-surrounding adipocytes
strongly stimulated the invasive behavior of breast cancer cells both
in vitro (two-dimensional coculture system) and in mouse models.13
At least in vitro, the stimulatory effect of adipocytes was far more
pronounced on nonaggressive tumor cell lines.13 Interestingly, adi-
pocytes that are in close contact with tumor cells exhibit specific
traits including delipidation and decrease in late adipose markers
and inflammatory phenotype, traits that are found in human breast
tumors confirming the clinical relevance of our findings.13 In our
study, the proinvasive effect of adipocytes was mainly mediated by
interleukin 6. Interestingly, the human breast tumors of larger size
and/or with lymph node involvement exhibit the higher levels
of interleukin 6 in tumor-surrounding adipocytes.9,13 Other teams
have stressed the role of ECM (such as collagen VI) and ECM-
remodeling enzymes in the paracrine effect of adipocytes on breast
tumor progression. Finally, a wide range of molecules that enhance
tumor growth, survival, and invasion in both paracrine and endo-
crine manners are also secreted by adipocytes including, among
others, leptin and adiponectin.14
Adipose-derived stem cells are also a source of significant bio-
active molecules (for review, see Bertolini et al4). In autologous fat
transfer, ADSCs provide several benefits; they improve angiogene-
sis and graft vascularity and contribute actively to the adipocyte pool
allowing fat grafts to maintain their volume.15 As for mature adi-
pocytes, several studies demonstrated that ADSCs promote in vitro
and in vivo growth and survival of breast cancer cells as well as their
migratory and invasive capacities.4,9 Different functions of ADSCs
within the tumor should be considered. First, a number of different
studies have suggested that ADSCs might be activated by tumor
cells and in turn express activated fibroblasts markers such as >-
smooth muscle actin, as well as fibronectin and tenascin C.9 A recent
study demonstrated that these activated ADSCs led to ECM depo-
sition and contraction in vivo, thereby enhancing breast cancer tissue
stiffness, a parameter clearly contributing to breast cancer progres-
sion.16 Second, ADSCs might also contribute to tumor vasculari-
zation (for review, see Bertolini et al4). Recent elegant studies have
demonstrated that, in mice, ADSCs are recruited by experimental
tumors and promote cancer progression.17,18 These studies using
fluorescent-tagged cells show that these ADSCs contribute to the
formation of most vascular and fibrovascular stroma (pericytes, >-
smooth muscle actinYpositive myofibroblasts, and endothelial cells)
in murine tumors.18 Finally, the role of AT in tumor vascularization
is also sustained by the presence of CD34+ endothelial cell pro-
genitors within the AT itself, which have been reported to generate
endothelial cells and vessels in vitro and in vivo.19
Taken together, these studies convincingly demonstrate that
cellular components of mammary AT are key players in actively
growing and disseminating tumor cells. Could these results be ob-
served with subcutaneous AT that is generally used as a source in
lipofilling? In immunodeficient mice, when human AT (obtained
from lipotransfer procedures for breast reconstruction in breast
cancer patients) was coinjected with triple-negative breast tumor
cells, a clear increase in tumor volume was observed in comparison
to control group injected with tumor cells alone.19 Given the data
obtained before on the negative crosstalk between breast cancer and
AT, these results were as expected. However, 2 new results obtained
in this study merit our attention. First, the authors demonstrated that
this effect on tumor growth was mainly due to the CD34+ population
representing endothelial cell progenitors. Second, following tumor
resection, an increase in both lung and axillary metastases was ob-
served in mice injected with CD34+ cells from AT compared with
the control group without an AT graft.19 Although these experiments
were performed in mice, these results provide the first experimental
evidence that at least a certain population of cells present in sub-
cutaneous AT might favor the resurgence of quiescent and minority
tumor cells. In the context of these findings, what do the clinical
studies tell us?
CLINICAL STUDIES ON THE ONCOLOGICAL
SAFETY OF FAT GRAFTING
A bibliographic survey of past studies concerned with the applica-
bility and safety of autologous fat for the reconstruction of the breast
was published in 2012.20 This review included 60 articles with
around 4600 patients, of which only 3 studies specifically address the
risk of breast cancer (616 patients, mean follow-up of 45.2 months).20
From these 3 studies, which used standard Coleman techniques, there
was no evidence that fat grafting significantly increases the risk of
breast cancer.21Y23 However, of note and as underlined in this review,20
only our study conducted at the European Institute ofMilan included a
case-control group.23 A systematic review of the literature on the on-
cological safety of autologous lipoaspirate grafting in breast cancer
patients has been published this year.24 Again, this review underlines
the lack of cohort including a case-control group except our own study
and insists that larger prospective trials with longer follow-up are
needed.23 Given the previously described interaction between normal
and tumoral mammary epithelial cells and AT, the risk of recurrence in
patients who undergo either mastectomy or quadrantectomy should be
afforded greater consideration. These 2 different groupswere analyzed
in our study, and no differenceswere observed.23 Of note, although not
significant, the lipofilling group showed a higher risk of local events
when the analysis was limited to intraepithelial neoplasia.23 On the
whole, this study suggested that lipofilling is a safe procedure in breast
cancer patients but also that the group of in situ breast carcinomas
needs further attention. To this end, we set up a new matched cohort
study, limited to patients with intraepithelial lesions and including a
large number of patients with a longer follow-up as comparedwith our
former study.23 A higher risk of local events was observed in
intraepithelial neoplasia patients following lipofilling as compared
with control groups with a 5-year cumulative incidence of 18% and
3%, respectively.25 Taken together, these results confirmed the recur-
rence risk for in situ breast cancer. Because of the small samples of the
study (59 patients), a definitive conclusion could not be drawn, but
additional studies are urgently needed to confirm or deny the highlighted
risk. Concerning invasive breast cancers, the procedure appears safe,
although long-term follow-up and larger sample population are also
clearly needed. To definitively assess this latter point would require at
least the use of a control group or, ideally, randomized controlled trials.
Moreover, all the reported clinical studies that assess the relative safety
of fat graftingwere obtained using only theColeman techniquewith no
specific enhancement of the ADSC pool in the reinjected fat. It is
therefore urgent to perform matched cohort study with breast cancer
patients treated with any kind of enrichment of the reinjected fat.
CONCLUSIONS: BACK TO THE BENCH?
From the oncologist point of view, AT has emerged these last 10
years as a rather active player in breast cancer progression. Intimate
and bidirectional interaction with adjacent mammary epithelium,
during mammary gland development, pregnancy lactation, and in-
volution, is one of the hallmarks of mammary adipocytes.9 There-
fore, the fact that this crosstalk persists in pathophysiological conditions
such as cancer does not come as a great shock. Of interest, tumor-
surrounding adipocytes exhibit specific changes including delipidation,
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inflammatory phenotype, and overexpression of ECM and ECM-
modifying molecules.13 It would be worth characterizing the phenotype
of adipocytes harvested by lipoaspiration because one might overlook
that mechanical stress in AT induces an inflammatory phenotype. In
addition, although the definitive answer would come only from well-
designed clinical studies, the coinjection of human AT (obtained from
lipotransfer procedures for breast reconstruction in breast cancer pa-
tients)withmurinemodels of in situ breast carcinomamight be of use. In
fact, it would be interesting to investigate if intraepithelial lesions are
more receptive to supportive signals by AT, and if AT confers a more
aggressive phenotype on them.
Recent fat transfer and lipoinjection protocols have focused on
the addition of autologous ADSCs or freshly isolated adipose stro-
mal vascular cells to promote graft volume retention.26 In mice, it
has been demonstrated that the use of collagenase for AT digestion
(a necessary step in the purification procedure) induces inflamma-
tory mediators and down-regulates adipocyte genes, a phenotype
reminiscent of the tumor-surrounding adipocyte.13,27 This type of
procedure should also be considered with even greater caution with
respect to conventional techniques, regarding the results obtained in
mouse models with the use of CD34+ sorted cells.19 In addition to
prospective clinical studies required to address the issue of these
specific strategies, similar experimental approaches to those of
Martin-Padura et al19 with specific sorted cell population should be
helpful to delineate the risk of cancer recurrence after tumor re-
section in mice to provide reliable preclinical data. Fat grafting
represents a strong interest in breast cancer patients to improve the
results of breast cancer reconstruction. Efforts made by both the
research and clinical community would undoubtedly contribute to
define the risk-benefit balance for the patients.
ACKNOWLEDGMENTS
The authors thank Jamie Brown for the English editing of the manuscript.
REFERENCES
1. Chan CW, McCulley SJ, Macmillan RD. Autologous fat transferVa
review of the literature with a focus on breast cancer surgery. J Plast
Reconstr Aesthet Surg 2008;61:1438Y1448
2. Gutowski KA. Current applications and safety of autologous fat grafts:
a report of the ASPS fat graft task force. Plast Reconstr Surg
2009;124:272Y280
3. Coleman SR. Structural fat grafts: the ideal filler? Clin Plast Surg
2001;28:111Y119
4. Bertolini F, Lohsiriwat V, Petit JY, et al. Adipose tissue cells, lipotransfer
and cancer: a challenge for scientists, oncologists and surgeons.
Biochim Biophys Acta 2012;1826:209Y214
5. Coleman SR. Structural fat grafting: more than a permanent filler.
Plast Reconstr Surg 2006;118:108SY120S
6. Schafer M, Werner S. Cancer as an overhealing wound: an old
hypothesis revisited. Nat Rev Mol Cell Biol 2008;9:628Y638
7. Dvorak HF. Tumors: wounds that do not heal. Similarities between
tumor stroma generation and wound healing. N Engl J Med
1986;315:1650Y1659
8. Polyak K, Kalluri R. The role of the microenvironment in mammary
gland development and cancer. Cold Spring Harb Perspect Biol
2010;2:a003244
9. Wang YY, Lehuede C, Laurent V, et al. Adipose tissue and breast
epithelial cells: a dangerous dynamic duo in breast cancer. Cancer
Lett 2012;324:142Y151
10. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and
metabolic disease. Nat Rev Immunol 2011;11:85Y97
11. Huang SJ, Fu RH, ShyuWC, et al. Adipose-derived stem cells: isolation,
characterization and differentiation potential AQ2. Cell Transplant 2012
12. Dirat B, Bochet L, Escourrou G, et al. Unraveling the obesity and breast
cancer links: a role for cancer-associated adipocytes? Endocr Dev
2010;19:45Y52
13. Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit
an activated phenotype and contribute to breast cancer invasion.
Cancer Res 2011;71:2455Y2465
14. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects
of adipose tissue on cancer development and progression. Endocr Rev
2011;32:550Y570
15. Yoshimura K, Sato K, Aoi N, et al. Cell-assisted lipotransfer for facial
lipoatrophy: efficacy of clinical use of adipose-derived stem cells.
Dermatol Surg 2008;34:1178Y1185
16. Chandler EM, Seo BR, Califano JP, et al. Implanted adipose progenitor
cells as physicochemical regulators of breast cancer. Proc Natl
Acad Sci U S A 2012;109:9786Y9791
17. Zhang Y, Daquinag A, Traktuev DO, et al. White adipose tissue cells are
recruited by experimental tumors and promote cancer progression in
mouse models. Cancer Res 2009;69:5259Y5266
18. Kidd S, Spaeth E,WatsonK, et al. Origins of the tumormicroenvironment:
quantitative assessment of adipose-derived and bone marrow-derived
stroma. PLoS One 2012;7:e30563
19. Martin-Padura I, Gregato G, Marighetti P, et al. The white adipose
tissue used in lipotransfer procedures is a rich reservoir of CD34+
progenitors able to promote cancer progression. Cancer Res
2012;72:325Y334
20. Claro F Jr, Figueiredo JC, Zampar AG, et al. Applicability and safety
of autologous fat for reconstruction of the breast. Br J Surg
2012;99:768Y780
21. Rietjens M, De Lorenzi F, Rossetto F, et al. Safety of fat grafting in
secondary breast reconstruction after cancer. J Plast Reconstr Aesthet
Surg 2011;64:477Y478
22. Rigotti G, Marchi A, Stringhini P, et al. Determining the oncological
risk of autologous lipoaspirate grafting for post-mastectomy breast
reconstruction. Aesthetic Plast Surg 2010;34:475Y480
23. Petit JY, Botteri E, Lohsiriwat V, et al. Locoregional recurrence risk
after lipofilling in breast cancer patients. Ann Oncol 2012;
23:582Y588
24. Krastev TK, Jonasse Y, Kon M. Oncological safety of autologous
lipoaspirate grafting in breast cancer patients: a systematic review. Ann
Surg Oncol 2013;20:111Y119
25. Petit JY, Rietjens M, Botteri E, et al. Evaluation of fat grafting safety in
patients with intraepithelial neoplasia: a matched-cohort study. Ann
Oncol. In press AQ3
26. Donnenberg VS, Zimmerlin L, Rubin JP, et al. Regenerative therapy
after cancer: what are the risks? Tissue Eng Part B Rev 2010;
16:567Y575
27. Ruan H, Zarnowski MJ, Cushman SW, et al. Standard isolation of
primary adipose cells from mouse epididymal fat pads induces
inflammatory mediators and down-regulates adipocyte genes. J Biol
Chem 2003;278:47585Y47593
The Journal of Craniofacial Surgery & Volume 24, Number, May 2013 Special Editorial
* 2013 Mutaz B. Habal, MD 3
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARTICLE I: 
 
Cancer-associated adipocytes exhibit an activated phenotype 
and contribute to breast cancer invasion 
(Dirat et al, 2011, Cancer Res) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microenvironment and Immunology
Cancer-Associated Adipocytes Exhibit an Activated
Phenotype and Contribute to Breast Cancer Invasion
Beatrice Dirat1,2,3, Ludivine Bochet1,2,3, Marta Dabek1,2, Daniele Daviaud1,3, Stephanie Dauvillier1,2,
Bilal Majed6, Yuan Yuan Wang1,2,3, Aline Meulle1,2,3, Bernard Salles1,2,
Sophie Le Gonidec1,3, Ignacio Garrido4, Ghislaine Escourrou5, Philippe Valet1,3, and
Catherine Muller1,2
Abstract
Early local tumor invasion in breast cancer results in a likely encounter between cancer cells and mature
adipocytes, but the role of these fat cells in tumor progression remains unclear. We show that murine and human
tumor cells cocultivated with mature adipocytes exhibit increased invasive capacities in vitro and in vivo, using
an original two-dimensional coculture system. Likewise, adipocytes cultivated with cancer cells also exhibit an
altered phenotype in terms of delipidation and decreased adipocyte markers associated with the occurrence of
an activated state characterized by overexpression of proteases, including matrix metalloproteinase-11, and
proinflammatory cytokines [interleukin (IL)-6, IL-1b]. In the case of IL-6, we show that it plays a key role in the
acquired proinvasive effect by tumor cells. Equally important, we confirm the presence of these modified
adipocytes in human breast tumors by immunohistochemistry and quantitative PCR. Interestingly, the tumors
of larger size and/or with lymph nodes involvement exhibit the higher levels of IL-6 in tumor surrounding
adipocytes. Collectively, all our data provide in vitro and in vivo evidence that (i) invasive cancer cells
dramatically impact surrounding adipocytes; (ii) peritumoral adipocytes exhibit a modified phenotype and
specific biological features sufficient to be named cancer-associated adipocytes (CAA); and (iii) CAAs modify the
cancer cell characteristics/phenotype leading to a more aggressive behavior. Our results strongly support the
innovative concept that adipocytes participate in a highly complex vicious cycle orchestrated by cancer cells to
promote tumor progression that might be amplified in obese patients. Cancer Res; 71(7); 2455–65. 2011 AACR.
Introduction
Cells that compose the tumor stroma are associated, if not
obligate, partners in tumor progression (1–3). In breast can-
cer, stromal cells include resident adipocytes and fibroblasts, a
wide range of recruited hematopoietic cells, and newly formed
blood vessels with their associated cells (3). Dynamic and
reciprocal communication between epithelial and stromal
compartments occurs during breast cancer progression
(1, 2). Cancer cells usually go about generating a supportive
microenvironment by activating the wound-healing response
of the host (4). Conversely, the stromal cells, such as cancer-
associated fibroblasts or tumor-associated macrophages, pro-
mote tumor progression by secreting growth factors, chemo-
kines, and promigratory extracellular matrix components (2).
To date, most of the studies focused on cancer cell–mesench-
ymal cell interactions have emphasized the contribution of
fibroblasts, endothelial, and inflammatory cells (1). Little
attention has been given to the mature adipocytes despite
the fact that in breast cancers, early local tumor invasion
results in immediate proximity of cancer cells to adipocytes
(3). Until recently, adipocytes were mainly considered as an
energy storage depot, but there are now clear evidences
pointing adipocytes as endocrine cells producing hormones,
growth factors, cytokines, and other molecules named adipo-
kines (5). Therefore, mature adipocytes represent excellent
candidates to influence tumor behavior through heterotypic
signaling processes.
Adipokines, such as leptin, adiponectin (APN), hepatocyte
growth factor, or collagen VI, stimulate the growth and
survival of breast tumor cells even in estrogen-negative cells
(6, 7). Moreover, it has been shown that metalloproteinase
(MMP)-11/stromelysin-3 is induced in adipose tissue by can-
cer cells as they invade their surrounding environment (8).
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Obesity, wherein the normal balance of adipose tissue secre-
tory proteins is disturbed, has been recently identified as a
negative prognosis factor for breast cancer (9, 10). This poor
prognosis seems to be independent of menopausal status,
tumor stage, and tumor hormone–binding characteristics (for
review, see refs. 11–13). Several studies pointed out that obese
women exhibit at diagnosis an increase in lymph nodes
involvement and a higher propensity to distant metastasis
(10, 11, 14–17). Furthermore, obesity is also associated with
the occurrence of tumors of high grade with increased local
and distant invasion in prostate cancer (18). Taken together,
these compelling observations suggest that excess adiposity
may favor tumor invasiveness by yet uncharacterized mechan-
ism(s). We show here that tumor-surrounding adipocytes
exhibit profound phenotypic changes in vitro and in human
tumors, and these modified adipocytes promote tumor cell
invasion and metastasis.
Materials and Methods
Cell culture
The murine 3T3-F442A preadipocyte cell line was differ-
entiated as described previously (19). To estimate the adipo-
cyte phenotype, triglyceride (TG) content was quantified using
a colorimetric kit (Wako Chemicals), and red oil staining was
carried out as previously described (20). The human breast
cancer cell line ZR 75.1 (provided by Prof. K. Bystricky,
Laboratoire de Biologie Moleculaire Eucaryote, Toulouse,
France) and the murine 67NR and 4T1 breast cancer cell lines
(ref. 21; provided by Dr. S. Vagner, INSERM U563, Toulouse,
France) were cultured in Dulbecco's modified Eagle's medium
supplemented with 10% (ZR 75.1 and 67NR) and 5% (4T1) fetal
calf serum (FCS). The human breast cancer cell line
SUM159PT (provided by Dr. J Piette, IGMM, Montpellier,
France) was grown in Ham F12 (50:50) medium complemen-
ted with 5% FCS, 1 mg/mL hydrocortisone (Sigma), and 0.2 UI/
mL insulin. All the cell lines were used within 2 months after
resuscitation of frozen aliquots. Cell lines were authenticated
on the basis of viability, recovery, growth, and morphology.
For ZR 75.1 and SUM159PT cell lines, the expression status of
estrogen receptor (ER) a, E-cadherin, N-cadherin, and vimen-
tin was confirmed by immunoblotting before they were used
in the experiments (22). For all cell lines, their invasive
behavior was confirmed using Boyden chamber assays before
they were used in the experiments. Cell lines 67NR and 4T1
were also tested for their ability to form (4T1) or not (67NR)
metastatic tumors when injected in syngenic BALB/c mice
(21).
Human samples
Breast adipose tissue samples were collected from
reduction mammoplasty (RM) or tumorectomy (TU),
according to the guidelines of the Ethical Committee of
Toulouse-Rangueil. All subjects gave their informed con-
sent to participate in the study, and investigations were
conducted in accordance with the Declaration of Helsinki
as revised in 2000. In cases of TU, the fat tissue samples
obtained were immediately close to the tumor mass and
were devoid of fibrosis, as assessed macroscopically (data
not shown). Adipose tissue pieces were immediately used
for collagenase digestion as previously described (23) and
centrifuged (20 minutes, room temperature, 1,000 rpm) to
separate adipocytes from the stroma vascular fraction
(pellet, SVF).
Coculture and invasion assays
Tumor cells and adipocytes were cocultured using a Trans-
well culture system (0.4-mmpore size; Millipore). A total of 5
104 (67NR), 1.5  105 (SUM159PT, 4T1), or 3  105 (ZR 75.1)
cells were seeded in the top chamber of the Transwell system
in the culture medium of adipocytes and cocultivated with or
without mature adipocytes in the bottom chamber for the
indicated times. Adipocytes or tumor cells cultivated alone in
similar conditions served as controls. To evaluate the effect of
adipocyte-conditioned medium (Ad-CM) on tumor cell inva-
sion, mature adipocytes were cultivated overnight with
serum-free medium containing 1% of delipidated bovine
serum albumin (Sigma) and medium was collected. CM
was also collected from adipocytes previously cocultivated
during 3 days with tumor cells [cancer-associated adipocytes
conditioned medium (CAA-CM)]. After 3 days of coculture in
the presence of mature adipocytes, Ad-CM, or CAA-CM (com-
plemented with 10% FCS), tumor cells were used to conduct
Matrigel invasion assays as previously described (24). A total
of 35 to 40 fields per filter were counted using an optical
microscope. Invasion assays were also conducted with tumor
cells previously cultivated for 3 days with recombinant human
IL-6 (PeproTech).
Western blot analysis
Whole cell extracts and immunoblots were prepared as
previously described (25). All the antibodies used in our study
are presented in Supplementary Information.
Tail vein metastasis assays
A total of 1  106 4T1 cells, previously cocultivated either
with or without mature adipocytes for 4 days, were injected
intravenously in BALB/c mice (6 animals per condition). Mice
were sacrificed after 14 days, and lungs were taken for
analyses. Nodules were scored from 1 to 5 according to their
likelihood to represent metastasis to lung (0, normal lung
tissue; 1, tissue with 1–5 nodules; 2, 6–10 nodules; 3, 11–20
nodules; 4, 21–30 nodules; and 5, >31 nodules). Lungs were
then fixed in 4% paraformaldehyde and embedded in paraffin.
Sections were stained with hematoxylin and eosin (H&E) and
nodules were observed. The mean number of nodules per lung
area and the mean nodule area as a function of lung area (that
defined the nodule area index) were measured by ImageJ
software program. The local Institutional Animal Care and
Use Committee approved the experimental protocols
described in the study.
Immunofluorescence, immunohistochemistry, and
determination of adipokines secretion
Immunofluorescence and immunohistochemistry were car-
ried out as previously described (8, 24). Concentration of
Dirat et al.
Cancer Res; 71(7) April 1, 2011 Cancer Research2456
Research. 
on July 9, 2013. © 2011 American Association for Cancercancerres.aacrjournals.org Downloaded from 
secreted factors in supernatants was determined using the
xMAP Technology (Luminex), with a Milliplex kit (Millipore).
RNA extraction and quantitative PCR
Gene expression was analyzed using real-time PCR as
described previously (23). The sequences of the primers are
presented in Supplementary Information.
Statistical methods
Quantitative expression of biological markers measured by
quantitative PCR (qPCR) in isolated human adipocytes was
assessed using estimations of means and SDs. Hence, a normal
distribution of these measures was assumed. However, the
size of subpopulations was limited in most cases. Thus, we
tested differences about the expression of biological markers
between subpopulations of interest, using nonparametric
tests (i.e., Wilcoxon's nonparametric rank test). Quartiles were
also computed; box plots permitted to appreciate the presence
of outliers and to illustrate differences in the expression of
biological markers. The threshold of statistical significance
was fixed at alpha risk at 5%. SPlus statistical software was
used for the data analysis (26). For the in vitro experiments, the
statistical significance of differences between the means (at
least 3 independent experiments) was evaluated using
Student's t test, done using Prism (GraphPad Inc.). The values
of *P  0.05, **P < 0.01, and ***P < 0.001 were deemed as
significant whereas "NS" stands for not significant.
Results and Discussion
Tumor cells cocultivated with mature adipocytes
exhibit an enhanced invasive phenotype
Human cancer cells with low (ZR 75.1) or high (SUM159PT)
invasive capacities (27) were grown for 3 days on Transwells,
allowing the diffusion of soluble factors, in the presence or
absence of murine mature adipocytes (28). After 3 days, tumor
cells were trypsinized and Matrigel invasion assays were
conducted in a medium containing either 0% or 10% FCS.
As shown in Figure 1A, the invasive capacity of ZR 75.1 tumor
cells in 10% FCS containingmediumwas increased by 3-fold in
cells previously cocultivated for 3 days with adipocytes as
compared with tumor cells grown alone (P < 0.01). No addi-
tional increase in the invasive capacity of ZR 75.1 was
observed when the time of coculture with adipocytes was
increased up to 5 days (data not shown). This effect was not
observed when tumor cells were cocultivated with preadipo-
cytes (Supplementary Fig. S1A). Similar results were obtained
with the SUM159PT cell line, although to a lesser extent
(Fig. 1A, P < 0.05). Experiments were also carried out with
the mouse mammary cell line 4T1 and its nonmetastatic
sibling cell line 67NR (21). Coculture with adipocytes increases
both 67NR and 4T1 invasive capacities by 2-fold (Fig. 1B, P <
0.05 and 0.01, respectively). Therefore, mature adipocytes are
able to stimulate the invasive capacities of murine and human
breast cancer cell lines that are either positive (ZR 75.1) or
negative (SUM159PT, 67NR, 4T1) for the ER. In addition, the
proinvasive effect was independent from the tumor growth–
promoting effect because coculture with adipocytes has no
effect on ZR 75.1 or murine tumor cell lines proliferation in
contrast to SUM159PT cells (Supplementary Fig. S1B). When
tumor cells were grown in the presence of CM obtained from
adipocytes, which have never been cocultivated with tumor
cells (Ad-CM), invasive capacities were not significantly
increased for any of cell lines (Fig. 1C). When CMwas prepared
from adipocytes previously cocultivated with tumor cells
(CAA-CM), a significant stimulation of tumor invasive capa-
cities was observed in all the tested models as compared with
cells grown in control medium (P < 0.05 for the 67NR cells, P <
0.01 for the ZR 75.1, SUM159PT, and 4T1 cells). These results
highlight that a cross-talk between the 2 cell populations is
necessary to obtain this effect (Fig. 1C).
Noncocultivated ZR 75.1 cells displayed a characteristic
epithelial morphology and form compacted colonies. Yet,
when these cells were cocultivated with adipocytes from 3
to 5 days, morphologic changes became apparent. Cells
formed less compacted colonies and exhibited a more scat-
tered aspect. In addition, these cells displayed a downregula-
tion of membrane E-cadherin expression, in association with
b-catenin redistribution, resulting into a disorganized state in
the cytoplasm (Fig. 2A). Decreased E-cadherin expression was
observed both at mRNA (Fig. 2B) and protein levels (Fig. 2C)
without an increased expression of mesenchymal markers
(Fig. 2B and C), suggesting the occurrence of an incomplete
epithelial-mesenchymal transition (EMT). For the SUM159PT
cell line, which has already undergone a complete EMT,
morphologic changes were also observed along with the
reorganization and polarization of vimentin (Fig. 2A) without
a change in its expression level (Fig. 2C).
Our coculture system shows that adipocytes stimulate the
invasiveness of tumor cells in vitro. To test the hypothesis that
"priming" tumor cells with adipocytes regulate tumor cell
distal organ seeding and growth, we conducted tail vein
metastasis assays, using the 4T1 cell line. 4T1 tumor cells
were cultured in vitro for 4 days in the presence or absence of
adipocytes, harvested, and injected intravenously into BALB/c
mice. As shown in Figure 3A, the number of lung metastases
was enhanced in mice injected with 4T1 cells previously
cocultivated with adipocytes as compared with mice injected
with 4T1 grown alone (P < 0.05). Histologic analysis (Fig. 3B)
confirmed that both the number and size of the nodules were
significantly increased in mice injected with adipocytes-cocul-
tivated 4T1 compared with 4T1 cells grown alone (Fig. 3C and
D, P < 0.05 for the 2 parameters). Therefore, our results clearly
show that adipocytes promote the invasive phenotype of
breast tumor cells both in vitro and in vivo.
Cocultivated adipocytes exhibit extensive phenotypic
changes
Adipocytes have been shown to promote tumor survival
and growth in vitro and in vivo (6, 29), but their contribution
to tumor cell invasion is an emerging concept. Because our
results showed that a cross-talk between the 2 cell popula-
tions is necessary to observe the proinvasive effect (Fig. 1C),
we next examined the phenotype of cocultivated adipocytes.
As shown in Figure 4A (left), mature adipocytes cocultivated
with ZR 75.1 tumor cells exhibited a dramatic reduction in
Key Role of Mature Adipocytes in Breast Cancer Progression
www.aacrjournals.org Cancer Res; 71(7) April 1, 2011 2457
Research. 
on July 9, 2013. © 2011 American Association for Cancercancerres.aacrjournals.org Downloaded from 
the number and size of lipid droplets that correlated with a
significant decrease in lipid accumulation (Fig. 4A, right, P <
0.05). These adipocytes lose several terminal differentiation
markers exemplified by the strong decrease in HSL (hor-
mone-sensitive lipase), APN, resistin, and aP2 mRNA (ref. 5;
Fig. 4B, P < 0.05 for all the markers), this loss was also
confirmed at protein levels for APN and resistin (Fig. 4C, P <
0.05). In cocultivated adipocytes, the level of C/EBPa was
dramatically reduced (P < 0.001) whereas that of PPARg was
not significantly decreased (Fig. 4B). As previously stated,
Figure 1. Coculture of breast
tumor cells with mature
adipocytes stimulates their
invasive capacities. A, ZR 75.1
or SUM159PT cells were
cocultivated in the presence (C)
or absence (NC) of mature
adipocytes. After 3 days, tumor
cells were trypsinized and used
for Matrigel invasion assay in a
medium containing either 0%
(white bars) or 10% FCS (black
bars). B, similar experiments were
done with the 67NR and 4T1
murine cancer cells. A and B,
representative images of Matrigel
invasion assay conducted in a
medium containing 10% FCS are
shown below each graph. C,
indicated cells were cultivated
either in normal medium (control),
in CM obtained from adipocytes
(Ad-CM), or in CM obtained from
adipocytes previously grown in
the presence of tumor cells
(CAA-CM). After 3 days, tumor
cells were trypsinized and used
for Matrigel invasion assays in
a medium containing either 0%
(white bars) or 10% FCS (black
bars).
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MMP-11/stromelysin-3 is induced in vivo in adipose tissue
by cancer cells as they invade their surrounding environ-
ment (8). Similarly, an upregulation for this protease was
noted in the cocultivated adipocytes, highlighting the in vivo
relevance of this coculture model (Fig. 4B, P < 0.001). In
contrast, the levels of MMP-9 (Fig. 4B) and MMP-2 (not
shown) remain unchanged whereas a significant increase
(10-fold) of plasminogen activator inhibitor-1 (PAI-1)
expression was found (Fig. 4B, P < 0.01). In cocultivated
adipocytes, a 5-fold increase in levels of IL-6, IL-1b, and TNF-
a was shown at mRNA levels (Fig. 4B, P < 0.001 for all
cytokines). At protein levels, however, only IL-6 and IL-1b
were found to be significantly higher in the supernatant of
cocultivated cells (Fig. 4C, P < 0.05 for both cytokines)
whereas the levels of TNF-a remained undetectable in both
conditions (data not shown). Of note, these extensive adi-
pocyte phenotypic changes were obtained with other tumor
cells lines (Supplementary Fig. S2). Furthermore, these
results were confirmed with mammary adipocytes derived
from ex vivo differentiation of progenitors purified from
mammary adipose tissue of healthy donors undergoing
RM (6 independent donors; Supplementary Fig. S3). There-
fore, we extensively described tumor-induced changes in
adipocytes that are reproducibly displayed by both human
and mouse cocultivated adipocytes. Collectively, our obser-
vations clearly show that cocultivated adipocytes generally
exhibit a loss of lipid content, a decrease in late adipose
markers, and overexpression of inflammatory cytokines and
proteases. We named these cells "cancer associated adipo-
cytes" (11).
CAAs are found in human tumors
We next investigate whether these cells are present in
primary human tumors. To address this critical issue, we first
conducted a histologic analysis of human breast tumors. As
exemplified in Figure 5A, we consistently observed at the
invasive front of human breast tumors the presence of adi-
pocytes of smaller sizes with a dilated interstitial space, which
Figure 2.Cancer cells exhibit morphologic changes and incomplete EMT on coculture with adipocytes. A, ZR 75.1 or SUM159PT were grown on coverslips in
inserts, the lower wells cocultivated in the presence (C) or absence (NC) of mature adipocytes. After 3 or 5 days, cells were fixed and stained with the
indicated antibodies. Nuclei were labeled with TO-PRO-3; scale bars, 40 mmol/L. B, relative mRNA expression of N-cadherin and E-cadherin in indicated tumor
cell lines cocultivated in the presence (C) or absence (NC) of murine adipocytes for 5 days evaluated by qPCR. C, analysis of protein expression of the
indicated markers done by Western blots with extracts obtained from tumor cells cocultivated in the presence (C) or absence (NC) of adipocytes (5 days).
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might be related to extensive extracellular matrix occurring in
tumor-surrounding adipocytes such as collagen VI overex-
pression (6). Further characterization of these CAAs was done
by immunohistochemistry. As shown in Figure 5B (i and ii), we
observed a decreased expression of the adipocyte marker APN
in CAAs as compared with normal mammary adipose tissue.
Although MMP-11 and IL-6 were not detected in mature
adipocytes of RM (Fig. 5B, iii and v, respectively), these
proteins were expressed within the rim of cytoplasm of the
adipocytes located proximally to the invasive cancer cells
(Fig. 5B, iv and vi, respectively). To further assess the expres-
sion of these markers by a quantitative approach, adipocytes
were isolated from fat samples associated with TU or RM (23).
A series of 28 samples, with 14 samples in each group
(Supplementary Tables S1 and S2 for the clinical character-
istics of the patients), was used comparable with respect to
age (mean: 51.8  7.3 vs. 60  13) and BMI (26.2  2.8 vs. 25.2
 2.3). Adipocytes isolated from tumor samples overexpressed
MMP-11 (P ¼ 0.001), PAI-1 (P < 0.01), and IL-6 (P < 0.001), as
compared with adipocytes purified from normal mammary
gland, whereas the mRNA levels of IL-1b and TNF-a were not
statistically different (Fig. 5C). The adipose tissue also con-
tains stromal cells (present in the SVF), such as fibroblasts,
endothelial cells, and adipocyte precursors. The levels of
expression of MMP-11, PAI-1, IL-6, IL-1b, and TNF-a remained
unchanged between normal and tumor-surrounding adipose
SVF, highlighting that the observed increase in proinflamma-
tory molecules and proteases is an adipocyte-dedicated event
(Fig. 5C). Furthermore, when the expression levels of IL-6 in
adipocytes were analyzed as a function of tumor character-
istics, we found that higher levels of this cytokine were
associated with the tumors of larger size and with lymph
nodes involvement (Fig. 5D). This correlation was not found
either for PAI-1 or for MMP-11 (Supplementary Fig. S4). Taken
together, these results show that CAAs are found in human
tumors.
Our data strongly support the concept that an intimate
cross-talk is established between cancer cells and mature
adipocytes at the invasive front of the tumor. Invading tumor
cells are able to modify adipocytes phenotype, which, in turn,
stimulate cancer cells aggressive behavior (30). The mechan-
ism(s) responsible for the transition from mature adipocytes
to CAAs remain(s) unclear. Modification resembling to CAAs
is also observed in adipose tissue of tumor-bearing mice far
from the tumor site. In cachexia, adipocytes also exhibit
morphologic modification, decreased in adipogenic transcrip-
tion factors such as C/EBPa and late differentiation markers
such as leptin (31). However, during cancer cachexia, adipo-
cytes exhibit a decrease in resistin expression and upregula-
tion of lipolytic enzymes such as HSL or ATGL (adipose
triglyceride lipase) (31), events not found in CAAs (Fig. 4
and Supplementary Fig. S5), alluding to their unique phento-
type. Several molecules expressed by tumor cells have been
described as strong suppressors of adipogenesis such as IL-1b,
TNF-a, or even IL-6 (32), representing one mechanism by
which tumor cells might directly influence adipocyte behavior.
An alternative mechanism might be adipocytes themselves as
the source of autocrine signals that induce the CAAs pheno-
type. In favor of the latter hypothesis, we showed that tumor
CM was not able to reproduce CAAs phenotype, suggesting
that either adipocyte factors or inducible factors in tumor cells
are necessary to observe this effect (Supplementary Fig. S6).
Adipocyte IL-6 plays a key role in mediating adipocyte-
dependent invasive activity of tumor cells
Our results show that IL-6 is overexpressed in tumor-
surrounding adipocytes both in vitro and in vivo. We showed
Figure 3. Coculture with adipocytes stimulates the metastatic potential of
4T1 cells in vivo. A, left, representative lungs harvested at necropsy after
tail vein injection of 4T1 cocultivated in the presence (C) or absence (NC) of
adipocytes during 4 days prior to injection. Right, metastatic score as
determined by macroscopic examination. B, left, H&E stained transverse
sections of host lungs from mice injected with 4T1 cells previously
cocultivated in the presence (C) or absence (NC) of adipocytes during
4 days (original magnification  40). Examples of invading lesions are
shown by arrows. Right, magnified views of invading lesions. C and D,
metastasis number obtained from mice injected with 4T1 cells, previously
cocultivated in the presence (C) or absence (NC) of adipocytes during
4 days, is expressed either as the average number of metastasis sites per
lung area (C) or as nodule area index (D) representing the average
metastasis area normalized by total lung area.
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that IL-6 (at 10 ng/mL, a dose equivalent to the levels
secreted by CAAs, Fig. 4C) significantly increased the inva-
sive capacities in ZR 75.1 and 67NR cells (Fig. 6A, P < 0.01 for
the 2 cell lines). As compared with untreated cells, the
epithelial-like ZR 75.1 cells exposed to IL-6 form less com-
pacted colonies and exhibit a more scattered aspect
(Fig. 6B). A downregulation of membrane E-cadherin expres-
sion resulting into a disorganized state in the cytoplasm, in
association with b-catenin redistribution (Fig. 6B), was
observed in treated cells in accordance with the literature
(33–35). Strikingly, when ZR 75.1 cells were cocultivated with
adipocytes in the presence of murine IL-6 blocking antibody,
the adipocyte proinvasive effect was significantly decreased
(Fig. 6C, P < 0.01). mIL-6 blocking antibody specifically
Figure 4. Adipocytes cocultivated
with breast tumor cells undergo
extensive phenotypic changes. A,
left, mature murine adipocytes
cocultivated in the presence (C) or
absence (NC) of ZR 75.1 tumor
cells were stained with red oil.
Right, the TG content was dosed
in adipocytes. B, adipocytes were
cocultivated in the presence (C) or
absence (NC) of ZR 75.1 tumor
cells. After 3 days, mRNAs were
extracted and expression of the
indicated genes was analyzed by
qPCR. C, dosage of the indicated
murine secreted factors in the
supernatants of adipocytes grown
alone (NC) or in the presence of
breast tumor cells (C).
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inhibits the proinvasive effect of CAA-CM in both 67NR and
4T1 models and had no effect on the invasive capacities of
cells grown in control medium (Fig. 6D, P < 0.01 and P < 0.05,
respectively). Altogether, these results indicate that IL-6
plays a key role in the CAAs proinvasive effects.
In breast cancer patients, the extent of the increase in
serum IL-6 correlates with poor disease outcome and reduced
prognosis (36). Recent evidence shows that fibroblast-derived
IL-6 supports breast tumor growth and metastasis (37). Our
results show that the stromal IL-6 is also produced by mature
adipocytes surrounding the tumors. The absence of IL-6
overexpression in the SVF of human adipose tissue isolated
from breast tumor biopsies (Fig. 5C) apparently contradicts a
recent study conducted ex vivo, and not in vivo, using human
adipose tissue–derived stromal cells cocultivated with tumor
cells (38). Our results obtained in human tumors suggest that
within the cellular complexity of the adipose tissue, the cross-
talk with tumor cells is rather established with mature, than
with precursors, adipose cells (Fig. 5C and D). In addition,
because mature adipocytes are the most abundant cells in the
breast tumor stroma (3), their cumulative secretion of IL-6
could therefore have profound impact on tumor progression.
Finally, this work paves the way for future clinical and
cellular studies aimed at determining the impact of this
Figure 5. CAAs from human
breast tumor exhibit extensive
phenotypic changes in
accordance with the in vitro
coculture assays. A, top,
histologic examination of an
invasive breast tumor after H&E
staining (original magnification 
200). Ad, adipose tissue; IF,
invasive front; C, tumor center.
Bottom, histologic magnification
of the invasive front of the tumor.
Note that the number and the size
of adipocytes were reduced
(adipocytes of smaller size are
indicated by arrows). B, the
expression of APN (i and ii), MMP-
11 (iii and iv), and IL-6 (v and vi)
was visualized (in brown) in
adipocytes (lipids in white,
nucleus in blue) located adjacent
to invading cancer cells (right) as
compared with normal adipose
tissue (left). Arrows indicate the
expression of proteins of interest
within the rim of cytoplasm of
adipocytes. C, top, the expression
of the indicated genes was
analyzed by qPCR in mature
adipocytes obtained from RM or
TU (14 independent samples per
group). Bottom, similar
experiments were done with the
SVF of the samples. D, the
expression of IL-6 was measured
as a function of tumor
characteristics. G, grade; IDC,
invasive ductal carcinoma; ILC,
invasive lobular carcinoma; N,
lymph node involvement.
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cross-talk in obesity conditions. Indeed, our results suggest
that the cross-talk between the CAAs and tumor compo-
nents might be amplified in obesity in which the normal
balance of adipose tissue secretory proteins is disturbed.
Obesity is related to a condition of low chronic inflammation
characterized by the abnormal production of inflammatory
cytokines involved in insulin resistance (5). Obesity and the
now-defined profile of CAAs share inflammation as common
Figure 6. IL-6 is involved in the
adipocyte-driven proinvasive
effect. A, ZR 75.1 and 67NR cells
were cultivated either alone (NT) or
in the presence of IL-6, and after 3
days, they were harvested to
conduct Matrigel assays in a
medium containing either 0 or
10%serum. B, similarly treated ZR
75.1 cells were fixed and stained
with the indicated antibodies.
Nuclei were labeled with TO-PRO-
3; scale bars, 40 mmol/L. C, ZR
75.1 were cocultivated for 3 days
in the presence (C) or absence
(NC) of murine adipocytes. As
indicated, blocking antibody
directed against murine IL-6
(aIL-6) or control antibody (IgG)
was added in the culture medium.
Tumor cells were then harvested
to conduct Matrigel invasion
assays in a medium containing
10% FCS. D, 67NR and 4T1 cells
were cultivated in normal medium
(control), normal medium
containing control
immunoglobulin (controlþ IgG), or
blocking antibody directed
against murine IL-6 (control þ
aIL-6) conditioned medium
obtained from adipocytes
previously grown in the presence
of tumor cells (CAA-CM), CAA-CM
containing control (CAA-CM þ
IgG), or IL-6 blocking antibody
(CAA-CM þ aIL-6). After 3 days,
tumor cells were harvested to
conduct Matrigel invasion assay in
a medium containing either 0% or
10% FCS.
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traits, including overexpression of IL-6 with the noticeable
absence of overexpression of TNF-a in CAAs (Fig. 5). Inter-
estingly, the association of high levels of IL-6 in CAAs with
high tumor size and enhanced local invasion reflects those
traits present in obese patients (10, 16, 17). Therefore, CAAs
within a context of obesity should be more prone to amplify
the negative cross-talk with tumor cells that we have iden-
tified and characterized in this study. This is a hypothesis
that remains to be shown in both murine and human
models. Such studies will provide unique opportunities to
set up specific strategies for the treatment of the subsets of
patients exhibiting aggressive diseases.
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Adipocyte-Derived Fibroblasts Promote Tumor Progression
and Contribute to the Desmoplastic Reaction in Breast
Cancer
Ludivine Bochet1,2,3, Camille Lehuede1,2,3, Stephanie Dauvillier1,2, Yuan Yuan Wang1,2,3, Beatrice Dirat1,2,3,
Victor Laurent1,2, Cedric Dray1,3, Romain Guiet1,2, Isabelle Maridonneau-Parini1,2, Sophie Le Gonidec1,3,
Bettina Couderc4, Ghislaine Escourrou5, Philippe Valet1,3, and Catherine Muller1,2
Abstract
Cancer-associated fibroblasts (CAF) comprise the majority of stromal cells in breast cancers, yet their precise
origins and relative functional contributions to malignant progression remain uncertain. Local invasion leads to
the proximity of cancer cells and adipocytes, which respond by phenotypical changes to generate fibroblast-like
cells termed as adipocyte-derived fibroblasts (ADF) here. These cells exhibit enhanced secretion of fibronectin
and collagen I, increased migratory/invasive abilities, and increased expression of the CAF marker FSP-1 but not
a-SMA. Generation of the ADF phenotype depends on reactivation of the Wnt/b-catenin pathway in response to
Wnt3a secreted by tumor cells. Tumor cells cocultivated with ADFs in two-dimensional or spheroid culture
display increased invasive capabilities. In clinical specimens of breast cancer, we confirmed the presence of this
new stromal subpopulation. By defining a new stromal cell population, our results offer new opportunities for
stroma-targeted therapies in breast cancer. Cancer Res; 73(18); 5657–68. 2013 AACR.
Introduction
Oneof the features of breast cancer is the presence of a dense
collagenous stroma, the so-called desmoplastic response, com-
prising of fibroblast-like cells known as cancer-associated
fibroblasts (CAF; ref. 1). Accumulating experimental evidence
has shown that CAFs play an active role in breast cancer
progression through the release of growth factors and chemo-
kines andby contributing to the remodeling of the extracellular
matrix (for review see refs. 2–4). CAFs are "activated" fibro-
blasts and were first identified upon morphologic criteria and
a-smooth muscle actin (a-SMA) expression, in the same
manner as wound-healing myofibroblasts (5). However, this
marker is not ubiquitous, highlighting that CAFs is a hetero-
geneous cell population (6). Indeed, CAFs are alternatively
reported to stem from resident localfibroblasts, bonemarrow–
derived progenitor cells, or trans-differentiating epithelial/
endothelial cells (for review, see refs. 4, 7). At present, neither
the origin of these cells, nor the extent to which their origin
determines their contribution to tumor progression can be
unanimously agreed upon.
We have recently shown that invasive cancer cells have a
dramatic impact on surrounding adipocytes. Both in vitro and
in vivo, these adipocytes exhibit a decrease in lipid content, a
decreased expression of adipocyte markers, and an activated
state indicated predominantly by the overexpression of proin-
flammatory cytokines (8). These cells are present in vivo at the
tumor invasive front and retain an adipocyte-like rounded
morphology. We named them cancer-associated adipocytes
(CAA; reviewed in refs. 8–10). CAAs also display overexpression
of extracellular matrix (ECM, such as collagen VI) and ECM-
relatedmolecules (11–13), events contributing to breast cancer
progression. As the origin of CAFs is unclear, one attractive
hypothesis is that during tumor evolution, peritumoral adipo-
cytes undergo "dedifferentiation", first into CAAs then into
fibroblast-like cells that may account for a part of the CAFs
population present in the desmoplastic reaction of breast
cancers. Although suggested in several reviews (14, 15), this
hypothesis has never been directly shown experimentally using
combined in vitro and in vivo approaches. Independent of the
effect of cancer cells, several recent studies have shown that
mature adipocytes are in fact plastic cells capable of "dedif-
ferentiation" towards fibroblast-like cells (16). Although lim-
ited data exists on the mechanisms that could potentially be
involved in this effect, the role of soluble factors such as TNF-a,
Wnt3a (17), or specificmitochondrial uncoupling (18) has been
described. In vitro, recombinant MMP-11 is also able to "dedif-
ferentiate" mature adipocytes (11). However, the existence of
this phenomenon in human pathology remains elusive. In the
present study, we use both in vitro and in vivo (including human
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tumors) approaches to show that breast cancer cells are able to
force mature adipocytes towards fibroblast-like cells, named
adipocyte-derived fibroblasts (ADF), in aWnt-dependentman-
ner. We also extensively describe the distinctive phenotype of
these new stromal cells, expressing some CAFs markers like
fibroblast-specific protein 1/S100A4, but not a-SMA, and
underline their ability to promote the spread of breast cancer
cells.
Materials and Methods
Antibodies, probes, and drugs
All the primary antibodies used in this study are presented in
Supplementary Table S1. The Wnt/b-catenin inhibitor, ICG-
001 (19) was from Enzo Life Sciences and was used at 2.5 and 5
mmol/L final concentrations. The bodipy lipid probe (used at 1
mg/mL) and TO-PRO-3 (used at 1 mmol/L final concentration)
were obtained from Invitrogen.
Cell culture, cell lines, and isolation of primary
adipocytes
The murine 3T3-F442A preadipocytes cell line was differ-
entiated as previously described (20). To estimate the adi-
pocyte phenotype, triglyceride content was quantified using
a colorimetric kit (Wako Chemicals) and Red Oil staining
was conducted as previously described (20). The murine 4T1
breast cancer cell line (provided by Dr. S. Vagner, INSERM
U563, Toulouse, France) was cultured in Dulbecco's Modi-
fied Eagle Medium (DMEM) supplemented with 5% fetal calf
serum (FCS). The human breast cancer cell line SUM159PT
(provided by Dr. J Piette, IGMM, Montpellier, France) was
grown in Ham F12 (50:50) medium complemented with 5%
FCS, 1 mg/mL hydrocortisone (Sigma), and 0.2 UI/mL insu-
lin. All the cell lines were used within 2 months after
resuscitation of frozen aliquots. Cell lines were authenticat-
ed on the basis of viability, recovery, growth, and morphol-
ogy. The expression status of E-cadherin, N-cadherin, and
vimentin using immunofluorescence approaches, as well as
their invasive behavior, was confirmed before they were used
in the experiments (8). Coculture of tumor cells and adipo-
cyte was carried out using a Transwell culture system (0.4
mm pore size, Millipore) as previously described (8). In
certain experiments, cells genetically modified by lentiviral
vectors encoding either eGFP (Genethon, Evry; 3T3-F442A)
or Hc-Red (vector core ICR; SUM159PT) were used. The
isolation of mammary adipocytes either from tumor or
reduction mammoplasty was carried out as previously de-
scribed by our group (8).
In vivo GFP-subcutaneous fat pad formation and tumor
injection
A total of 1  107 confluent GFP-3T3-F442A preadipocytes
were injected into the flank of athymic nudemice, as described
(21). Fat pad formation was allowed to proceed for 5 weeks,
after which fat pads were injected with 4  104 4T1 breast
cancer cells. Mice with fat pad alone or tumor cells alone were
used as controls. Five mice were used in each group. After 10
days, mice were sacrificed and fat pad, tumors, and fat pads
containing tumors were embedded in paraffin after 48 hours of
fixation in buffered formalin. The local Institutional Animal
Care and Use Committee approved the experimental protocol
used in our study.
Immunofluorescence and immunohistochemistry
Adipocytes differentiated on coverslips grown alone, or
cocultivated for the indicated times with breast cancer cells
were processed for immunofluorescence as previously des-
cribed (8). Fluorescence images were acquired with a confocal
lasermicroscopy system (Leica SP2). The image resolution was
512  512 pixels and scan rate was 400 Hz. For each sample,
more than 100 cells were examined in at least three indepen-
dent experiments. Immunohistochemistry was conducted as
previously described (11). Adjacent sections were stained with
hematoxylin and eosin or Masson trichrome to visualize
collagen fibers (murine fat pad experiments). Images were
captured on a Leica DMRA2.
Western blot analysis
Whole-cell extracts and immunoblots were prepared as
previously described (22). All the antibodies used in this study
are presented in Supplementary Table S1.
RNA extraction and quantitative PCR
RNA extraction and quantitative PCR (qPCR) were con-
ducted as previously described (23). All the primers used in
this study are presented in the Supplementary Table S2.
Migration and invasion assays (two-dimensional)
After 3 or 8 days of coculture in the presence of SUM159PT
cells, adipocytes were trypsinized and used to conduct migra-
tion or Matrigel invasion assays as previously described (23).
Similar Matrigel invasion assays were conducted with tumor
cells grown alone or cocultivated with ADFs or with mature
adipocytes during 3 days (8). In these assays, FCS (10%) was
used as a chemoattractant, and similar experiments were
run in parallel in the absence of serum (no chemoattractant,
negative control).
Spheroids formation and invasion in a three-
dimensional collagen matrix
The hanging-drop method has been adapted to produce
spheroids of similar diameter (24). Drops (20 mL) containing
1,000 tumor cells alone or mixed with 1,000 ADFs or preadi-
pocytes were suspended on the lid of 2% agar-coated 24-well
dishes containing culture media. After the 7 days required for
cell aggregation, the spheroids were transferred to the bottom
of a well containing culture medium. Multicellular spheroids
were then allowed to grow for 14 days and the spheroids used in
the invasion experiments had an average diameter of 500 mm.
The spheroid invasion in collagen I matrix was conducted as
previously described (25).
Glucose uptake experiments
Differentiated adipocytes cocultivated or not during 3 and 8
days with SUM159PT cells were used to measure the uptake of
2-deoxy[3H]glucose in the presence or not of insulin as previ-
ously described (26).
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Statistical analysis
The statistical significance of differences (at least three
independent experiments) was evaluated using Student t test
or ANOVA using Prism (GraphPad Inc.). P values less than 0.05
(), 0.01, (), and 0.001 () were deemed as significant while
"NS" stands for not significant.
Results and Discussion
Breast tumor cells are able to causemature adipocytes to
revert to fibroblast-like cells in vitro and in vivo
To test our main hypothesis in vitro, we took advantage of
the coculture model recently set up in our laboratory. As
previously described, mature 3T3-F442A adipocytes coculti-
vated in the presence of breast cancer cells exhibited a decrease
in the number and size of lipid droplets (8). We show here that
this decrease is time-dependent and, after 8 days of coculture,
these cells were almost devoid of lipid droplets (Fig. 1A, top). In
contrast with CAAs (typically obtained after 3 days of cocul-
ture), which retain their rounded morphology (8), adipocytes
that have been cocultivated for longer times in the presence of
tumor cells took on a highly elongated, fibroblastic shape (Fig.
1A, middle). Preadipocyte factor 1 (Pref-1) expression, a pre-
adipocyte transmembrane protein that inhibits adipogenesis
(27), is progressively detected in cocultivated adipocytes (Fig.
1A, bottom). After 8 days of coculture, we also observed that
mature adipocytes exhibit a loss in adiposemarkers expression
that was more accentuated than in CAAs (8). An overall
dramatic reduction of all the tested adipogenicmarkers includ-
ing Adipisin, Adiponectin (APN), Ap2, HSL, as well as C/EBPa
and PPARg2mRNAwas observed by qPCR analysis (reduced by
more than 70% for all tested genes, P < 0.001, Fig. 1B). These
results were confirmed byWestern blots for HSL, Adiponectin,
PPARg2, and C/EBPa expression, whose expression was no
longer detected in cocultivated adipocytes (Supplementary
Fig. S1A). Similar results were obtained by cocultivating adi-
pocytes with the human ZR 75.1, HMT3522-T4.2 or mouse 4T1
breast cancer cell lines (Supplementary Fig. S1B), as well as
when human mammary adipocytes derived from ex-vivo dif-
ferentiation of progenitors, purified from mammary adipose
tissue of healthy donors undergoing reduction mammoplasty,
were used (Supplementary Fig. S1C). At 8 days, cocultivated
Figure 1. Breast cancer cells revertmature adipocytes into fibroblast-like cells in vitro. A,mature adipocyte cultivated in the presence (C) or in the absence (NC)
of tumor cells during the indicated times were stained with Bodipy (top), Pref-1 antibody (bottom; scale bars, 20 mm), or observed through phase
contrast microscopy (middle; scale bar, 50 mm). Nuclei were labeled with TO-PRO-3. Similar experiments were conducted with 3T3-F442A preadipocytes
used as a control. B, expression of the indicated genes analyzed by qPCR in mature adipocytes cocultivated for 8 days in the presence (C) or in the absence
(NC) of SUM159PT tumor cells. C, GLUT4 and GLUT1 gene expression in mature adipocytes cultivated in the presence (C) or in the absence (NC) of
SUM159PT cells during the indicated times (left). Analysis of Glut1 andGlut4 protein expression was done byWestern blot analysis with extracts frommature
adipocytes cultivated in the presence (þ) or in the absence () of SUM159PTcells for the indicated times (right). D, glucose uptake assay in the presence of the
increasing concentrations of insulin conducted in adipocytes cultivated in the presence (C) or in the absence (NC) of tumor cells during 3 and 8 days.
Bars and errors flags represent themeansSD of at least three independent experiments; statistically significant by Student t test; ,P < 0.01; ,P < 0.001
relative to NC cells or to untreated cells for glucose uptake experiments.
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adipocytes exhibited a marked decrease in GLUT4 expression
and a concomitant increase in GLUT1 expression (Fig. 1C) and
became resistant to insulin (Fig. 1D). No gain of proliferative
ability was observed in these cocultivated adipocytes exhibit-
ing insulin resistance and a fibroblast-like shape. Indeed, the
cell number, as well as the cell-cycle distribution, remained
unchanged during the coculture period (see Supplementary
Fig. S2).
We next investigated whether this process might be obs-
erved in vivo. To address this critical issue, we usedGFP-tagged
confluent 3T3-F442A preadipocytes implanted subcutaneous-
ly into athymic BALB/c nude mice, where they developed into
typical fat pads after 5 weeks (21). Murine breast cancer cells
4T1 were then either injected into the newly formed fat pads or
used alone as a control, whereas untreated fat pads also
provided a separate control. Immunohistochemical staining
for GFP was conducted in fat pads removed 10 days after the
injection (Fig. 2A). Tagged-mature adipocytes were used to
ensure that the cells with a fibroblast-like shape present in the
tumors did in fact arise from local adipocytes and not from
other sources. The fat pads derived from 3T3-F442A–confluent
preadipocytes exhibited histologic features of adipose tissue.
Adipocytes were positive for GFPwhereas tumor cells were not
(Fig. 2B, bottom). In the case of tumors injected into the fat
pads, adipose tissue at the tumor periphery was composed of
adipocytes of small size and elongated cells containing many
small lipid droplets—all cells that are GFP positive (Fig. 2B,
bottom, indicated by arrows). Within the tumor, GFP-positive
cells with fibroblast-like shape appear to interdigitate with
tumor cells (Fig. 2B, bottom, indicated by asterisks). Staining of
the tissue sections with Masson trichrome revealed a signif-
icant amount of collagen fibrils in the tumor grown within the
fat pad, whereas few collagen fibrils were seen in tumor grown
alone (Fig. 2B, top). Taken together, these results are consistent
with the fact that breast tumor cells induce phenotypical
changes in mature adipocytes, leading to cells exhibiting low
(if any) lipid content and profound morphologic changes
associated with a marked increase in the expression of matrix
proteins in the tumors. Therefore, our results compellingly
suggest that cells with a fibroblast-like shape could be derived
from mature adipocytes in a tumor-context both in vitro and
in vivo.
ADFs overexpress FSP-1, but not aSMA, and exhibit an
activated phenotype
We then investigated the expression of major markers,
previously used to identify CAFs in these cells (6). As shown
in Fig. 3A, adipocytes cocultivated with tumor cells exhibit a
gradual increase in FSP-1 expression, as opposed to a-SMA or
FAP expression that remains very low. We confirmed that
mature adipocytes cocultivated for 8 days with tumor cells
overexpressed FSP-1 mRNA by 3-fold, compared with mature
adipocytes grown alone (P < 0.01), whereas the difference in
mRNA levels of a-SMA between these two conditions was not
statistically significant (Fig. 3B). These results were confirmed
with human mammary adipocytes (Supplementary Fig. S3).
Functionally activated fibroblasts surrounding tumors are
highly contractile and motile and also display increased ECM
expression (3). As shown in Fig. 3C, increased expression of the
ECM proteins, type I collagen and fibronectin, was also
observed during adipocyte conversion. The fibrotic network
produced by these cells in vitro is in accordancewith the results
obtained withMasson trichrome staining in vivo (see Fig. 2). As
shown in Fig. 3D (top), coculture of adipocytes with tumor cells
was associated with a profound reorganization of actin cyto-
skeleton, marked by the occurrence of stress fibers and the
formation of punctuate spots of vinculin at the ends of actin
bundles. Accordingly, cocultivated adipocytes, as they acquire
a fibroblast-like phenotype, progressively exhibit increased
migratory (Fig. 3D, bottom left) and invasive (Fig. 3D, bottom
right) abilities. Therefore, our compelling results show that
tumor cells can causemature 3T3-F442A adipocytes, as well as
human mammary adipocytes, to revert to an activated FSP-1
fibroblastic cell population. Because of the common charac-
teristics of CAFs and these cells, highlighting that they repre-
sent a subpopulation of CAFs, we named them ADFs. In vitro,
the CAA toADF transition is time dependent (Figs. 1 and 3) and
intermediate forms of adipocyte phenotypical changes (from
small adipocytes to fibroblast-like cells that may or may not
still contain small lipid droplets) could be observed in vitro and
in vivo (Figs. 1 and 2). Once modified at the tumor invasive
front, where the cross-talk between breast tumor and adipo-
cytes is established (8), our data strongly suggests that ADFs
are able to join the center of the tumor and participate in the
desmoplastic reaction by exhibiting increased migratory and
invasive abilities (Fig. 3), as shown in the murine fat pad
experiments (Fig. 2).
The Wnt/b-catenin pathway is reactivated in ADFs and
contributes to the occurrence of the ADFs phenotype
Among the many signaling networks involved in relaying
information fromextracellular signals during adipogenesis, the
Wnt/b-catenin pathway plays a prominent role (28). This
pathway negatively regulates precursors' commitment and
differentiation along the adipocyte lineage (28) and its activa-
tion has recently been shown to also induce a "dedifferentiated"
state in mature adipocytes (17). As shown in Fig. 4A (top),
adipocytes cocultivated with tumor cells exhibit a gradual
increase in b-catenin expression, associated with its redistri-
bution from the cell membrane to the cytoplasm. During
activation of this pathway by Wnt ligands (the so-called
canonical pathway), the b-catenin is hypophosphorylated and
translocated into the nucleus where it contributes to the
activation of Wnt target genes (28). A progressive increase in
active b-catenin in the nucleus of cocultivated adipocytes was
detected (Fig. 4A, bottom). In accordance, cocultivated adipo-
cytes exhibit an upregulation of all Wnt target gene mRNAs
analyzed as described for Dishevelled-1 (Dvl1), Wnt10b, End-
othelin-1 (EDT1), andmetalloprotease-7 (MMP7; Fig. 4B). Taken
together, our results show that the canonical Wnt/b-catenin
pathway is reactivated during coculture and is likely to con-
tribute to the occurrence of the ADFs. Given our results, we
reasoned that targeted inhibition of this signaling using ICG-
001, a unique small molecule that selectively inhibits TCF/
b-catenin transcription in a CBP-dependent fashion (19)might
be able to mitigate the tumor-induced changes in adipocytes.
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As shown in Fig. 4C, exposure to ICG-001 for 3 days signifi-
cantly inhibits the increase in Wnt10b expression induced by
coculture (about 3-fold decrease in 5 mmol/L ICG-001–treated
cells compared with untreated cells, P < 0.05) and partially
restores lipid accumulation in cocultivated adipocytes in a
dose-dependent manner. We next investigated the signal
emanating from tumor cells that could have reactivated the
canonical Wnt/b-catenin pathway. Soluble Wnt3a or TNF-a
has been recently shown to induce the "dedifferentiation" of
murine and human adipocytes through activation of the Wnt/
b-catenin pathway (17). TNF-a was undetectable in the super-
natant of all breast cancer cell lines thatwere cultivatedwith or
without adipocytes. In contrast, Wnt3a was expressed and
secreted by the breast cancer cells, as shown in Fig. 4D for the
Figure 2. The phenotypic changes ofmature adipocytes towards fibroblast-like cells are observed in vivo. A, GFP-tagged confluent 3T3-F442A preadipocytes
were implanted subcutaneously into athymic BALB/c nude mice, where they develop into fat pads after 5 weeks. Murine breast cancer cells 4T1 were
then injected into the newly formed fat pads or assayed separately. Immunohistochemical staining for GFPwas conducted in fat pads removed 10 d after the
injection, tumor cells alone being also used as a control. B, representative Masson trichrome–stained sections from fat pads alone, tumors grown
alone, or tumors grown into the fat pads with collagen stained in blue and nucleus in red (top). Representative images of the expression of GFP (brown)
visualized in fat pads alone, tumors grown alone, or tumors grown into the fat pads (lipids, white; nucleus, blue; middle). Arrows indicate GFP-positive
elongated cells with small lipid droplets present at the tumor periphery, whereas asterisks identify GFP-fibroblast–like cells within the tumor; scale bars,
50 mm. The bottom panel shows a two-fold magnified view of the framed areas.
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SUM159PT cells. The levels of Wnt3a expression and secretion
were not regulated by coculture. Similar results were obtained
with the human breast cancer cell lines ZR 75.1 and MDA-
MB231 (Supplementary Fig. S4). As shown in Fig. 4E (left), in
the presence of Wnt3a blocking antibody, we observe a clear
inhibition of b-catenin upregulation and redistribution ind-
uced by coculture, suggesting thatWnt3a is indeedupstreamof
theb-catenin stabilization. Of note, cells that have been treated
withWnt3a blocking antibody exhibit a significant decrease of
Wnt10b mRNA expression (1.6-fold decrease in antibody-trea-
ted cells compared with untreated cells, P < 0.05) and con-
versely, an increase in lipid content as compared with untreat-
ed cells (Fig. 4E, right). Therefore, the occurrence of ADFs is
associated with activation of the Wnt/b-catenin pathway and
blocking this pathway partially reversed the ADFs phenotype
(Fig. 4C and E). Elevated levels of cytoplasmic and/or nuclear
b-catenin are detectable by immunohistochemistry in the
majority of breast tissue samples and high b-catenin activity
significantly correlated with poor prognosis of the patients
(29). This activation might rely onWnt ligands because several
studies have described overexpression of Wnt protein them-
selves, including Wnt3a, in breast cancer cells lines as well as
breast tumors relative to normal tissue (30). Expression of
these ligands is generally thought to activate the canonical
Wnt/b-catenin pathway in tumor cells by an autocrine mech-
anism (31) to favor tumor growth, migration, inhibition of
Figure 3. ADFs overexpress FSP-1, but not a-SMA, and exhibit an activated phenotype. A, 3T3-F442A mature adipocytes were grown on coverslips and
cultivated in thepresence (C) or in theabsence (NC) of tumor cells during 3, 5, and8days (D3,D5, andD8). After this period, cellswerefixedand stainedwith the
indicated antibodies. 3T3-F442A preadipocytes served as a control. Nuclei were labeled with TO-PRO-3; scale bars, 20 mm. B, a-SMA and FSP-1 gene
expression was evaluated by qPCR in adipocytes cultivated in the presence (C) or in the absence (NC) of tumor cells during 8 days with tumor cells.
Bars and errors flags represent themeansSEMof at least three independent experiments; statistically significant byStudent t test, ,P <0.01 relative toNC
cells. NS, non significant. C, fibronectin and collagen 1expressionwere assessedby immunofluorescence in adipocytes cultivated in thepresence (C) or in the
absence (NC) of tumor cells during 3, 5, and 8 days (D3, D5, and D8). 3T3-F442A preadipocytes served as a control. Nuclei were labeled with
TO-PRO-3; scale bars, 20 mm. D, top, 3T3-F442A mature adipocytes were grown on coverslips and cultivated in the presence (C) or in the absence (NC) of
tumor cells during 3, 5, and 8 days (D3, D5, and D8). After this period, cells were fixed and stained with the indicated antibodies. 3T3-F442A
preadipocytes served as a control. Nuclei were labeled with TO-PRO-3; scale bars, 20 mm. Bottom, adipocytes grown alone (NC) or in the presence of tumor
cells (C) for 3 (D3) and 8 (D8) days. Adipocytes were then trypsinised and used for migration (left) or Matrigel invasion (right) assays towards a medium
containing either 0% (white bars) or 10% FCS (black bars). Bars and errors flags represent the means SEM of three independent experiments; statistically
significant by Student t test; , P < 0.05, , P < 0.01, , P < 0.001 relative to NC cells.
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Figure 4. The Wnt/b-catenin pathway is reactivated in ADFs and contributes to the occurrence of this new stromal cell population. A, adipocytes cultivated in
the presence (C) or in the absence (NC) of tumor cells during 3, 5, and 8 days (D3, D5, D8) and 3T3-F442A preadipocytes were fixed and stained with the
indicated antibodies. Nuclei were labeled with TO-PRO-3; scale bars, 20 mm. B, mRNA expression (qPCR) of the indicated Wnt/b-catenin targets was
evaluated in adipocytes cultivated in the presence (C) or in the absence (NC) of tumor cells during 3, 5, and 8 days (D3, D5, D8). C,Wnt10bmRNA expression
(right) and Bodipy accumulation or morphology observed through phase contrast microscopy (left; scale bars, 20 mm) were evaluated in adipocytes
cultivated in thepresence (C) or in theabsence (NC) of tumor cells for 3dayswith tumor cells in thepresenceof increasingconcentrations of ICG-001.D,Wnt3a
expression and secretion was measured in the SUM159PT cells cultivated in the presence (C) or in the absence (NC) of adipocytes. E, adipocytes were
cultivated in the presence (C) or in the absence (NC) of breast tumor cells in the presence (þ) or absence () of a Wnt3a blocking antibody. In these
adipocytes, the expression of Wnt10b mRNA was measured by qPCR (right), and the b-catenin expression and lipid accumulation were evaluated by
immunofluorescence. Nuclei were labeled with TO-PRO-3 (left); scale bars, 20 mm. Bars and errors flags represent the means  SEM of three independent
experiments; statistically significant by Student t test or ANOVA; , P < 0.05, , P < 0.01, , P < 0.001 relative to NC cells.
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apoptosis, and potentially stem cell renewal in certain tissues
(32).Wepropose here a new and paracrine effect ofWnt ligands
in promoting the occurrence of a subpopulation of CAFs.
ADFs stimulate tumor cells' invasive phenotype in two-
dimensional and three-dimensional coculture systems
Mature adipocytes were cocultivated with breast cancer
cells for 5 days to obtain ADFs, which were then used to carry
out two-dimensional (2D) coculture experiments or to produce
mixed spheroids with "na€ve or unprimed" tumor cells. In 2D
coculture experiments, ADFs strongly stimulated the invasive
properties of SUM159PT cells (increase of 2.4-fold compared
with tumor cells grown alone, P < 0.01; Fig. 5A), this effect being
more pronounced in the presence of ADFs than in the presence
of mature adipocytes (1.5-fold increase as compared with
tumor cells grown alone, P < 0.05; 1.6-fold increase in cells
cocultivated with ADFs as compared with mature adipocytes,
P < 0.05). In addition to the increased cell invasive abilities, we
have previously shown that cocultivated SUM159PT exhibit
morphologic changes along with the reorganization and polar-
ization of vimentin (8). As shown in Fig. 5B, after 3 days of
coculture, ADFs induce similar but more pronounced effects
Figure 5. ADFs enhance tumor cells invasion in 2D and 3D coculture models. A, tumor cells cultivated in the presence (C) or in the absence (NC) of mature
adipocytes or ADFs for 3 d were used for Matrigel invasion assay toward a medium containing either 0% (white bars) or 10% (black bars) FCS. Representative
images of Matrigel invasion assay conducted towards a medium containing 10% FCS are shown below each graph; scale bar, 50 mm. Bars and errors flags
represent the means  SD of three independent experiments; statistically significant by Student's t test; , P < 0.05, , P < 0.01 relative to NC cells. B,
immunofluorescence experiments usingmonoclonal antibodyagainst vimentin or rhodaminphalloidinwere conductedon tumor cells cultivated in the presence
(C) or in the absence (NC) ofmature adipocytes or ADFs for 3 days. Nuclei were labeledwith TO-PRO-3; scale bar, 20mm.C, a representative picture of spheroid
invasion in a collagen matrix [left, scale bar, 250 mm and measurement of the invasion distance (in mm) 48 h after collagen embedding (right)]. Bars and
errors flags represent themeans SEMof three independent experiments, statistically significant by Student t test; ,P < 0.01 relative to spheroids composed
by tumor cells alone (SUM), NS, nonsignificant. D, confocal microscopy analysis of spheroids invasion 48 hours after collagen inclusion, spheroids being
composed by HcRed-SUM, by mixed HcRed-SUM þ GFP-3T3-F442A, or by HcRed-SUM159PT þ GFP-ADF; scale bar, 100 mm. SUM159PT, SUM.
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on vimentin expression that was associated with profound
actin reorganization, leading to the occurrence of stress fibers.
As three-dimensional (3D) invasionmodelsmore closely follow
the cell behavior observed in vivo (33), we confirmed our results
using a spheroid invasion model within a collagen matrix (25;
see Fig. 5C, left, for a representative experiment).We found that
mixed ADFs/tumor cells spheroids exhibit higher invasive
capacities compared with spheroids of tumor cell alone (P <
0.01), yet the presence of preadipocytes had no effect on 3D
tumor cells' invasion (Fig. 5C, right), in accordance with the
results previously obtained in 2D (8). HcRed-SUM159PT cells,
GFP-preadipocytes, and GFP-ADFs were used to investigate
the invasive behavior of each cell subpopulation. Interestingly,
ADFs (and preadipocytes) remained in the center of the
spheroids in contrast with tumor cells that invaded the col-
lagen matrix (Fig. 5D). These combined results indicate that
ADFs stimulate the invasive behavior of tumor cells.
Reorientation of mature adipocytes into ADFs is
observed in human tumors
We next investigated whether ADFs are present in primary
human tumors. To address this critical issue, we first con-
ducted a histologic analysis of human breast tumors to inves-
tigate the presence of cells exhibiting ADF traits. As defined in
vitro and in vivo in murine fat pads, ADFs originate from
progressive changes of the morphology of adipocytes, giving
rise to small adipocytes and of elongated cells containingmany
small lipid droplets. As shown in Fig. 6A, we observed a
profound reorganization of the adipose tissue at the tumor
invasive front (see left for the adipose tissue aspect at distance
of the tumors) with numerous cells exhibiting the features of
intermediate forms of ADFs. Of note, elongated cells with lipid
droplets could be observed within the dense desmoplastic
reaction surrounding the tumors (Fig. 6A, bottom, indicated
by arrows).
Figure 6. ADFs are found in human
tumors. A, histologic examination
of human breast cancers showing
distant adipose tissue (left) and
tumor tissue containing
reorientated adipocytes (middle)
after H&E staining (original
magnification, 200; scale bar, 50
mm.). The right panels showa2-fold
magnification of the framed area.
Results of representative
experiments were obtained using
tumors issued from 2 independent
donors. B, histologic examination
of adipose tissue (lipids, white;
nucleus, blue) in a representative
breast tumor after anti FSP-1
staining (brown). The results
obtained in different areas from the
adipose tissue away from the
tumor to the tumor center are
shown (scale bar, 50 mm). C, left,
the expression of FSP-1 andaSMA
was visualized (brown) in
adipocytes (lipids, white; nucleus,
blue) located adjacent to invading
cancer cells (TU) as compared with
normal adipose tissue [reduction
mammoplasty (RM)]. Right, the
expression of the indicated genes
was analyzed by qPCR in mature
adipocytes obtained from RM or
TU (8 independent samples per
group), statistically significant by
Student t test; , P < 0.05. NS, non-
significant.
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To further characterize these cells, we investigated FSP-1
expression in the breast-cancer surrounding adipocytes at
variable distances from the tumor center. As shown in Fig.
6B, the mature adipocytes further from the tumor are negative
for FSP-1 expression, whereas those closer to the tumor exhibit
FSP-1 expression. FSP-1 positivefibroblasts were present in the
center of the tumors as previously described (6). Therefore, as
observed in vitro, we consistently observed a gradient of FSP-1
expression in mature adipocytes exhibiting first CAA, then
ADF phenotype (Fig. 6B). Finally, we investigated the differ-
ential expression of both aSMA and FSP-1 in tumor-surround-
ing adipocytes by immunohistochemistry. In fact, one of the
key findings of our study is that ADFs, at least in vitro, express
FSP-1 but not aSMA (see Fig. 3A and B). Interestingly, using
experimentally generated tumors in mice, Sugimoto and col-
leagues found unique FSP-1-expressing CAFs, which are clearly
distinct from the a-SMA–positive myofibroblasts (6). This
subpopulation of CAFs is very important functionally, because
FSP-1–positive fibroblasts promote tumor metastasis (34).
Mammary carcinoma cells injected into FSP1/mice showed
significant delay in tumor uptake and decreased tumor inci-
dence (34). Coinjection of carcinoma cells with FSP1þ/þmouse
embryonic fibroblasts partially restored the kinetics of tumor
development and the ability to metastasize, underlying the
role of this specific subset of stromal population in invasive
processes (34). As shown in Fig. 6C (left), we found that a-SMA
expression was not upregulated in adipocytes close to tumors
when compared with normal breast adipose tissue (reduc-
tion mammoplasty) whereas in the same sample, an upregula-
tion of FSP-1 expression was found. To further assess the
expression of these markers by a quantitative approach, adi-
pocytes were isolated from fat samples associated with tumors
or reduction mammoplasty. A series of 16 samples, with 8
samples in each group (Supplementary Table S3 for the clinical
characteristics of the patients), was used, matched with
respect to age (mean: 54.5  10.4 vs. 51.1  8.3 years) and
BMI (mean: 26.1 3.5 vs. 24.9 2.3 kg/m2). Adipocytes isolated
from tumor samples overexpressed FSP-1 mRNA when com-
pared with adipocytes isolated from normal mammary
glands, whereas the mRNA levels of a-SMA were not statis-
tically different between the two groups (Fig. 6C, right).
Therefore, the phenotype described here both in vitro and
in vivo for ADFs is clearly reminiscent of the one of FSP-1–
positive CAFs, including the absence of a-SMA expression
and the invasion-promoting effect. Because mature adipo-
cytes represent the most abundant cellular type in breast
cancer stroma, the process of adipose "dedifferentiation" is
likely to provide a large part of this CAFs subpopulation.
Interestingly, the impact of tumor cells on various compo-
nent of adipose tissue might also participate in the hetero-
geneity of CAFs phenotype. In fact, it has been shown both
in vitro and in vivo that breast cancer cells activate adipose
stem cells towards a CAFs-like phenotype associated with
a-SMA overexpression (for review see refs. 35, 10). Therefore,
mature and precursor adipose cells could contribute to diver-
gent CAFs subpopulation, whose relative contributions in
cancer progression remain to be determined in lean and obese
conditions.
To conclude, the proposedmechanism to explain the occur-
rence and the role of ADFs in breast cancer is summarized
in Fig. 7. In our model, early local tumor invasion in breast
cancer results in immediate proximity of tumor cells and
adipocytes. Cancer cells secrete soluble factors, including
Wnt3a, that are able to activate Wnt/b-catenin pathway in
mature adipocytes, leading to adipocyte "dedifferentiation".
Adipocytes undergo morphologic changes, first marked by a
decrease in adipocyte size and lipid content (CAAs), then by
acquiring a fibroblast-like morphology (ADFs), yet still con-
taining small lipid droplets. At the start of this process, tumor-
primed adipocytes express FSP-1. ADFs exhibit increased
migratory and invasive abilities and are able to join the center
of the tumor, where they significantly promote tumor invasion.
In the center of the tumor, these cells no longer express adipose
markers nor exhibit lipid droplets, which render them indis-
tinguishable from other CAFs cell population. Studying the
process of occurrence of ADFs in breast cancer is of major
clinical importance. In fact, the occurrence of specific stromal
cells, such as ADFs, is critical to the aggressiveness of nearby
tumor cells and they need to be identified to develop targeted
therapeutic strategies inhibiting their development and/or
tumor-promoting activity. Implicating adipose tissue in this
crosstalk is also of major interest because several studies
pointed out that obese women exhibit higher propensity for
local invasion and distant metastasis (10). Obesity condition is
also associated with an increase in adipose tissue fibrosis (15).
Therefore, further studies should address whether ADFs are
over-represented in the breast tumor stroma of obese patients
Figure 7. Mechanism of ADFs occurrence and role in tumor progression.
Schematic representation of the described bidirectional crosstalk
established between breast cancer and adipose cells, underlying the
presence of ADFs in the desmoplastic reaction of breast cancers.
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in which they would provide an invasion-promoting popula-
tion. Such studies will provide unique opportunities to set up
specific strategies for the treatment of the subsets of patients
exhibiting aggressive diseases.
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 2 
Summary 
One of the key features of the peritumoral adipocytes named Cancer-Associated Adipocytes (CAAs) is their loss 
of lipid content observed both in vitro (2D coculture system) and in human breast tumors. We demonstrate here 
that part of this delipidation is due to the ability of tumor, but not normal, breast epithelial cells to induce 
lipolysis in adipocytes. The FFAs released during the lipolysis process are transferred, processed and stored in 
tumor cells as triglycerides (TG), contained in lipid droplets. When needed, these TG can be released as FFAs by 
an ATGL-dependent lipolytic pathway specifically present in tumor cells as shown both in vitro and in human 
tumors. These released FFAs are used for fatty acid β-oxidation (FAO), an activity present in cancer, but not 
normal, breast epithelial cells and regulated by coculture with adipocytes. Inhibition of these lipolytic/FAO 
coupled pathways either by pharmacological or gene repression strategies strongly decreases the invasive 
abilities of tumor cells that have been cocultivated with adipocytes. Taken together, these results show a 
metabolic symbiosis between cancer cells and tumor surrounding adipocytes that stimulate tumor progression.  
 
Graphical abstract: 
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Introduction 
 
Cancer tissues exhibit greater plasticity than normal tissues in their energy metabolism, since they have to 
survive in a dynamic environment where oxygen and nutrients are often scarce [1];[2]. One of the first described 
adaptation to this metabolic stress was the demonstration by Otto Warburg that anaerobic metabolism of glucose 
occurred even in the presence of oxygen (aerobic glycolysis) in cancer cells, but not in normal untransformed 
cells [3]. However, accumulating evidence now demonstrate that in human tumors both mitochondrial oxidative 
phosphorylation (OXPHOS) and aerobic glycolysis coexist, their relative proportion being dependent on both the 
genetics background of the tumors as well as its microenvironment [4];[5]. In addition to glucose and glutamine, 
free fatty acids (FFAs) are extremely relevant energy source, through the mitochondrial fatty acid oxidation 
(FAO) pathway [6]. At physiological levels, FAO is carried out in energy-demanding tissues (such as the heart 
and skeletal muscle) and, in cancer recent works bring to light a role for this metabolic pathway during stress 
conditions. For example, FAO is induced during loss of attachment (LOA) of epithelial tumor cells and rescued 
the cells from death by anoikis [7]. Pandolfi et al recently described a novel mechanism in which FAO is 
regulated by the promyelocytic leukemia (PML) protein and again, the ability of PML to increase FAO activity 
promoted cell survival on LOA [8]. Finally, in lung cancers, the expression of an atypical isoform of carnitine 
palmitoyltransferase 1, CPT1C, promote FAO and ATP production, tumor growth and rescue from metabolic 
stress [35]. Accordingly, FAO should be considered as a metabolic pathway that is highly responsive to 
microenvironmental changes.  
The metabolism of cancer cells is also regulated by the crosstalk with cellular components of the tumor 
microenvironment. For example, epithelial cells can induce aerobic glycolysis in Cancer-Associated Fibroblasts 
(CAFs) with produce lactate, ketones and pyruvate that, in turns, participate to OXPHOS in cancer cells [9];[10]. 
One very important source of FFAs for tumor cells in order to fuel FAO could be the tumor-surrounding 
adipocytes. In fact, we have initially demonstrated in breast cancers that in vitro and in vivo, these adipocytes 
exhibit a decrease in lipid content, a decreased expression of adipocyte markers and an activated state indicated 
predominantly by the overexpression of proinflammatory cytokines [11]. We named them Cancer-Associated 
Adipocytes (CAAs) [11];[12], reviewed in[13]. The loss of lipid content in CAAs might suggest that these lipids 
are released and transferred to cancer cells. Such a direct transfer of lipid from adipocytes to cancer cells has 
been demonstrated in both prostate [14] and ovarian cancer [15]. In their very elegant study, Nieman et al 
demonstrated that lipid transfer from adipocytes to cancer cells fuel the tumor growth in vitro and in vivo 
because inhibiting the adipocytes released of FFAs, through inhibition of the small Fatty Acid Binding Protein 4 
(FABP4) expression, impaired this tumor promoting effect [15]. The fact that ovarian cancer cells exhibit FAO 
activity that is slightly up-regulated in the presence of adipocytes suggest, without demonstrating it directly, that 
these FFAs are used as an energy source for cancer cells. For example, monoacylglycerol lipase (MAGL) an 
enzyme that liberates FFAs from lipid stores promotes cancer progression and aggressiveness independently of 
FAO [16]. Therefore, the goal of our current study was to investigate whether FAO is directly involved in 
adipocyte-cancer cell crosstalk and the network that allowed the FFAs to be available to this metabolic pathway. 
Our work underlines the very important role of FAO in breast cancer invasion and the importance of a paired 
lipolytic activity to fully support its role in tumor aggressiveness.   
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Results and Discussion 
 
A lipid transfer occurs between breast cancer cells and tumor-surrounding adipocytes. In the presence of 
breast cancer cells, both murine and human mammary adipocytes (obtained from ex vivo differentiation of 
progenitors isolated from mammary adipose tissue of healthy donors undergoing reduction mammoplasty) 
exhibit a dramatic reduction in the number and size of lipid droplets that correlated with a significant decrease 
in triglycerides (TG) accumulation in accordance with our previous results [11] (Fig. 1A). We speculated that, in 
addition to a “dedifferentiation” process, the observed loss of lipid content observed in CAAs could involve a 
lipolysis process. Glycerol, one of the products of TG hydrolysis along with FFAs, was detected when 
adipocytes were incubated in the presence of tumor cells conditioned medium (CM) (fig. 1B). Of note, the CM 
of normal mammary epithelial cells was unable to induce lipolysis in adipocytes, showing that this event is 
tumor-specific (fig. 1B). To further confirm the presence of a lipolytic process in tumor-surrounding adipocytes, 
we showed in adipocytes grown in the presence of CM of tumor, but not normal, breast epithelial cells a 
disappearance of perilipin which serves as a gate-keeper of lipid droplet [17] (fig. 1C) as well as the activation of 
the Hormone-Sensitive Lipase (HSL) as revealed by its phosphorylation (fig. 1D). As shown in fig.1B, no 
product of lipolysis was detected when adipocytes were cocultivated with tumor cells and not with their CM. 
These results suggest that the released FFAs and glycerol are uptaken and stored by cancer cells themselves, as 
other tissues use them during energy deprivation. As shown in fig. 1E, cocultivated ZR 75.1 exhibit multiple, 
small lipid droplets as revealed by two probes that stain neutral lipids either the lipophilic fluorescent dye 
Bodipy 493/503 (left, upper panel) or red oil (left, lower panel). Such a lipid accumulation was associated to less 
compacted colonies and a more scattered aspect. Dosage of TG in these cells revealed a 5-fold increase as 
compared to non cocultivated cells in accordance with the visualization of lipid droplets (right panel). Similar 
results were obtained with another tumor cell line SUM159PT (fig. 1F). Total lipids were extracted and analyzed 
by high performance thin layer chromatography (HPTLC), and electrospray ionization mass spectroscopy (ESI-
MS). Cocultivated tumor cells showed significantly higher levels of TG than non cocultivated cells. In contrast 
to TG no changes were observed in the levels of DG and cholesteryl-esters, whereas MG was undetectable (fig. 
S1). Saturated fatty acids (SFA) levels  (both C 16:0 and C18:0) were increased in cocultivated cells whereas 
unsaturated fatty acid levels were not modified by coculture (fig. S1).  Breast cancer cells frequently exhibit 
exacerbated lipogenesis, caused by the up-regulation of lipid metabolizing enzymes such as Fatty Acid Synthase 
(FAS), but also as a result of increased intermediate metabolites of pathways such as anaerobic glycolysis [18]. 
To further confirm that the lipid accumulation in tumor cells was issued from adipocytes-released FFAs, we 
differentiate the preadipocyte 3T3-FF442A with a differentiation medium containing radiolabeled palmitate acid. 
The radiolabeled mature adipocytes obtained were then cocultivated with ZR 75.1 cells for 3 and 5 days. As 
shown in fig. 1G, a progressive decrease of radioactivity was observed in adipocytes that was parallelized with a 
progressive increase of radioactivity contained in tumor cells. In addition, we further demonstrate that the key 
lipogenic enzyme FAS was not upregulated by coculture and that inhibition of its function by the broad inhibitor 
C75 [19]  did not modify the increase of lipid content observed in cocultutivated tumor cells (fig. S2). Taken 
together, these compelling results show that a bidirectional crosstalk is established between breast tumor and 
surrounding adipocytes that favors a transfer of lipid between the two populations. In an adipocyte-rich 
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microenvironment, the continued cellular fatty acid import in tumor cells lead to accumulation of lipids as TG 
within lipid droplets, as already described for other non adipose cells. 
 
Coculture with adipocytes reprogramm the breast cancer cells to use FAO. FFAs might provide cancer cells 
with membrane building blocks, signaling lipid molecules, posttranslational modifications of proteins as well as 
energy supply through FAO. To our knowledge, the existence and relevance of FAO in breast cancer cells has 
been poorly investigated except as the initiation of carcinogenesis process [7]. As shown in fig. 2A, we found 
that the two tumor cell lines used were able to perform FAO at significantly higher levels than the normal 
HMEC cells. Coculture with adipocytes increases the ability of tumor cells to completely oxidize the FA 
whereas the incomplete FAO decreases (left and middle panel). As a result, the oxidative efficiency was 
significantly elevated in cocultivated cells as compared to non cocultivated one (right panel). We also 
investigated whether altered mitochondria accompanied the metabolic switch observed above. As shown in fig. 
2B, OXPHOS-associated proteins involved in the electron transport chain (complex I) were increased in co-
cultivated breast tumor cells compared to non-cultivated one. In addition, non-cultivated and co-cultivated ZR 
75.1 cells were subjected to transmission electron microscopy (TEM). Electron micrographs revealed significant 
changes in the ultrastructure of particular mitochondria in co-cultivated tumor cells with the occurrence of dense 
mitochondrial matrix and aggregated cristae (Fig 2C). Taken together, these results show that within a context of 
surrounding adipocytes, breast tumor cells exhibit increased FAO. Whether the FFAs derived from adipocytes 
are used in this metabolic pathway is further demonstrated by the results obtained with the FAO pharmacological 
inhibitor etomoxir (ETO). ETO inhibits the entry of FFAs into mitochondria by blocking the activity of the long-
chain fatty acids transporter carnitine palmitoyl transferase 1 (CPT1) [20]. A dose-dependent effect of FAO 
inhibition by ETO was performed and we shows that complete FAO was efficiently inhibited by ETO in a dose 
dependent manner between 1 to 30 µM ETO (fig. 3D). When tumor cells were cocultivated with adipocytes in 
the presence of ETO, a 2 to 3-fold increase in TG content was observed (3E, left panel). This increase in lipid 
droplets is also illustrated by the immunofluorescence study performed with bodipy (3E, right panel). Similar 
results were obtained with the SUM159PT cells (fig. S3). The metabolic switch towards the use of FAO was 
further confirmed by the fact that AMP-activated protein kinase (AMPK) phosphorylation is enhanced in 
cocultivated cells, and that this phosphorylation was inhibited by ETO (Fig. 2F). In fact, AMPK favors energy 
producing processes by inhibiting lipogenesis and activating β-oxidation [21]. Finally, we demonstrated that 
ATP production was efficiently inhibited by ETO in these cocultivated cells (fig. 2G).  
 
Inhibition of FAO by pharmacological agents and gene repression strategies specifically impairs 
invasiveness of cocultivated breast cancer cells 
We have previously demonstrated that coculture with adipocytes stimulates cell invasion [11]. Within this 
context, we investigate the effect of the inhibition of FAO by ETO. As shown in fig. 3A (left panel), the invasive 
capacity of ZR 75.1 tumor cells toward 10 % FCS containing medium was increased by 3-fold in cells 
previously co-cultivated for 3 days with adipocytes as compared to tumor cells grow alone (p< 0.05), and this 
effect was completely abrogated by ETO. By contrast, ETO was without effect on cell proliferation (fig. 3A, 
right panel). Similar effect was observed in SUM159PT cells although the effect of adipocytes on tumor cell 
invasion was less pronounced in these aggressive cells (fig. 3B). Our co-culture system shows that adipocytes 
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stimulate the invasiveness of tumor cells in vitro, and that this effect is abrogated by the use of ETO. To test the 
hypothesis that “priming” tumor cells with adipocytes regulates tumor cell distal organ seeding and growth, we 
performed tail vein metastasis assays using the TS/A cell line. It has been previously shown that when injected 
intravenously in syngenic immunocompetent BALB/c mice, these cells form metastases in lung and liver, after 1 
to 2 weeks [22]. Before performing these in vivo experiments, we assessed that TS/A cells was a suitable model. 
As shown in fig. S4, these cells exhibit increase in lipid content when cocultivated with adipocytes, an increase 
in the ratio of complete-to incomplete FAO as well as a decrease in invasiveness in the presence of ETO in vitro. 
Untreated or ETO-treated TS/A tumor cells were cultured in vitro for 4 days in the presence or not of adipocytes, 
harvested, and injected i.v. into BALB/c host mice. As shown in fig. 3C, the number of lung metastases was 
enhanced in mice injected with TS/A cells previously co-cultivated with adipocytes as compared to mice 
injected with TS/A grown alone. This effect was abrogated in the presence of ETO. Histological analysis (fig. 
3D) confirmed that when the TS/A cells have been previously co-cultivated with adipocytes, the lesions replaced 
large areas of the lung parenchyma, whereas cocultivated  cells in the presence of ETO exhibited less 
parenchymal involvement. We have previously demonstrated that cocultivated ZR75.1 exhibit incomplete EMT 
[11]. As shown in fig. 3E (left panel), all the hallmarks of EMT observed in cocultivated cells, such as a more 
scattered aspect and less compacted colonies, the development of multiple extended protrusions shown by β-
actin staining as well as the down-regulation of membrane E-Cadherin expression to a disorganized state in the 
cytoplasm, were inhibited by ETO treatment. Accordingly, the overexpression of the transcription factor snail 
that contributes to EMT, was also inhibited in ETO treated cells as both mRNA and protein levels (fig. 3E, right 
panel). As shown before, the FAO is controlled at the step of FA import into the mitochondria, a process 
executed by tissue-specific isoforms of CPT1- the so-called ‘liver’ (CPT1A), ‘muscle’ (CPT1B) and ‘brain’ 
(CPT1C). It has been recently demonstrated that CPT1C is overexpressed in lung cancer [23]. While 
investigating the expression of CPT1 isoforms in breast cancer cell lines, we observed that only CPT1a was 
specifically expressed in breast cancer, but not normal, cell lines (Fig. 3F). Similar results have been previously 
observed using different couple of tumor/normal cells [24]. Interestingly, CPT1a expression was increased in 
cocultivated cells as exemplified for ZR75.1 cells (Fig. 3G). CPT1a expression was efficiently inhibited by 
stable ShRNA expression (fig. 3H). As shown in fig. 3I, deficiency in CPT1a expression does not affect 
proliferation at baseline or in the presence of adipocytes. By contrast, the absence of CPT1a expression 
specifically interferes with the increase in tumor aggressiveness induced by adipocytes (fig. 3J). In fact, 
cocultivated CPT1a Sh cells do no longer exhibit increased invasion, nor EMT as shown both by morphological 
changes or snail/E-cadherin expression changes (fig. 3K). These results suggest that inhibition of FAO by 
pharmacological or gene repression strategies impairs aggressiveness of cancer cells, at least in part, through 
reversion of EMT. Therefore, we have directly demonstrated here for the first time that the FFAs transferred 
between adipocytes and tumor cells are used to perform FAO.  
 
Importance of the lipolytic pathway to supply FAO with FFAs over time. As seen above, FFAs that are 
transferred to tumor cells are used for FAO and the excess of FFAs are stored in lipid droplets (to protect cells 
again lipid toxicity). Once the lipids are stored as TG, they should be liberated as FFAs to fuel FAO in order to 
sustain invasive activities following the initial crosstalk with adipocytes. As shown in fig. 4A, we found that 
when tumor that have been cocultivated for three days with adipocytes were grown alone, a progressive decrease 
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in TG content was observed during the first 48h. This was associated with a significant increase in the levels of 
glycerol release in the culture medium. The lipolysis process has been mostly studied in adipocytes where it is 
carried out by three major lipases, ATGL, HSL and MAGL [25]. Among these lipases, ATGL is the rate-limiting 
enzyme for the initiation of catabolism in adipose and non-adipose tissues such as heart and muscle [26].  
Expression of these lipases has not been studied in cancer cells with the exception of MAGL that have been 
shown to promote tumor growth through fatty acid release in cancer cells [16]. However, the spectrum of MAGL 
activity would not be efficient in releasing TG store in lipid droplets. We therefore investigated lipases 
expression in normal and tumoral breast epithelial cells representative of a range of poorly and highly aggressive 
cells. As shown in fig. 4B, ATGL expression was not detected in HMEC and its levels of expression was higher 
in aggressive than in non-aggressive cells. Close results were obtained with HSL (with the exception of its 
expression in HMEC cells) whereas by contrast MAGL was expressed in normal, poorly aggressive and highly 
aggressive cells with no large differences within the two groups. The regulation of ATGL expression was 
observed in cocultivated cells with the exception of the highly aggressive triple negative MDA-MB231 whereas 
at the opposite MAGL expression remains unaffected by coculture except a slight increased expression in the 
ZR75.1 cells (fig.4C). Due to its role in hydrolyzing TG, its pattern of expression and its regulation by coculture, 
we decided to invalidate ATGL in the ZR75.1 cells. As shown in fig. 4D, a significant decrease of more than 
80% was observed at protein levels in ATGL deficient cells. The doubling time of these cells were unaffected by 
ATGL deficiency (fig. 4E). In cocultivated cells, we observed that the TG content was stable after adipocytes 
removal (fig. 4F). The coculture was without effect on cell number in both control and ATGL Sh cells (fig. 4G), 
whereas adipocytes were able to stimulate cell invasion only in ATGL proficient cells (fig. 4H). Accordingly, 
cocultivated ATGL Sh cells do no longer exhibit increase EMT as shown both by morphological changes or 
snail/E-cadherin expression changes (fig. 4I). Taken together these results show that ATGL plays a key role in 
regulating lipid network and invasiveness of breast cancer cells cocultivated with adipocytes. Very interestingly, 
when cells were incubated with exogenous lipids, an increase in TG content was observed in tumor cells but 
these TG were not released over times when the lipid source was removed from the culture medium. In 
accordance, no positive regulation of ATGL expression is observed in the lipid-treated cells. Furthermore, these 
cells, despite a positive increase in lipid accumulation, do not exhibit increased cellular invasion (fig. S5). Given 
the exquisite importance of ATGL expression and function in the adipose/cancer crosstalk, we decided to study 
its expression in human tumors along with the two other lipases HSL and MAGL. A Tumor-MicroArray (TMA) 
of 69 patients exhibiting breast cancer as well as normal breast epithelial cells was used (Supplementary Table 
S1 for the clinical characteristics of the patients). As shown in fig. 4J, in accordance with the results obtained in 
cell lines, we observed that ATGL was only expressed in human cancer cells whereas MAGL expression was 
detected both in normal and canceroustissues. Surprisingly, HSL was not expressed in both normal and tumor, in 
apparent contradiction with the results obtained in vitro. ATGL expression was associated with aggressive 
features of the tumor. In fact, a significant increase in ATGL expression was observed in tumor of high grade, 
expressing HER2 and negative for ER and PR expression (see fig. 4L). By contrast, MAGL expression was not 
associated with poor prognosis factors in breast cancer (fig. S6). Another important finding of this 
immunohistochemistry study was the fact that when TMA contains adipose tissue, a highly significant increase 
of ATGL expression was observed in tumor cells at close proximity of adipocytes in all the available samples 
(fig. 4J). To further verify these findings, ten breast cancer biopsies corresponding to cases included in TMA 
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were further analyzed for ATGL expression. As seen in fig. 4K for one representative case, we observed for 
ATGL a gradient of expression with a higher level at the tumor invasive front at proximity of adipocytes. 
Therefore, these results show both in vitro and in human tumors that ATGL is associated to aggressiveness in 
breast cancer and that its level of expression is regulated in areas of the tumor where the dialog with adipocytes 
is engaged. These results strongly reinforced the idea of a metabolic crosstalk between adipose tissue and human 
tumors involving ATGL , an enzyme that plays a key role in regulating lipid network and invasiveness in breast 
cancer cells in an adipocyte-rich microenvironment as shown in vitro. Our results are in apparent contradiction 
with the work of Nomura et al, that shows that MAGL is highly express in aggressive human cancer cells where 
it regulates a fatty acid network enriched in oncogenic signaling lipids that promotes tumor progression [16].  In 
fact, in breast cancer, both in vitro and in vivo, we found only a slight differences in MAGL expression between 
normal epithelial cells, non aggressive and aggressive tumors, in contrast to their data which was limited for 
breast tumors to two cell lines (MCF-7 and 231MFP). Therefore, our results suggest that in breast cancer, this 
enzyme might be less important for tumor progression than in melanomas or ovarian cancer [16]. However, our 
work, like their, sustains the concept that lipogenesis or accumulation of lipid from exogenous sources required a 
paired lipolytic activity to promote tumor progression. In accordance with our results that link ATGL expression 
and function with invasion, it has also been described that MAGL is part of a gene signature correlated with 
EMT properties of cancer cells [27]. Implicating adipose tissue in a metabolic crosstalk with tumor is also of 
major interest since several studies pointed out that obese women exhibit higher propensity for local invasion 
and distant metastasis [28]. In obese patients, the basal rates of lipolysis in adipocytes could be enhanced, which 
could favor in turns the metabolic symbiosis with tumor and tumor aggressiveness. Further studies specifically 
addressing these questions will provide unique opportunities to set up specific strategies for the treatment of the 
subsets of patients exhibiting aggressive diseases. 
 
EXPERIMENTAL PROCEDURES 
 
Cell Lines and Reagents.  
The murine 3T3-F442A pre-adipocyte cell line was cultured in DMEM medium supplemented with 10% of fetal 
calf serum (FCS). Differentiation was induced by incubating confluent cells in differentiation medium (DMEM 
supplemented with 10% FCS plus 50nM insulin) for up to 14 days as described previously [29].  Human 
mammary epithelial cells (HMEC) (provided by Dr J Piette, IGMM, Montpellier, France) were grown in MEBM 
medium (Lonza), containing transferrin (5μg/ml) andisoproterenol (10-5M). The human breast cancer cell line 
ZR 75.1 (Sigma, France) was cultured in DMEM medium supplemented with 10% FCS, and the SUM159PT 
(provided by Dr J Piette, IGMM, Montpellier, France) was grown in Ham F12 (50:50) medium complemented 
with 5% FCS, 1µg/ml hydrocortisone (Sigma, Saint-Quentin les Ulysses, France) and 0.2UI /mL insulin. HMT-
3522-T4-2 mammary epithelial cells (provided by Dr E. Liaudet-coopman, IRCM, Montpellier, France) were 
cultured in H14 medium [30] consisting in DMEM/F12 with 250 ng/ml insulin, 10 mg/ml transferrin, 2.6 ng/ml 
sodium selenite, 10-10 M estradiol and 1.4 x10-6 M hydrocortisone. The human breast cancer cell line MCF-7, 
T47D, MDA-MB-231 (provided by Dr K. Bystricky, LBME, Toulouse, France) and the murine breast cancer 
cell line TS/A cell lines (provided by Dr V. Philippe, INSERM U563, Toulouse, France) were cultured in RPMI 
1640 medium supplemented with 10% FCS. All the cell lines were maintained at 37oC in a humidified 
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atmosphere of 5% CO2/95% air. At 80% confluence, cells were trypsinized and counted using a hemocytometer, 
preparing for use. All the cell lines used within 2 months after resuscitation of frozen aliquots. Antibodies 
against perilipin (D418), hormone-sensitive lipase (HSL), p-HSL (ser660), adipose triglyceride lipase (ATGL), 
Snail (C15D3), AMP kinase (AMPK), p-AMPK (thr172) were purchased from Cell signaling. Monoglyceride 
lipase (H-300), PGC-1 (H-300) antibodies were purchased from Santa Cruz. The CPT1A (ab53532) and 
OXPHOS antibodies were obtained from Abcam. E-cadherin antibody was from Calbiochem. Actin and 
Tubulin-α antibodies were from Thermo Scientific. Dimethyl Sulfoxide (DMSO), Oil red O, Toluidine Blue O, 
Etomoxir (used at 1-30μM final concentration), C75 (used at 10 and 20μM final concentration) were purchased 
from Sigma. The bodipy lipid probe (used at 1μg/ml) and TO-PRO-3 (used at 1μM final concentration) were 
obtained from Invitrogen. 
 
Coculture, Cell Proliferation and Invasion Assays.  
Coculture and invasion assays were conducted as described [11]. Briefly, 5x104 (SUM159PT), 1x105 (ZR 75.1) 
cells were seeded in the top chamber of the Transwell system (0.4 µM pore size, Millipore) cocultivated with or 
without mature adipocytes in the bottom chamber. In indicated experiments, cells were treated or not with 
Etomoxir for 3 days.  
After coculture, tumor cells were fixed with methanol, stained with Toluidine Blue O buffer. Then washed 
several times with distilled water, air-dried, dissolved in dissolving buffer (125μl Tris HCL pH 6.8, 2g glycerol, 
2ml 20% SDS, 2ml Beta mercaptoethanol, made up to 20ml with distilled water), the optical density was then 
read at 570 nm using a MicroQaunt plate reader for cell proliferation assay. 
After coculture, tumor cells were cultivated with serum-free medium overnight, cells were then trypsinized and 
used for Matrigel invasion assay. 6x104 cells were allowed to migrate for 4h (SUM159PT) and 24h (ZR 75-1) in 
Transwell chambers (8µm pore size, Greiner Bio one) towards a medium containing either 0% or 10% serum. 
Cells in the upper chamber removed with cotton swabs, cells on the bottom surface of the filter were fixed with 
methanol, stained with Toluidine Blue O. The invaded cells were quantified in 5 fields per well in triplicate. 
 
MTT Assay. 
4x103 of ZR 75.1 shControl and shCPT1A, ZR 75.1 shControl and shATGL cells were seeded in 96 well plates 
in quadruplicate and incubated for 24hr, 48hr and 72hr. Following this period 100μl of Thiazolyl Blue 
Tetrazolium Bromide (0.05g dissolved in 50ml PBS) was added before further 2 hours incubation. All medium 
was then removed, 100μl of DMSO added for staining and then the colorimetric absorbance at a wavelength of 
570nm. 
 
Animal Studies. 
Eight- to twelve-week-old female syngeneic BALB/c host mice (Janvier, Le Genest St-Isle, France) with an 
average body weight of 22g were used in this study. A catheter was indwelled into the femoral vein under 
anesthesia (sodium pentobarbital, 1:10; 0.2ml per mice; Ceva, Libourne, France), sealed under the back skin, and 
glued on the top of the skull. The mice were housed individually and allowed to recover for 4 days. Then, a total 
of 1x105 TS/A cells, previously cocultivated or not with mature adipocytes in the presence or not of  Etomoxir 
(30μm) for 4 days, were injected through the catheter in BALB/c mice (NC, n=6; NC+E, n=7; C, n=7; C+E, 
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n=8). All the mice received the cells injection in less than 1.5 hours. Mice were sacrificed after 25 days, the 
lungs were immediately excised, and the number of tumor nodules on the lung surface was recorded. Lungs were 
then fixed in 4% paraformaldehyde and embedded in paraffin. Sections were stained with hematoxylin and eosin 
(H&E) and nodules were observed microscopically. The mean number of nodules per lung area and the mean 
nodule area as a function of lung area (that defined the nodule area index) were measured by ImageJ software 
program. The local Institutional Animal Care and Use Committee approved the experimental protocols described 
in the study. 
 
Immunofluorescence and Immunohistochemistry.  
Mature adipocytes differentiated on glass coverslips grown alone or treated with HMEC and SUM159PT CM for 
3 days. Breast tumor cells ZR 75.1 (8 x 104) grown on coverslips in inserts which were cocultivated in the 
presence or absence of adipocytes treated with or without Etomoxir (30μM) for 3 days. The coverslips were 
fixed in 3.7% paraformaldehyde for 20 min at room temperature (RT). After blocking with 10% FCS and 2% 
BSA in PBS for 1 hour, cells were incubated 2 hours at RT with the following antibodies: Perilipin (1:200), p-
HSL (1:150) for adipocytes and E-cadherin (1:50), rhodamine-phalloidin (1:200) for tumor cells. The secondary 
antibody, Alexa fluor 488-conjugated anti-rabbit (1:500) or anti-mouse (1:400) was used for 30 min at RT. 
Coverslips were examined using an Olympus FV-1000 with 60X oil PLAPON OSC objective or a Zeiss LSM 
710 confocal microscope with 40× oil PlanApo objective (1.4 N.A.). A minimum of three independent 
experiments were performed.  Images were processed to filter the noise with Fiji software and a similar filter 
was used to analyze all acquisitions for the experiment. 
Immunohistochemistry was performed as previously described [31]. Histologic examinations of human normal 
breast tissue and breast invasive tumors were done using Haematoxylin & Eosin staining. Tissue sections were 
stained using the following primary antibody dilutions: ATGL (1:100), HSL (1:100) and MAGL (1:50). 
 
Transmission Electron Microscopy. 
1x105 cells/well of ZR 75.1 were seeded in the upper chamber of the Transwell system for co-cultivated with or 
without adipocyte for 4 days. Cells were then fixed in 2% glutaraldehyde, 3% paraformaldehyde in 0.1M pH7.4 
cacodylate buffer, and treated with 1% osmium tetraoxide. Specimens were rinsed with distilled water and 
embedded in 0.5% uranyl acetate. After dehydration in ethanol gradients and embedded in Epon812 resin (Delta-
Microscopies, France). Tissue sections of 80nm were cut on Ultracut Reichert ultratome, then placed on copper 
grides, stained with uranyl acetate and lead citrate and examined in a Jeol JEM-1400 Transmission electron 
microscope coupled to a digital camera Gatan (Toulouse RIO-imaging, CNRS FRBT). 
 
RNA Extraction and Quantitative RT-PCR (qPCR).  
Total RNAs were extracted using the RNeasy mini kit (Qiagen GmbH, Hilden, Germany). Gene expression was 
analyzed using real time PCR as described previously [32]. Total RNAs (1 µg) were reverse-transcribed for 60 
min at 37°C using Superscript II reverse transcriptase (Invitrogen, Auckland, NZ) in the presence of a random 
hexamer. A minus reverse transcriptase reaction was performed in parallel to ensure the absence of genomic 
DNA contamination. Real time PCR was performed starting with 25 ng of cDNA and the indicated 
concentrations of both forward and reverse primers (Snail 300nM: forward, TCCCAGATGAGCATTGGCAG; 
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reverse, CGCGCTCTTTCCTCGTCAG, CPT1A 300nM: forward, TGTGCTGGATGGTGTCTGTCTC; reverse, 
CGTCTTTTGGGAT CCACGATT) in a final volume of 25 μl using the SYBR Green TaqMan Universal PCR 
master mix (Applied Biosystems, Foster City, CA). Fluorescence was monitored and analyzed in a GeneAmp 
7300 detection system instrument (Applied Biosystems, Foster City, CA). Analysis of 18S ribosomal RNA was 
performed in parallel using the ribosomal RNA control TaqMan assay kit (Applied Biosystem), or HPRT RNA 
(100 nM: forward, TGACACTGGCAAAACAATGCA; reverse, GCTTGCGACCTTGACCATCT) or GAPDH 
RNA (300 nM: forward, TGCACCACCAACTGCTTAGC; reverse, GGCATGGACTGTGG TCATGAG) to 
normalize for gene expression. Oligonucleotide primers were designed using the Primer Express software 
(PerkinElmer Life Sciences) as previously described [32]. 
 
RNA Interference Studies in Human Cancer Cell lines. 
To stably switch off ATGL (NM_020376) and CPT1A (NM_001876) gene expressions in ZR 75.1 cells, we 
used replicative short hairpin (shRNA) expressing vectors (pEBVsiRNA) which impose a very strong and stable 
gene silencing in human cells even after several months in culture. siRNA design was performed using the DSIR 
program [33]. RNAi sequences against ATGL stretched from nucleotides 11-29 (with ATGL as the first 
nucleotide, GCGAGAAGACGTGGAACAT; pBD2338) and against CPT1A nucleotide 203-221 
(GCGTGATGACAACGATGTA, pBD2405 or pBD2408). pEBVsiRNA vectors were transfected into ZR 75.1 
cells by using Lipofectamine and knock down (KD) cell populations were selected with 30 µg/mL of 
hygromycin B (Invitrogen, Life Technologies).. ATGL and CPT1A silenced cells were termed as ATGLKD and 
CPT1AKD cells. These cells were currently analyzed by Western blot and RT-qPCR for the loss of ATGL and 
CPT1A gene expression. As control, we used the pBD650 plasmid which expresses an inefficient shRNA 
sequence. 
 
Western Blot Analysis.  
Total proteins were extracted as described previously [34]. Briefly, cells were resuspended in lysis buffer (1μl/ml 
aprotinine, 10μl/ml phosphatase inhibitor cocktail 1, 10μl/ml phosphatase inhibitor cocktail 2, 1μl/ml pepstatin, 
2μl/ml leupeptin, 10μl/ml PMSF). 50μg proteins were electrophoresed on SDS-polyacrylamide gels and 
transferred onto polyvinyl difluoride (PVDF) membrane. After being blocked with 5% skimmed milk in Tris-
buffered saline (TBS 1Х), the membranes were incubated with appropriate primary antibodies. Then the 
membranes were washed with 0.1% TBS-T and incubated with HRP-conjugated secondary antibodies. The 
immunoreactive protein bands were detected by ECL. Primary antibodies were used at the following dilutions: 
p-AMPK, total AMPK, ATGL, HSL, MAGL, Snail, OXPHOS, PGC-1, Actin and Tubulin-α, 1:1000; CPT1A, 
1:500. 
 
Transfer of radioactive lipids between mature adipocytes and tumor cells.  
The preadipocyte 3T3-F442A cells at confluence were incubated in differentiation medium (DMEM 4.5g/L 
glucose supplemented with 10% FCS plus 50 nM insulin) plus 0.12 µCi/ml of radiolabeled palmitate acid. At 11 
days of differentiation, the human breast cancer cell line ZR 75.1 were seeded in the upper chamber of the 
Transwell system for co-culture or not with adipocyte for 3 and 5 days using a medium that do not contain any 
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more radiolabeled palmitate acid. ZR 75.1 and adipocytes were washed 3 times with PBS, then resuspendeds in 
500µl of lysis buffer and the radioactivity was counted in the samples.  
 
Oil Red O Staining.  
The intracellular lipid content was evaluated with the lipophilic dye Oil Red O. Cells in culture were fixed in 
3.7% paraformaldehyde for 20 min at room temperature (RT), rinsed twice with distilled water, and then air-
dried. The fixed cells were then stained for 20 min with solution of Oil Red O in 60% (v/v) isopropanol and then 
washed several times with distilled water. 
 
Measure of adipocyte lipolysis.   
HMEC and tumor cells (ZR 75.1, SUM159PT) conditioned-medium (CM) containing 0.2% of delipidated 
bovine serum albumin (Sigma) were collected for 12h in the absence of serum. Glycerol released in the medium 
was measured in 30µl aliquot using the Glycerol-Free Reagent Kit (Sigma) in mature adipocytes 3T3-F442A 
grown alone, in the presence of CM or cocultivated with tumor cells for 3 days.  
 
Triglyceride (TG) Content Dosage.  
Tumor cells  or adipocytes were grown in the conditions indicated in the Results Section. Cells were were 
pelleted and resuspended in 15µl of TG buffer (10mM Tris.HCL pH 7.5, 1mM EDTA made up to 50ml with 
distilled water). TG content was quantified using a colorimetric kit (Wako Chemicals) and read at a wavelength 
of 505nm. 
 
Fatty Acid Oxidation.  
HMEC and ZR 75.1, SUM159PT were cultivated alone or with mature adipocytes in inserts for 3 days. Cells 
were then incubated with 2ml of warmed (37oC), pre-gazed (95% O2-5% CO2, PH 7.4), modified Krebs-
Henseleit buffer containing 1.5% FA-free BSA, 5mM glucose, 1mM palmitate and 0.5 µCi/ml (14C) palmitate 
(Perkin Elmer) for 120 min. At the end of the incubation, tumor cells were removed and placed in a tube 
containing 800µl of lysis buffer. A 0.5ml microtube containing 300µl of benzethonium hydroxide (Sigma) was 
placed in the vial to capture the 14CO2. The incubation buffer was then acidified with 1ml of 1M H2SO4 and the 
vial was quickly sealed with parafilm. After 120 minutes, the microtube was removed and placed in a 
scintillation vial and the radioactivity, corresponding to complete oxidation, incomplete oxidation and total 
oxidation were counted (cytoscint. MP Biomedicals). C2C12 was used as a positive control. 
 
Cellular ATP Measurement.  
Luminescence was used to determine the relative ATP level in  tumor cells exposed to different conditions. 
1x105 cells/well of ZR 75.1 or 5x104 cells/well of SUM159PT were seeded in the upper chamber of the 
Transwell system and co-cultivated or not with adipocytes in the presence or not of Etomoxir (30μm) for 3 days. 
According to ATP Bioluminescence Assay Kit HSII (Roche), harvested cells were plated in 96 microwell plate 
(MWP). Luminescent intensity from each well was measured using Centro LB 960 Microplate Luminometer.  
 
Statistical Analysis. 
 13 
The statistical significance of differences between the means (at least three independent experiments) was 
evaluated using Student`s t-tests, performed using Prism (GraphPad Inc.). p values below 0.05 (*), <0.01 (**) 
and <0.001 (***) were deemed as significant while “NS” stands for not significant. 
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Figure 1. Lipid transfer from adipocytes to cancer cells.
(A) Left, mature murine and human adipocytes cocultivated in the presence (C) or in the absence (NC) of ZR 75.1 tumor cell were stained with 
red oil. Right, the TG content was dosed in murine adipocytes. 
(B) Glycerol release is detected in 3T3-F442A mature adipocytes treated or not (Adi) with normal mammary epithelial cells (HMEC) and breast 
tumor cells (ZR 75.1, SUM159PT) conditioned medium (CM) for 3 days. In certain experiments, adipocytes were cocultivated (COC) with the 
indicated tumor cells.  
(C, D) Immunofluorescence staining using confocal microscopy for perilipin and phosphorylated HSL (p-HSL) expression  (in green) in mature 
adipocytes alone and mature adipocytes treated with HMEC and SUM159PT conditioned medium (CM) for 3 days (scale bars, 20µM). 
Nucleus were labeled with TO-PRO-3 (in blue).
(E) Left, lipid accumulation (staining using fluorescent dye Bodipy 493/503, upper panel, or red oil, lower panel, in ZR 75.1 cells cultured alone 
or with murine mature adipocytes for 3 days. Right, the TG content was dosed in ZR 75.1 cells in cells cocultivated (C) or not (NC) with adipocytes. 
(F) Left, lipid accumulation in SUM159PT cocultivated (C)  or not (NC) with adipocyes, shown after staining with Bodipy (left) or 
by measure of TG content (right). 
(G) Murine adipocytes that were labeled with radioactive palmitate during in vitro differentiation were cocultivated in the presence (C) 
or absence (NC) of ZR 75.1 tumor cells for 3 and 5 days. The redioactivity level was detected in both adipocytes and tumor cells.
Bars and errors flags represent the means ± SD of at least three independent experiments; 
statistically significant by Student’s t-test, * p < 0.05, ** p<0.01, *** p<0.001.
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Figure 2. In the presence of adipocytes, co-cultivated breast cancer cells undergo a metabolic switch towards mitochondrial Fatty acid β-oxidation.
(A) Complete (left panel) and incomplete (middle panel) FAO in HMEC and breast tumor cells (ZR 75.1 and SUM159PT cultured alone (NC) or with 
murine adipocytes (C) (the myoblast cell line C2C12 is used as a positive control). The ratio between incomplete and complete FAO was calculated 
and reflect FAO efficiency (right panel).
(B) Expression of mitochondrial OXPHOS complexes determined by Western blot in breast tumor cells cultured alone (NC) or with murine mature 
adipocytes (C). Actin is shown as a control for equal protein loading.
(C) Transmission electron microscopy pictures showing pronounced ultrastructural changes in ZR 75.1 cells co-cultivated (C) with mature 3T3-F442A for 
4 days as compared to non-cultivated (NC) cells. Scale bars, from left to right: 5μm-2μm-1μm.
(D) Complete FAO levels in ZR 75.1 treated or not (NT) with increasing doses of Etomoxir.
(E) Left, the TG content was dosed in non-cultivated (NC) and co-cultivated (C) ZR 75.1 cells in the presence of increasing doses of etomoxir. 
Right, confocal microscopy images of lipid accumulation (green) in non-cultivated (NC) and co-cultivated (C) ZR 75.1 cells in the presence of 
30μM Etomoxir (NC+E, C+E) for 3 days (nuclei in blue).
(F) Immunoblot for total and p-AMPK in non-cultivated (NC) and co-cultivated (C) ZR 75.1 cells in the presence of 30μM Etomoxir (NC+E, C+E) for 3 days.
(G) ATP production was evaluated in non-cultivated (NC) and co-cultivated (C) ZR 75.1 cells in the presence of 30μM Etomoxir (NC+E, C+E). 
Bars and errors flags represent the means ± SD of at least three independent experiments; 
statistically significant by Student’s t-test, * p < 0.05, ** p<0.01, *** p<0.001.
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Figure 3. Metabolic crosstalk between adipocytes and breast cancer cells contribute to EMT and tumor invasion.
(A, B) 1x105 ZR 75.1 cells or 5x104 SUM159PT cells were grown for 3 days on Transwells in the presence or not of mature adipocytes and treated or not with Etomoxir. 
After 3 days, cells were dissolved and colorimetric absorbance of solution was measured for proliferation. In other wells, cells were trypsinized and 
used for Matrigel invasion assay against medium containing either 0% or 10% FCS. 
(C) BALB/c nude mice were inoculated with murine breast cancer cells TS/A cocultivated in the presence (C) or absence (NC) of adipocytes treated with 30μM Etomoxir 
(NC+E, C+E) during 4 days prior to tail vein injection. Left, representative picture of lungs from each group harvested at necropsy after 25 days. 
Right, number of tumor nodules on the surface of the lung from each group of mice. 
(D) Left, H&E stained transverse sections of host lungs from mice injected with TS/A cells previously cocultivated with adipocytes treated with (C+E) or without Etomoxir (C) 
during 4 days (original magnification Х2). Examples of invading lesions are shown by arrows. Right, magnified views of invading lesions.
(E) Left, ZR 75.1 cells were grown on coverslips in inserts which were cocultivated in the presence (C) or absence (NC) of adipocytes treated with 30μM Etomoxir (NC+E, C+E). 
After 3 days, cells were fixed and stained with E-cadherin and Actin antibody. Nucleus were labeled with TO-PRO-3 (scale bars 20μm). 
Relative mRNA expression (upper right) or Western blots of Snail (lower, right) in ZR 75.1 and SUM159PT incubated in similar conditions. 
(F) Relative mRNA expression of CPT1a in HMEC and breast tumor cells.
(G) Immunoblot for CPT1a in non-cultivated (NC) and co-cultivated (C) ZR 75.1 cells for 3 days.
(H) Quantification of the mRNA and protein levels of CPT1a in ZR 75.1 cells transfected with CPT1a shRNA and CPT1a shVector.
(I) Left, cell proliferation of ZR75.1 transfected with control or CPT1 ShRNAs determined by MTT assays. Right, 1Х105 CPT1a shRNA and CPT1a shVector cells were grown 
on Transwells in the presence or not of mature adipocytes for 3 days and the cells number was determined after this incubation period.
(J) CPT1a shRNA and CPT1a shVector cells were grown on Transwells in the presence or not of mature adipocytes. After 3 days, cells were trypsinized and used for Matrigel
invasion assay towards a medium containing either 0% or 10% FCS.
(K) Left, Immunofluorescence using confocal microscopy for E-cadherin (green) and Actin (red) in CPT1a shRNA and CPT1a shVector cells cocultivated in the presence (C) or 
absence (NC) of adipocytes for 3 days. Nuclears were labeled with TO-PRO-3 (scale bars 20μm). Right, the Snail protein expression was detected by western blot.
Bars and errors flags represent the means ± SD of at least three independent experiments; statistically significant by Student’s t-test, * p < 0.05, ** p<0.01, *** p<0.001.
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Figure 4. Breast cancer cells possess an ATGL-dependent lipolytic pathway that favor cancer aggressiveness in the presence of adipocytes.
(A) Left, ZR 75.1 cells were cocultivated in the presence (C) or absence (NC) of adipocytes for 3 days, then the adipocytes were removed. 
The TG content in tumor cells was dosed after 2hr, 24hr and 48hr. Right, Glycerol release was detected at the same time.
(B) ATGL, HSL, MAGL protein levels were analyzed in HMEC and non-aggressive breast tumor cells (ZR 75.1, MCF-7 and T47D) and aggressive 
breast tumor cells (SUM159PT, MDA MB231 and T4-2) by Western blotting. 
(C) ATGL, HSL, MAGL protein levels were analyzed in tumor cells cocultivated in the presence (C) or absence (NC) of adipocytes for 3 days. 
β-actin was blotted as a loading control. 
(D) ATGL protein levels were analyzed in ZR 75.1 cells transfected with ATGL shRNA and ATGL shVector.
(E) Cell proliferation of ZR75.1 transfected with control or ATGL ShRNAs determined by MTT assays.
(F) TG content was detected in ATGL shRNA and ATGL shVector cells after cocultivated with adipocytes for 3 days.
(G) 1Х105 ATGL shRNA and ATGL shVector cells were grown on Transwells in the presence or not of mature adipocytes for 3 days and the cells number 
was determined after this incubation period.
(H) ATGL shRNA and ATGL shVector cells were grown on Transwells in the presence or not of mature adipocytes. After 3 days, cells were trypsinized 
and used for Matrigel invasion assay in a medium containing either 0% or 10% FCS for 24hr of invasion assay.
(I) Right, Immunofluorescence using confocal microscopy for E-cadherin (green) and Actin (red) in ATGL shRNA and ATGL shVector cells cocultivated 
in the presence (C) or absence (NC) of adipocytes for 3 days. Nucleus were labeled with TO-PRO-3 (scale bars 20μm). 
Left, the Snail protein expression was detected by western blot.
(J) Representative immunohistochemical staining (bottom) for ATGL obtained in TMA in areas containing or not adipocytes.
(K) Representative experiment of ATGL staining obtained in a tumor biopsie, in the center of the tumor and at the tumor invasive front. 
(L) Expression of ATGL as a function of tumor characteristics in the series of 69 tumors included in the TMA. 
Bars and errors flags represent the means ± SD of at least three independent experiments; 
statistically significant by Student’s t-test, * p < 0.05, ** p<0.01, *** p<0.001.
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Supplementary Figure 1. Cocultivated tumor cells exhibit increase in TG and saturated free fatty acids. 
ZR75.1 cells were cocultivated (C) or not (NC) in the presence of adipocytes. 
Total lipids were extracted and analyzed by high performance thin layer chromatography (HPTLC),
 and electrospray ionization mass spectroscopy (ESI-MS). 
Left panel, dosage of the different lipid species. middle and right panels, dosage of FFAs. 
Abbreviations : CHOE, esterified cholesterol, Chol, cholesterol, SFA Saturated fatty acids, 
MUFA, monounsaturated fatty acids, PUFA, polyunsaturated fatty acids. 
Bars and errors flags represent the means ± SD of at least three independent experiments; 
statistically significant by Student’s t-test, * p < 0.05. 
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Supplementary Figure 2. The increase of TG content in cocultivated tumor cells is not dependent of lipogenesis. 
Left panel: ZR75.1, SUM159PT and T47D cells were cocultivated (C) or not (NC) in the presence of adipocytes. 
After three days, the proteins were extracted and used for the detection of Fatty Acid Synthase (FAS) expression. 
Right panel:ZR75.1 were cocultivated in the presence or not of adipocytes and treated or not with the FAS inhibitor 
C75 for three days. After this incubation period, the TG content of tumor cells was dosed. 
Bars and errors flags represent the means ± SD of at least three independent experiments; 
statistically significant by Student’s t-test, * p < 0.05. NS, not significant 
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Supplementary figure 3. Etomoxir increases TG content in cocultivated SUM159PT tumor cells. 
SUM159PT cells were cocultivated (C) or not (NC) in the presence of adipocytes, and treated or not with 
etomoxir for 3 days. After this time, TG content was dosed in tumor cells 
Bars and errors flags represent the means ± SD of at least three independent experiments; 
statistically significant by Student’s t-test, * p < 0.05. 
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Supplementary figure 4. The TS/A cell line exhibit a similar crosstalk with adipocytes in vitro.
 A, Complete (left panel) and complete to incomplete ratio of FAO in TSA/cells cocultivated (C) or not (NC)
in the presence of adipocytes. After this time, TG content was dosed in tumor cells (B) and invasion assays 
were performed in cells cocultivated or not in the presence of adipocytes and treated or not with etomoxir (C). 
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Supplementary figure 5. Treatment with intralipids do not stimulate ATGL expression and activity, 
nor tumor cell invasion. 
ZR 75.1 cells were exposed or not to 0.025% intralipids (IL) for three days. 
A, the TG content is show after staining with bodipy (left) or dosage (right). 
B, Expression of ATGL in SUM159PT and ZR75.1 cells exposed or not for three days to intralipids. 
C, Cells were exposed to IL for three days, then washed. The TG content and the lipolysis activity was measured 
at the indicated times after IL removal. 
D, Invasion assays performed in ZR75.1 cells exposed or not to IL. 
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Supplementary figure 6. MAGL expression is not associated to tumor aggressiveness.
MAGL expression was stratified according to tumor characteristics. 
Abbreviations: ER, oestrogen receptor, PR, progesterone receptor, LN, lymph nodes. 
  
 
 
 
 
  
Table 1. Clinical characteristics of the patients used in the TMA. 
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Conclusions and perspectives  
There is now accumulative evidence that cells immediately adjacent to a tumor are not only passive 
structural elements but also active actors in tumor progression. Among the many different cell types 
surrounding breast cancers, the most abundant are those that compose mammary adipose tissue, 
mainly adipocytes and progenitors. Since current epidemiological evidence convincingly showed 
that obesity is associated with greater breast cancer specific mortality and poor disease free survival 
[424], the involvement of fat cells in the progression of cancer appears of major interest.  
During my thesis, I participate to the efforts of my team to characterize the phenotypical changes 
induced by tumor cells in surrounding adipocytes. We have defined during these 4 years, two new 
stromal populations CAAs (Experimental article 1) and ADFs (Experimental article 2). In addition, 
we have shown that these modified adipocytes strongly stimulate tumor local and distant invasion. 
This effect appears to be dependent of different soluble signals such as inflammatory mediators (IL-
6) by CAAs or potentially through the secretion of the S100A4/FSP-1 protein by CAAs/ADFs. 
Moreover, during my thesis, I have shown that a metabolic crosstalk is established between cancer 
cells and tumor-surrounding adipocytes (Experimental article 3). The FFAs that are uptaken and 
stored by breast cancer cells are used for FAO and our results highlight the important and rather 
unexpected role of FAO in tumor cell invasion. Furthermore, we show here for the first time that 
ATGL expressed by tumor cells plays a key role in regulating lipid network and invasiveness in 
breast cancer cells cocultivated with adipocytes. Of importance, this enzyme is expressed at the 
tumor invasive front of human breast tumors where cancer cells and adipocytes meet. Taken 
together, these results offer new opportunities to inhibit the tumor/stroma crosstalk in order to 
inhibit tumor progression. In addition, our work raises the question of the amplification of this 
negative crosstalk in obesity conditions with appropriate in vitro and in vivo models that I will 
discuss here.  
 
The peritumoral adipocytes: characterization of two new stroma cell populations CAAs and 
ADFs 
Adipocytes surrounding tumors exhibit profound phenotypic changes that include both 
morphological and functional alterations. We have shown that adipocytes cultivated with cancer 
cells exhibit an altered phenotype characterized by a delipidation, a decreased in late adipose 
markers (HSL, APN, resistin and aP2) associated with the occurrence of an activated state marked 
by overexpression of proteases (such as MMP-11 and PAI-1), and pro-inflammatory cytokines (IL-
6 and IL-1β). We named these tumor-surrounding adipocytes, CAAs [68]; [425]. It is important to 
underline that the occurrence of CAAs (defined by the decrease in adipocyte size and loss of lipid 
content) is not restricted to breast cancer and is also observed in all the invasive cancer that reach 
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AT such as disseminated ovarian cancer, invasive colon, prostate and melanomas (review [426], our 
own unpublished results). However, whether the secretion profile that we defined in breast cancer is 
found also in other tumor types, remain to be determined.  
In tumors growing in an adipose tissue-dominated microenvironment such as breast cancer, 
adipocytes disappear, fibroblast-like cells accumulate, and a desmoplastic stroma ensues. As the 
origin of CAFs is unclear, we postulated that under “tumor pressure”, part of the CAAs population 
might revert to fibroblast-like cells therefore contributing to a sub-population of CAFs. We have 
demonstrated for the first time using both in vitro and in vivo approaches (including human 
samples) that part of the CAFs originate from the “dedifferentiation” of mature adipocytes, a 
process that is initiated at the tumor invasive front. We named this new stromal cell population 
ADFs. One of the very important characteristic of ADFs is that they express FSP-1 but not SMA 
protein. The expression of this protein might have important functional impact since it has been 
shown that FSP-1 express by fibroblasts could stimulate tumor invasion [427], as discussed in the 
following paragraph. As for CAAs, ADFs are probably present in other tumors than breast. For 
example, in both ovarian cancer and renal cell cancer, tumor cells replace and invade the adipocyte 
microenvironment and the adipocytes vanish. Histological studies of these and other abdominally 
metastasizing cancers (colon, gastric, pancreatic) confirm that adipocytes at the tumor invasive front 
become smaller and the number of fibroblast-like cells increases [426]. Again it would be very 
important to determine whether or not ADFs exhibit the same phenotype (FSP1+/ SMA-) 
regardless of the tumor at proximity.  
Other important phenotypical changes might occur in the AT at proximity of tumor cells that are not 
described in the works presented here. In fact, it has been described that WAT can acquire BAT-
like properties which are generally referred as “browning” and this have been proven to be of great 
of importance in protecting against diet-induced obesity and metabolic diseases [428]. BAT 
activation is mediated by thyroid hormone and β3-adrenergic signaling pathways, which stimulate 
β-oxidation of fatty acids and heat production via the electron transport chain-uncoupling protein 
UCP1 [429]; [430]. Under the “tumor cell pressure”, the metabolic change occurring in adipocyte is 
still unknown. Our preliminary result showed that after being co-cultivated with tumor cells, 
adipocytes acquire UCP1 expression which suggest that they can undergo the “browning process”. 
Given BAT huge capacity for energy expenditure and thermogenesis, it would be of high interest to 
investigate this aspect in both cancer progression and cachexia.  
 
What are the signals emanating from tumor cells that explain the occurrence of CAAs/ADFs?  
In the data presented, we show that the occurrence of the ADF phenotype depends on the 
reactivation of Wnt/β-catenin pathway in response to Wnt ligands (Wnt3a) secreted by tumor cells 
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and blocking this pathway partially reversed the ADF phenotype. However, these results need to be 
confirmed in vivo by showing for example that in human tumors the FSP1+ population also express 
an activated Wnt/ -catenin pathway.  
An important finding of my study is that in addition to dedifferentiation, the CAAs exhibit 
enhanced lipolytic activity, both processes probably contributing to the delipidation of tumor 
surrounding-adipocytes. The best known mechanism regulating adipocytes lipolysis is the 
activation of the β-adrenergic G protein-coupled receptors on the plasma membrane that generates a 
signaling cascade activating cAMP-dependent PKA. As we have described in the introduction, 
other pathways are able to induce lipolysis like the inhibition of the α2-adrenergic receptors, or the 
involvement of proinflammatory cytokines IL-6 and TNF-α [175]. For the moment, the tumor-
derived signals that contribute to induce lipolysis in adipocytes in our study remain unresolved. In 
the study of Nieman et al., the use of the β-adrenergic antagonist, propranolol, partially reverses the 
lipolysis induced by ovarian tumor cells. However, in our hands, propranolol did not inhibit breast 
cancer cell-induced lipolysis (data not shown). The use of the α2-adrenergic receptor agonist 
UK14304 as well as IL-6 blocking antibody (TNF  was not detected in the supernatant of our 
breast cancer cells) has no effect as well (data not shown). Therefore, the differences between our 
results and the study of Nieman [71], clearly suggest that the lipolysis in tumor surrounding 
adipocytes might be differentially regulated depending on the tumor type.  
We are currently addressing the role of AMP-activated protein kinase (AMPK) in tumor-induced 
lipolysis using either AMPK pharmacological activator AICAR or inhibitor Compound C. To date, 
the role of AMPK in regulation of adipocytes lipolysis remains controversial. Some studies have 
described its anti-lipolytic role, whereas other studies have suggested the converse [431]; [432]. 
However, given the activation of AMPK in our coculture model, we think that this hypothesis 
deserves further investigation.  
 
CAAs modify the cancer cell characteristics leading to a more aggressive behavior through 
secretions of soluble factors. 
Meanwhile, we found that both CAAs and ADFs strongly enhance the aggressiveness of tumor cells 
both in vitro and in vivo. CAAs secrete adipokines which stimulate the adhesion, migration, and 
invasion of tumor cells. We have shown that CAAs overexpress IL-6 both in vitro and in vivo and 
that, in the coculture system, IL-6 blocking antibody inhibits the CAAs-dependent proinvasive 
effect. Interestingly, the human breast tumors of larger size and/or with lymph nodes involvement 
exhibit the higher levels of IL-6 in tumor surrounding adipocytes. Such an inflammatory state in the 
tumour-surrounding adipose tissue has also been described for other cancers. High levels of IL-6 
were found in the periprostatic adipose tissue of tumor-bearing patients and the levels of IL-6 
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correlated with the aggressiveness of the prostate tumor [269], Such results are not surprising since 
IL-6 has been shown to induce EMT [272]. The secretion of IL-6 is not specific to adipocytes since 
this proinflammatory cytokine is also secreted by TAMs/CAFs [433]; [434]. Obesity is associated 
to systemic low-grade inflammation, which has been suggested to have an important role in the 
pathogenesis of cancer. In obesity, the expanding visceral AT makes a different substantial 
contribution to the development of obesity-linked inflammation via enhanced secretion including 
IL-6 [238]. To date, a new therapeutic approach to block the actions of IL-6 by use of a humanized 
anti-IL-6R antibody has been proven to be therapeutically effective for rheumatoid arthritis, 
systemic juvenile idiopathic arthritis and Castleman`s disease [435] and these antibodies are 
currently evaluated in cancer patients. Therefore, it would be of high interest to stratify the patient 
population and to investigate if there is a higher effect in obese patients.  
We found that CAAs also exhibit increased expression of MMP-11. MMP-11 plays a role in 
adipogenesis and acquisition of fibroblast-like phenotypes of adipocytes [70]. Overexpression of 
MMP-11 is associated with poor clinical outcome in patients in numerous carcinomas [436]. 
Furthermore, MMP11 combine with collagen VI (COLVI) contribute to ECM remodeling. 
Adipocyte-derived COLVI is abundantly expressed in tumor-surrounding adipocytes and is 
involved in mammary tumor progression in vivo [257]; [69]. Increase local fibrosis and its 
permanent remodeling (generating ECM components functioning as signaling molecules) have been 
clearly implicated in tumor progression. These results underline that the contribution of CAAs to 
tumor progression is probably like CAFs or TAMs, multifactorial.  
Another very interesting candidate is S100A4, also known as FSP-1, that belongs to the S100 
protein family of small Ca
2+
-binding protein, Members of this family have been implicated in 
cytoskeletal-membrane interactions, calcium signal transduction, and cellular growth and 
differentiation [437]. S100A4 is localized in the nucleus, cytoplasm, and in extracellular space and 
in cancer possesses a wide range of biological functions, such as regulation of angiogenesis, cell 
survival, motility, and invasion. Accordingly, its expression is tightly correlated with poor 
prognosis in patients with numerous types of cancer [438]. Several investigations have reported the 
expression of S100A4/FSP-1 in lymphocytes, macrophages, endothelium and smooth muscle cells 
of vessel walls adjacent to tumor tissue in various organs, suggesting the involvement of FSP-1 in 
the tumor/stroma crosstalk [439]; [440]; [441]; [442]. It has been shown that S100A4 is markedly 
up-regulated in activated fibroblasts both in normal conditions (e.g., wound healing) and in tumor 
stroma [443]; [444]. Coculture of fibroblasts and tumor cells stimulated the release of S100A4 from 
fibroblasts. When S100A4 is released into the extracellular compartment, it strongly contributes to 
tumor progression by creating a favorable microenvironment for tumor invasion and 
neovascularization (activation of MMPs, VEGF, induction of the key transcriptional EMT-regulator 
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Snail as well as NF-κB) [445]; [427];  [446]; [447]. Our results clearly shown that ADFs express 
S100A4/FSP-1, an expression that could contribute to stimulate tumor invasion. Thus, it would be 
of high interest to investigate whether or not FSP-1 expression is the key event that contributes to 
ADFs-dependent stimulation of cancer invasion, by down-regulating its expression by gene 
repression strategies. If positive results are obtained, the representation of this FSP1+ population in 
breast cancers in obese versus lean conditions (both animal and human models) should be studied. 
In fact, it is reasonable to speculate that the increase of the ADFs population in obese patients could 
contribute to the poor prognosis observed.  
 
Adipocyte/tumor cell metabolic coupling contribute to cancer progression 
The best characterized and most widely appreciated metabolic phenotype observed in tumor cells is 
the “Warburg effect”, which is a shift of ATP generation from oxidative phosphorylation to 
glycolysis, even under normal oxygen concentrations. Warburg originally proposed that the 
elevated aerobic glycolysis in cancer cells was due to a permanent impairment of mitochondrial 
oxidative phosphorylation (OXPHOS). However, recent investigations found that defects of 
mitochondrial OXPHOS are not common in spontaneous tumors and that the function of 
mitochondrial OXPHOS in most cancers is intact [326]; [319]. According to the “reverse Warburg 
effect”, epithelial cancer cells induce aerobic glycolysis in CAFs which produce lactate, ketones 
and pyruvate that as fuels for tumor cells in a subset of micro-environmental setting [328]; [329]. 
According to this concept, we speculated that CAAs may also contribute to the “metabolic 
symbiosis” with tumor cells. In a study published during my thesis, Nieman et al demonstrated that 
lipid transfer from adipocytes to cancer cells fuel the tumor growth in vitro and in vivo [71]. 
Inhibiting the adipocytes released of FFAs, through inhibition of the small Fatty Acid Binding 
Protein 4 (FABP4) expression, impaired this tumor promoting effect [71]. The fact that ovarian 
cancer cells exhibit FAO that is slightly upregulated in the presence of adipocytes suggest, without 
demonstrating it directly, that these FFAs are used as an energy source for cancer cells [71]. During 
my PhD work, we showed that the FFAs released during the lipolysis process by adipocytes are 
transferred, processed and stored in tumor cells as triglycerides (TG), contained in lipid droplets. 
When needed, these TG can be released as FFAs by an ATGL-dependent lipolytic pathway 
specifically present in tumor cells as shown both in vitro and in human tumors. These released 
FFAs are used for fatty acid β-oxidation (FAO), an activity present in cancer, but not normal, breast 
epithelial cells and regulated by coculture with adipocytes. Inhibition of these lipolytic/FAO 
coupled pathways either by pharmacological or gene repression strategies strongly decreases the 
invasive abilities of tumor cells that have been cocultivated with adipocytes.  
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Our study underlines a very important link between tumor invasion and FAO. The molecular 
mechanism contributing to this effect remains for the moment undetermined. AMPK is a central 
metabolic sensor that, upon phosphorylation, favors energy producing processes by activating β-
oxidation [448]; [449]. Beside its key role in regulation of cellular energy homeostasis, one study 
suggested that AMPK is able to modulate Smad3 transcriptional activity, which plays an important 
role in TGF-β1-induced epithelial-to-mesenchymal transition (EMT) [450]. We observed in our 
study that cocultivated tumor cells exhibit activation of AMPK and incomplete EMT. Conversely, 
the FAO inhibitor etomoxir (ETO) efficiently blocked AMPK phosphorylation and reversed EMT 
process, thus impairing the aggressiveness of cancer cells. Therefore, this molecular link could 
deserve further investigation.  
Another very important finding of our study is the fact that ATGL expression is highly regulated by 
coculture and at the invasive front of human tumors. Regulation of ATGL activity might also be 
related to AMPK activity. In fact, it has been shown that ATGL is phosphorylated by AMPK, 
therefore increasing its TAG hydrolase activity [451]. On the opposite, Atgl deficiency in mice 
decreases mRNA levels of PPAR-α and PPAR-δ target genes. In the heart, this leads to decreased 
PGC-1α and PGC-1β expression and severely disrupted mitochondrial substrate oxidation and 
respiration [452]. Until now, expression of these lipases has not been studied in cancer cells with 
the exception of the work of Nomura et al, showed that MAGL is highly express in aggressive 
human cancer cells where it regulates a fatty acid network enriched in oncogenic signaling lipids 
that promotes tumor progression [421]. Our results suggest that in breast cancer, this enzyme might 
be less important for tumor progression than in melanomas or ovarian cancer [421]. However, our 
work, like their, sustain the concept that lipogenesis or accumulation of lipid from exogenous 
sources required a paired lipolytic activity to promote tumor progression. Furthermore, Nomura et 
al demonstrated that MAGL is part of a gene signature correlated with EMT and support the tumor 
aggressive behavior [422]. Whether ATGL correlated also with an EMT signature as well remain to 
be determined. Therefore, inhibition of ATGL expression and activity by selective inhibitors and/or 
genetic repression strategies should be investigated both in vitro and in vivo to evaluate its effect on 
tumor progression.  
 
Other therapeutic and investigate opportunities: 
The concept of metabolic coupling between tumor cells and their hosts raises the possibility for new 
therapeutic avenues. As discussed above, FFAs are another crucial source of metabolic fuel derived 
from adipocytes, supporting both energetic and anabolic requirements of tumor cells. Therefore, 
drugs that target lipolysis and FFAs efflux from adipocytes to cancer cells, as well as drugs that 
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interfere with FFA oxidation in cancer cells may provide additional mechanism-based strategies to 
curb tumor progression.  
The adipocyte lipid binding protein FABP4 was identified as a key mediator of ovarian-cancer cell-
adipocyte interaction in the host, mediating increased lipid availability leading to a more effective 
support of metastatic growth [71]. The “metabolic coupling” can be reversed by inhibiting lipid 
transport from adipocytes to carcinoma cells. Pharmaceutical companies have since begun to 
explore the potential for FABP4 inhibition in oncology [358]. In an in vitro study, adipocytes 
treated with BMS309403 (FABP4 small-molecule inhibitor) showed decrease of fatty acids uptake 
[361] and inhibition of lipolysis ability [362]. However, in our lab, we found that there is dramatical 
decrease of FABP4 expression in cocultivated adipocyte (data not shown).  Breast tumor cells 
poorly express this protein and its expression was not regulated after coculture. Furthermore, when 
we used FABP4 inhibitor BMS309403, we observed only a slight effect of inhibition of tumor-
induced adipocyte lipolysis and TG accumulation in tumor cells (data is not shown). These results 
suggested breast tumor cells may not dependent on FABP4 but other member of FABP family like 
FABP3, FABP7 or FABP9 [453] which are also expressed in mammary gland [358]. Other proteins 
that have been implicated as functionally linked to fatty acid transport like Caveolin-1, Fatty acyl 
CoA synthetases (FATP and ACSL) and Fatty acid translocase (FAT/CD36) [358] might also 
represent good targets whose function in adipocytes/cancer crosstalk needs to be investigated. 
Two key enzymes in the FAO pathway are particularly interesting as potential targets for 
pharmacological intervention. 1) CPT1 is considered the rate-limiting enzyme in FAO and can be 
pharmacologically targeted. We and others [401] found that etomoxir has promising anti-tumoural 
effects in vitro and in vivo. However, its clinical use could not be envisioned since it has been 
reported that etomoxir treatment in patients results in hepatotoxicity [454]. Other CPT1 inhibitor, 
Perhexiline has been approved in Australia and some Asian countries for the treatment of heart 
disease but its effect on tumor progression remains unknown. 2) Drugs that target 3-
ketoacylthiolase (3-KAT), which catalyses the final step in FAO, are also available [455]. 
Trimedazidine [456] and ranolazine [457] which are 3-KAT inhibitors, are both licensed in Europe 
for the treatment of angina, and deserve also further investigation in adipocytes/cancer crosstalk. 
All the drugs information is summarized below. 
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Table 1. Pharmacological tools to manipulate FAO. Carracedo A et al., 2013, Nat Rev Cancer 
 
 
Several mechanisms have been suggested to explain the association between cancer and obesity, 
involving elevated lipid levels and lipid signaling, inflammatory responses, insulin resistance, and 
secretion of adipokines. Future area of study is to understand if there is a difference in the 
interaction of tumor cells with adipocytes in lean as compared to obese individuals.  In other words, 
does activated adipose tissue in obesity, with its high content of inflammatory cells and increased 
cytokine secretion, higher released level of FFAs will affect the interaction of adipocytes with 
tumor cells? Currently, conventional techniques used for studying the crosstalk between adipocytes 
and cancer is performed in 2D monolayer system, which is not compatible with the use of isolated 
primary adipocytes. In our lab, we have recently successfully set up three-dimensional (3D) 
coculture system. Coculture of adipocytes isolated from obese and lean mice/patient with human 
cancer cells will be performed to evaluate if obesity has an impact on tumor progression. For in vivo 
experiment, one way to assess the systemic role (endocrine/paracrine) of obese adipocytes on 
cancer progression is to use xenografts models in obese mice. We have recently obtained in the 
laboratory two models that are syngenic for C57BL/6 mice that is the model of reference for obesity. 
Therefore, MMTV-Wnt (ER/PR negative mouse mammary tumor cell line) or E0771 (ER positive 
medullary breast adenocarcinoma cells) will be injected into syngeneic obese and lean, and the 
effect on obesity on tumor growth, metastasis, angiogenesis, inflammatory state and metabolism 
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will be studied. More clinical studies are also warranted to assess the angiogenesis, fibrosis, 
inflammation state and lipid transfer in breast tumors with obese setting as well.  
 
 
Figure 21. Dialogue of adipose tissue and cancer in the context of obesity (Lehuede C et al;, 2013, 
cancers aux feminins).  
 
 
In conclusion, all our data brought in vitro and in vivo evidences that: i) invasive cancer cells 
dramatically impact surrounding adipocytes; ii) peri-tumoral adipocytes exhibit modified phenotype 
and specific biological features; iii) CAAs and ADFs play an essential role during the cancer cell 
invasion of adjacent connective tissues; iv) CAAs modify the cancer cell characteristics/phenotype 
leading to their more aggressive behavior, by secreting proteases, pro-inflammatory cytokines and 
by modulating cancer cell metabolism, which is the dedicated part that I develop during my thesis. 
Our work should help in fine in identifying adipocyte-related molecules as possible intervention 
points for innovative anticancer strategies. This is of particular interest since recent epidemiological 
studies have identified obesity as one of the major risk factors for cancer, and a large amount of 
adipose tissues has been associated with poor prognosis for breast and prostate cancers. The 
expected striking increase in the incidence of these aggressive cancers in the near future related to 
obesity turns the knowledge of this field of great impact as it is needed to the development of 
strategies to prevent and treat this disease. 
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Résumé  
Il est maintenant clairement établi que l’obésité favorise la survenue et affecte le pronostic de 
nombreux cancers dont le cancer du sein. En utilisant le cancer su sein comme modèle, nous montrons 
ici qu’un dialogue bidirectionnel s’établit entre les cellules tumorales et le tissu adipeux à proximité. 
Les adipocytes péritumoraux présentent une délipidation et une diminution des marqueurs 
adipocytaires, cellules que nous avons appelé CAAs pour « Cancer-Associated Adipocytes ». Via leur 
capacité à sécréter des molécules pro-inflammatoires, des protéines de la matrice extra-cellulaire ou à 
libérer des acides gras, les CAAs stimulent la prolifération, la survie, les capacités invasives des 
tumeurs et favorisent la résistance aux traitements. Le propos de cette revue est de décrire comment 
les adipocytes affectent le comportement des tumeurs et de présenter les conséquences cliniques de ce 
dialogue délétère. Deux situations seront abordées. Tout d’abord, l’obésité où le tissu adipeux présente 
des modifications morphologiques et fonctionnelles qui le rendent plus enclin à favoriser localement la 
progression tumorale, pouvant expliquer le pronostic défavorable observé chez ces patientes. D’autre 
part, le risque carcinologique du transfert de graisse utilisé en chirurgie reconstructrice dans le cancer 
du sein sera décrit au regard de ces nouveaux éléments de connaissance sur le dialogue entre tissu 
graisseux et cancer.  
 
Summary  
Several epidemiological studies demonstrate positive associations between the prevalence of obesity, 
as judged by increased body mass index (BMI), cancer incidence, and cancer-related mortality. We 
have recently demonstrated that a bidirectional crosstalk is established between breast cancer cells and 
tumour-surrounding adipocytes. Tumour cell secretions are able to modify tumour-surrounding 
adipocytes to an activated state that we have named Cancer-Associated Adipocytes (CAAs). CAAs, by 
their ability to secrete proinflammatory molecules, extracellular matrix proteins and to liberate free 
fatty acids, stimulate tumor growth, survival, invasive capacities as well as resistance to treatment. The 
purpose of this review is to emphasize the role that adipose tissue might play by locally affecting 
breast cancer cell behaviour and subsequent clinical consequences arising from this dialog. Two 
particular clinical aspects are addressed: obesity that was identified as an independent negative 
prognosis factor in breast cancer and the oncological safety of autologous fat transfer used in 
reconstructive surgery for breast cancer patients.  
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L’obésité influence la survenue mais aussi le pronostic de certains cancers  
Au cours des dernières décennies, l’obésité est devenue un problème de santé publique majeur. 
L’organisation mondiale de la santé prévoit qu’en 2015, 3 milliards d’adultes dans le monde seront en 
surpoids tandis que 700 millions seront obèses. Chaque année, environ 3 millions de personnes 
meurent du fait des complications de l’obésité et ces chiffres sont en constante progression. Si les 
complications métaboliques et cardiovasculaires de l’obésité sont maintenant connues du grand public, 
le lien entre obésité et cancer reste lui largement ignoré. En 2003, une large étude épidémiologique 
publiée par le New England Journal of Medecine établit pour la première fois qu’aux Etats-Unis, 
environ 14% des décès par cancer chez l’homme et 20% chez la femme seraient dus à l’obésité [1]. 
Parmi les cancers les plus fréquemment concernés, on trouve des cancers digestifs (adénocarcinomes 
œsophagiens, cancers colorectaux et pancréatiques), des cancers gynécologiques (endomètre, sein 
après la ménopause) ainsi que les cancers du rein [1]. Outre l’augmentation du nombre de cancers, un 
des aspects du lien entre cancers et obésité qui a retenu notre attention est l’impact de cette dernière 
sur le pronostic, en particulier dans le cancer du sein. En effet, dans les carcinomes mammaires, 
l’obésité est un facteur indépendant de mauvais pronostic [2], les femmes obèses présentant une 
diminution de la survie globale, une diminution de la survie sans maladie ainsi qu’une augmentation 
des métastases. Ce caractère péjoratif semble indépendant de la ménopause, du stade de la tumeur et 
de son statut hormonal [pour revue [2]; [3]; [4]]. Il existe incontestablement des facteurs non 
biologiques qui pourraient expliquer ce résultat, en particulier des retards de diagnostic et des 
difficultés à utiliser une approche thérapeutique adaptée tel que le sous-dosage de la chimiothérapie [5, 
6]. Cependant, des arguments convaincants montrent à l’heure actuelle que l’hôte, c’est à dire le sujet 
obèse, pourrait conduire à des modifications des propriétés de la tumeur à la faveur d’une 
augmentation de son agressivité [7] et [5].  
Une des particularités du cancer du sein est sa proximité avec le tissu adipeux (TA), un contact 
physique s’établissant entre TA et cancer dès que ce dernier devient invasif (figure 1). Ces vingt 
dernières années, il a clairement été montré que la progression tumorale dépend d’une interaction 
dynamique avec les cellules « normales » entourant la tumeur [8]; [9]. Ces cellules normales, encore 
appelées cellules du microenvironnement ou stroma, sont activées localement ou recrutées par la 
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tumeur. L’importance dans la progression tumorale de certaines de ces cellules telles que les 
fibroblastes associés au cancer (CAF pour Cancer Associated Fibroblast) ou encore des macrophages 
(TAM pour Tumor Associated Macrophage) a été clairement décrite [10]; [11]. Ainsi, dans ce 
contexte, parmi les cellules qui constituent le stroma tumoral, les cellules adipeuses sont probablement 
celles dont le rôle a été le moins bien caractérisé alors qu’ils représentent le type cellulaire 
prédominant du microenvironnement des carcinomes mammaires. Les adipocytes matures représentent 
les cellules majoritaires du TA qui contient aussi, dans une fraction dite « stroma vasculaire », d’autres 
cellules telles que des progéniteurs (Adipose Derived Stem Cells ou ADSCs et préadipocytes), des 
fibroblastes, des macrophages, des lymphocytes, des péricytes ainsi que des cellules endothéliales 
[12]. L’adipocyte gère les fluctuations énergétiques induites par l'apport alimentaire ou les états de 
jeûne en stockant l'énergie sous forme de triglycérides ou en la libérant sous forme d'acides gras (AG) 
[13]. Toutefois, à côté de sa fonction de réservoir d’énergie, l’adipocyte est également une cellule 
endocrine active qui sécrète une grande variété de molécules (appelées adipokines), incluant des 
hormones, des facteurs de croissance, des chimiokines ou des molécules pro-inflammatoires [12], 
clairement susceptible d’influencer le comportement des tumeurs. Ainsi, l’hypothèse principale de nos 
travaux est que le dialogue local entre adipocytes et cellules tumorales pourrait influencer la survie, la 
prolifération et le potentiel métastatique de ces dernières, cet effet pouvant être exacerbé au cours de 
l'obésité où les sécrétions adipocytaires  sont altérées [12].  
 
Rôle des adipocytes péri-tumoraux dans la progression tumorale : le concept de Cancer-
Associated Adipocytes (CAAs) 
Afin d’étudier l’influence des adipocytes péritumoraux, nous avons mis en place au laboratoire un 
système de coculture entre cellules cancéreuses et adipocytes, les deux populations étant séparées par 
un insert autorisant le passage de facteurs solubles (figure 2). Après trois à cinq jours de coculture, 
nous avons étudié le comportement de ces cellules tumorales « éduquées » par les adipocytes. Parmi 
les différentes caractéristiques des tumeurs ainsi modifiées, nous avons retrouvé une augmentation de 
leurs propriétés invasives à la fois in vitro et in vivo, qu’il s’agisse de cellules exprimant ou non le 
récepteur aux œstrogènes (RE). Ainsi, des cellules tumorales mammaires « éduquées » par des 
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adipocytes et injectées dans la queue d’une souris présentent une capacité à former des métastases 
pulmonaires très fortement augmentée [14]. Comment les adipocytes peuvent-ils influencer le 
comportement des tumeurs ? Quelle que soit la lignée de cancer du sein utilisée, ces adipocytes 
subissent d’importantes modifications. En effet, ils présentent une délipidation partielle et une 
diminution de l’expression des marqueurs adipocytaires. Cette « dédifférenciation » s’accompagne 
d’un état d’activation marqué par la surexpression de cytokines pro-inflammatoires (interleukine 6 ou 
IL6, interleukine 1β ou IL1β, Tumor Necrosis Factor α ou TNFα) ainsi que de protéines de la matrice 
extra-cellulaire (MEC) et de son remodelage. Fait majeur, nous avons montré que ces adipocytes 
modifiés sont retrouvées au front invasif des tumeurs humaines (figure 2), soulignant ainsi la 
relevance clinique des résultats obtenus dans le système de coculture [14].  
Quels sont les médiateurs les plus importants expliquant l’influence des CAAs sur la tumeur ? Tout 
d’abord l’inflammation et en particulier l’IL6. En effet, dans une série de 32 échantillons comparant 
les caractéristiques des adipocytes péritumoraux à des adipocytes normaux issus de mammoplastie de 
réduction, nous avons retrouvé une augmentation très importante de l’IL6 (7.5 fois) dans les CAAs. 
De façon très intéressante, le niveau d’expression de l’IL6 dans les CAAs est corrélé à la taille des 
tumeurs et à l’envahissement ganglionnaire mais non à l’expression du RE, du type ou du grade de ces 
dernières [14]. Dans notre modèle de coculture, le blocage par des anticorps spécifiques de l’IL6 
adipocytaire diminue l’effet pro-invasif des adipocytes, confirmant l’importance de l’inflammation 
dans le dialogue TA/cancer. Outre l’inflammation, l’importance des protéines de la MEC ou de son 
remodelage a été soulignée par différentes équipes. Une des protéines de la matrice qui est fortement 
exprimée par les adipocytes péritumoraux et qui favorise la croissance des tumeurs mammaires in vivo 
est le collagène VI (COL6) [15]. De plus, il a été récemment montré qu’un des fragments de clivage 
du collagène, l’endotrophine, agissait comme une molécule de signalisation et augmentait la fibrose, 
l’angiogenèse et l’inflammation dans le microenvironnement des tumeurs mammaires favorisant ainsi 
l’agressivité tumorale et en particulier l’apparition de métastases [16]. Les CAAs expriment aussi la 
MMP11 (ou Stromelysine 3) qui appartient à la famille des métalloprotéases [17]. L’expression de 
cette protéine de remodelage de la MEC par les CAAs favorise la progression tumorale via sa capacité 
à cliver la MEC (étape importante pour l’invasion), mais aussi certains de ces substrats, les rendant 
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ainsi plus actifs [18]. C’est le cas du COL6 puisqu’il a été montré que le COL6 est un substrat de la 
MMP11 [18]. La dernière caractéristique des CAAs, et qui pourrait être la plus originale, est la perte 
des AG contenus dans les gouttelettes lipidiques, perte que nous avons observé in vitro et in vivo 
(Dirat et al, 2011 ; voir figure 2). Nous avons récemment montré au laboratoire que ces AGs libérés 
par les adipocytes sont transférés dans les cellules tumorales (Wang et al, résultats non publiés). Ce 
même dialogue métabolique a été montré dans le cancer de la prostate [19] et dans le cancer de 
l’ovaire disséminé [20]. Les cellules de cancer de l’ovaire disséminent fréquemment au niveau de 
l’omentum, région péritonéale riche en adipocytes. Sous l’effet d’un processus de lipolyse, les 
adipocytes se délipident, et les tumeurs ovariennes se chargent ainsi en lipides relargués qu’elles 
accumulent sous forme de gouttelettes [20]. Ce transfert de lipides est important pour la croissance de 
la tumeur dans l’omentum [2]. Ces AGs pourraient être utilisés comme constituants des membranes 
plasmiques, comme molécules de signalisation mais aussi comme source d’énergie pour les tumeurs. 
En effet, un ensemble de travaux récents montrent que les tumeurs, outre le glucose, pourraient utiliser 
les AGs comme substrat énergétique au travers de la β−oxydation des lipides qui a lieu dans la 
mitochondrie [21]. Ces résultats suggèrent qu’il pourrait exister une véritable symbiose métabolique 
entre les adipocytes (« donneurs d’énergie ») et les cellules tumorales (« receveuses »). S’ils étaient 
confirmés, l’interaction délétère entre adipocytes et cancer pourrait être efficacement interrompue via 
l’inhibition du transfert de lipides mais surtout via l’inhibition de la β-oxydation des lipides, des 
molécules comme l’etomoxir étant déjà connues pour exercer cet effet [21]. Le dialogue paracrine 
entre adipocytes et cancer fait aussi intervenir d’autres adipokines importantes telles que la leptine et 
l’adiponectine qui n’ont pas été abordées dans cette revue mais que le lecteur pourra retrouver dans les 
revues suivantes [22] ; [23] ; [24]. L’ensemble de ces résultats montre donc qu’il existe un dialogue 
permanent entre adipocytes et cancer du sein favorisant la prolifération tumorale, la survie et surtout 
l’invasion locale et à distance [3] ; [4]. L’interaction entre cellules tumorales mammaires et TA ne se 
limite pas aux adipocytes matures puisque des travaux récents montrent que les précurseurs 
adipocytaires sont eux aussi capables de participer activement à l’environnement de la tumeur, soit en 
générant des cellules proches des CAFs qui vont faire partie de la réaction desmoplasique, soit en 
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favorisant l’angiogenèse tumorale (pour une revue détaillée, le lecteur est invité à se référer à [4]). 
Finalement, les CAAs sont également impliqués dans des processus de radio- et chimiorésistance. En 
effet, nous avons montré grâce au système de coculture précédemment décrit que les cellules 
tumorales mammaires cocultivées avec des adipocytes présentaient une radiorésistance associée à une 
diminution de la mort post-mitotique [25]. Cet effet semble dépendant de l’IL6 sécrétée par les 
cellules tumorales, sécrétion autocrine qui est stimulée par la présence d’adipocytes. De la même 
façon, il a été montré que des facteurs solubles d’origine adipocytaire protègent des cellules de 
leucémie aiguë lymphoblastique (LAL) de l’effet cytotoxique de la vincristine [26]. Cette protection 
vis-à-vis des médicaments antitumoraux a été retrouvée pour d’autres types de molécules 
(dexamethasone, daunorubicine et nilotinib), ce qui suggère l’émergence d’un phénotype de résistance 
pléiotropique (ou « multidrug résistance ») qui pourrait dépendre, dans le cadre des LAL, d’une 
diminution de la mort par apoptose [26]. Enfin, l’inhibition de l’endotrophine, le produit de clivage du 
COL6 sensibilise les tumeurs au cisplatine [27]. L’ensemble des modifications résultant de 
l’interaction entre cellules tumorales et adipocytes est résumé dans la figure 2. Du fait de la 
composition de la glande mammaire, la plupart des travaux concernant l’interaction entre TA et cancer 
ont été consacrés aux cancers du sein. Il n’en demeure pas moins que la plupart des cancers invasifs va 
se retrouver à un moment donné de l’histoire de la maladie à proximité du TA. C’est le cas du cancer 
de la prostate invasif qui va envahir la graisse périprostatique, du cancer du côlon qui va se retrouver 
au contact de la graisse périviscérale, du cancer de l’ovaire qui dissémine au niveau de l’omentum ou 
du mélanome qui va rejoindre les couches profondes du derme. Dans toutes ces situations, une 
délipidation et une dédifférentiation partielle des adipocytes est observée ([28] et résultats de notre 
équipe non publiés). Certaines modifications plus spécifiques identifiées dans le cancer du sein sont 
retrouvées dans d’autres types de cancer comme par exemple l’augmentation de l’IL6 dans la graisse 
périprostatique [29]. Le dialogue métabolique apparaît quant à lui assez ubiquitaire [28]. Cette 
« proximité dangereuse » débouchant sur un dialogue délétère pourrait donc permettre d’aboutir à des 
concepts plus généraux en cancérologie et surtout au développement de stratégies thérapeutiques 
d’application élargie.  
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Le dialogue local entre adipocytes et cancer explique-t-il les liens délétères entre obésité et 
cancer ? 
Il existe donc un lien maintenant établi entre l’obésité et le pronostic du cancer du sein, ce lien 
semblant aussi exister pour d’autres cancers tels que le cancer de la prostate ou du colon [2]. Comme 
montré précédemment, l’ensemble de nos résultats ainsi que ceux de nos collègues supportent le 
concept innovant selon lequel les adipocytes participent à un cercle vicieux, initié par les cellules 
cancéreuses et favorable à la progression tumorale [3] ; [4] ; [24]. Notre hypothèse est que les 
adipocytes présents à proximité des tumeurs seraient, chez l’obèse, encore plus enclins à stimuler la 
dissémination locale et à distance ce qui pourrait expliquer le pronostic défavorable observé chez ces 
patients [7]. Chez le sujet obèse, le nombre (hyperplasie), la taille (hypertrophie) ainsi que le profil de 
sécrétion des adipocytes est altéré [24]. Il est maintenant clairement établi que le TA viscéral (TAV), 
c’est à dire présent dans les couches profondes de l’abdomen, des sujets obèses présente un état 
d’inflammation dit de « bas bruit » participant aux nombreux effets délétères métaboliques et 
cardiovasculaires de l’obésité [30] ; [31]. Cet état inflammatoire est marqué par une augmentation de 
la sécrétion de cytokines pro-inflammatoires (dont l’IL6), et par une infiltration de macrophages 
entourant le plus souvent des adipocytes nécrotiques, structure en couronne encore appelée « Crown-
like structures » ou CLS [12]. Enfin, dans le TAV  de sujets obèses, l’expression des composants de la 
MEC est modulée (afin de s’adapter à l’expansion hypertrophique des adipocytes) pouvant créer un 
état local profibrotique. Si l’on résume, on trouve donc dans le TAV d’un individu obèse, 
indépendamment de tout cancer, des modifications qui sont présentes dans les CAAs telles que 
l’inflammation, la fibrose et une augmentation de la libération d’AGs (figure 3). Ainsi ce terrain 
pourrait être tout à fait favorable à un dialogue amplifié avec la cellule tumorale. Il est important ici de 
souligner que l’ensemble de ces modifications a été décrit pour le TAV. De façon très intéressante 
deux études récentes montrent que le tissu adipeux mammaire chez l’obèse présente des similitudes 
par rapport au TAV. Une hypertrophie adipocytaire, proportionnelle à l’IMC, est également observée 
dans le TA mammaire, ainsi qu’un état inflammatoire, caractérisé par la présence de CLS et 
l’augmentation de l’expression des  cytokines proinflammatoires [32] [33]. Ces résultats sont donc 
tout à fait en faveur de l’hypothèse proposée dans le cancer du sein qui reste notre modèle de 
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prédilection. Les modèles animaux offrent une opportunité intéressante de valider cette hypothèse. 
Ainsi, l’équipe de Stephen Hursting a récemment montré que l’implantation orthotopique dans la 
glande mammaire de lignées triple négatives (M-Wnt) dans des souris rendues obèses par un régime 
hyperlipidique, entraine une augmentation de la croissance tumorale, par comparaison à un groupe 
témoin. A l’inverse, des souris soumises à une restriction calorique présentent une diminution 
significative de la taille tumorale, comparée au même groupe témoin [34]. De la même manière, 
l’équipe de L. Miele a montré que la progression tumorale mammaire était également augmentée dans 
des souris obèses transplantées avec une lignée ER+, E0071, ce qui était associé à une augmentation 
de l’angiogenèse tumorale consécutive à une sécrétion accrue de VEGF [35]. Les mécanismes 
moléculaires impliqués dans ces effets restent encore à caractériser de façon fine à la fois dans des 
tumeurs humaines, dans des modèles murins et dans des modèles de coculture utilisant du TA isolé à 
partir de sujets obèses et normopondéraux. Enfin, si dans la progression tumorale nous pensons que la 
tumeur est probablement plus encline à utiliser le TA à proximité (effet paracrine), l’importance des 
mécanismes endocrines ne doit pas être négligée en particulier dans les étapes initiales de la 
carcinogenèse. L’obésité et les modifications métaboliques qui y sont associées pourraient favoriser la 
carcinogenèse via l’insulino-résistance, les modifications des taux d’adipokines circulantes (excès de 
sécrétion de leptine et de cytokines pro-inflammatoires, défaut de sécrétion d’adiponectine). 
L’augmentation de la production d’œstrogènes pour les cancers gynécologiques est aussi à prendre en 
compte, le TA étant pourvu d’une activité d’aromatisation des androgènes en œstrogènes, aspect 
important surtout en période post-ménopausique. Le lecteur intéressé par les facteurs endocrines 
pouvant contribuer à la carcinogenèse pourra lire les revues suivantes [24] ; [23] ; [36]. 
 
Risque oncologique de l’utilisation de tissu adipeux en chirurgie reconstructrice ? 
Le rôle des adipocytes dans la progression tumorale, notamment dans le cancer du sein peut  
également avoir un impact dans l’utilisation de l’injection de TA autologue dans des processus de 
chirurgie réparatrice après une mastectomie partielle ou totale. Cette technique, appelée lipotransfert 
ou lipofilling permet de « combler » les défauts, notamment d’irrégularité et le manque de volume ou, 
plus rarement, de reconstruire entièrement un sein. La simplicité, les résultats esthétiques et plastiques 
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de cette méthode suscitent un intérêt croissant [37]. Cette technique, développée par Sydney R. 
Coleman et connue sous le nom de « technique de Coleman » consiste à prélever du TA sous-cutané, 
classiquement au niveau de l’abdomen ou des cuisses et à le réinjecter dans le parenchyme mammaire, 
de la même patiente après une courte centrifugation, afin d’éventuellement éliminer l’huile, l’excès de 
fluides et les contaminants [37] [38]. Ainsi, la préparation administrée contient de nombreux types 
cellulaires présents dans le tissu adipeux comme des adipocytes et des précurseurs adipocytaires 
susceptibles de favoriser la progression tumorale [39]. En outre, on sait que la chirurgie, la 
chimiothérapie et la radiothérapie ne sont pas toujours suffisantes pour éradiquer toutes les cellules 
tumorales lors du traitement et de nombreuses études ont montré la présence de cellules quiescentes, 
« en dormance », cellules potentiellement très sensibles aux changements de leur microenvironnement 
[40]. Ainsi le risque carcinologique de cette technique doit être évalué, d’autant plus qu’un article 
récent montre chez la souris que le matériel utilisé pour le lipofilling pouvait, après tumorectomie, 
favoriser l’apparition de métastases secondaires [41]. Dans cette étude, les auteurs attribuent le risque 
carcinologique à une sous-population de cellules souches capables de favoriser la vascularisation 
tumorale. Une étude clinique rétrospective avec un groupe témoin a été publiée récemment par 
l’Institut Européen du Cancer de Milan. Cette étude ne montre pas de différence significative du taux 
de rechutes entre les deux groupes, toutefois une augmentation des rechutes chez les patientes ayant un 
cancer in situ a été noté dans le groupe ayant reçu un lipofilling [42]. Une autre étude rétrospective 
avec groupe témoin a été réalisée très récemment par la même équipe, centrée uniquement sur les 
patientes présentant des lésions intra-épithéliales, étude qui confirme les résultats précédents [43]. Si 
aucune conclusion définitive ne peut être tirée de ces premiers travaux (car elles concernent un faible 
nombre de patientes), des études supplémentaires sur des échantillons plus importants doivent être 
impérativement réalisées afin de confirmer ou d’infirmer les risques de cette technique sur les 
possibilités de récidives locales des cancers du sein in situ traités par tumorectomie. Enfin, les 
améliorations constantes de cette technique avec notamment l’apport de cellules souches adipocytaires 
nécessitent aussi des investigations cliniques spécifiques si l’on s’en réfère à la potentielle dangerosité 
des cellules souches révélée par les études effectuées chez la souris [41] [39] [44]. 
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Conclusion 
De nombreux arguments soulignent maintenant le rôle du tissu adipeux dans le cancer, notamment le 
cancer du sein. Ce tissu complexe, majoritairement composé d’adipocytes, peut être modifié dans des 
contextes pathologiques en particulier l’obésité. L’ensemble de nos résultats montre le dialogue 
bidirectionnel néfaste qui s’instaure entre les cellules tumorales mammaires et les adipocytes présents 
à proximité des tumeurs, influençant notamment leur capacité métastatique [14]. Ces adipocytes 
« activés » par les cellules tumorales ou CAAs présentent des modifications importantes, comme une 
délipidation, l’acquisition d’un phénotype inflammatoire et profibrotique [14] [20]. Comprendre et 
cibler les acteurs impliqués dans le dialogue entre cellules tumorales et adipocytes permettraient 
d’apporter un bénéfice thérapeutique important pour les patients atteints de cancer en particulier dans 
un contexte d’obésité.  
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Légendes des figures 
 
 
Figure 1. La proximité entre tissu adipeux et cellules tumorales est retrouvée dans les cancers du 
sein invasif. Coupe histologique de cancer mammaire après coloration à l’Hématoxyline-Eosine. Le 
tissu adipeux est noté TA, la tumeur T. Les flèches indiquent des zones représentatives ou les cellules 
tumorales sont  au contact du tissu adipeux.  
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Figure 2. Le dialogue entre les adipocytes et les cellules tumorales induisent des modifications 
phénotypiques caractéristiques dans les deux populations. A, Le dialogue entre adipocytes et 
cellules cancéreuses est étudié à l’aide d’un système de coculture en 2D ou les deux populations sont 
séparées par un insert permettant le passage des facteurs solubles entre les deux compartiments. Le 
phénotype des cellules tumorales et des adipocytes cocultivés est comparé respectivement à des 
cellules tumorales ou à des adipocytes cultivés seuls. B, Après coculture, les cellules tumorales 
présentent des caractéristiques différentes dont une augmentation de l’invasion. Cette augmentation de 
l’invasion est illustrée in vitro par un marquage de l’actine par une sonde fluorescente en rouge 
(panneau du haut). Les cellules cancéreuses non cocultivées (NC) montrent une organisation en îlot 
qui rappelle l’acinus mammaire alors que les cellules cocultivées (C) se séparent, s’étalent sur le 
support et montrent des extensions membranaires, modifications caractéristiques d’un phénotype 
invasif. In vivo (panneau du bas), les poumons des souris injectées par voie veineuse avec des cellules 
cancéreuses cocultivées (C) présentent des métastases (flèches blanches) dont le nombre et la taille 
sont fortement augmentés comparées aux cellules contrôles non cocultivées (NC). C, Les adipocytes 
cultivés in vitro (panneau du haut) sont marqués à l’huile rouge (marquage des lipides neutres) et 
observés au microscope. Les adipocytes cocultivés (C) présentent une diminution franche du nombre 
et de la taille des goutelettes lipidiques par rapport au contrôle non cocultivé (NC).Coupes 
histologiques de tissu adipeux à distance (TAD) ou péritumoral (TAP) de carcinome mammaire. Le 
phénotype « CAA »observé in vitro est retrouvé au front invasif dans ces tumeurs humaines. 
NC : non cocultivés, C : cocultivés, TAD : tissu adipeux à distance de la tumeur, TAP: tissu adipeux 
péritumoral. 
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Figure 3 : Dialogue adipocyte/cancer dans un contexte d’obésité. L’hyperplasie et l’hypertrophie 
des adipocytes rencontrées dans le tissu adipeux (TA) des sujets obèses ont pour conséquences la 
modification des sécrétions adipocytaires, l’apparition d’une fibrose et un état sub-inflammatoire. Ces 
modifications pourraient exacerber le dialogue entre ces deux composants, expliquant le pronostic 
défavorable observé pour les patients obèses. L’intensité de la coloration rouge représente le degré 
d’agressivité des tumeurs  
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ABSTRACT: 
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